sp_id,rp_id,seeker_post,response_post,level,rationales
1adc970c-d433-44d0-aa09-d3834986f7a2,1adc970c-d433-44d0-aa09-d3834986f7a2,there is a 13.2% difference between the results from the two the primary trial cohorts,"[PRIMARY] Outcome Measurement:  </s>   Event-free Survival </s>   Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. </s>   Time frame: 5 years </s> Results 1:  </s>   Arm/Group Title: Exemestane </s>   Arm/Group Description: Patients receive oral exemestane (25 mg) once daily for 5 years. </s>   exemestane: Given orally </s>   Overall Number of Participants Analyzed: 3789 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  88        (87 to 89) </s> Results 2:  </s>   Arm/Group Title: Anastrozole </s>   Arm/Group Description: Patients receive oral anastrozole (1 mg) once daily for 5 years. </s>   anastrozole: Given orally </s>   Overall Number of Participants Analyzed: 3787 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  89        (88 to 90)",0,"Outcome Measurement:  |   Event-free Survival |   Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. |   Time frame: 5 years | Results 1:  |   Arm/Group Title: Exemestane |   Arm/Group Description: Patients receive oral exemestane (25 mg) once daily for 5 years. |   exemestane: Given orally |   Overall Number of Participants Analyzed: 3789 |   Measure Type: Number |   Unit of Measure: percentage of participants  88        (87 to 89) | Results 2:  |   Arm/Group Title: Anastrozole |   Arm/Group Description: Patients receive oral anastrozole (1 mg) once daily for 5 years. |   anastrozole: Given orally |   Overall Number of Participants Analyzed: 3787 |   Measure Type: Number |   Unit of Measure: percentage of participants  89        (88 to 90)"
6b9162d0-0816-46d4-81af-c60028dcc63b,6b9162d0-0816-46d4-81af-c60028dcc63b,"Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over","[PRIMARY] Inclusion criteria: </s> Inclusion Criteria: </s>   Female patients age 18 years or older </s>   Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant, irrespective of prior hormone therapy metastatic disease (stage IV); </s>   HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative) </s>   At least one measurable tumour lesion (RECIST); </s>   Availability of tumour samples </s>   Written informed consent that is consistent with ICH-GCP guidelines and local law </s>   Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 - 2. </s> Exclusion criteria: </s> Exclusion Criteria: </s>   Active infectious disease </s>   Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea </s>   Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol </s>   Active/symptomatic brain metastases </s>   Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) </s>   ANC less than 1500/mm3 platelet count less than 100 000/mm3 </s>   Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent) </s>   AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases </s>   Serum creatinine greater than 1.5 mg/dl (>132 and#61549 mol/L, SI unit equivalent) </s>   Patients who are sexually active and unwilling to use a medically acceptable method of contraception </s>   Pregnancy or breast-feeding </s>   Concomitant treatment with other investigational drugs or other anti-cancer-therapy during this study and/or during the past two/four weeks, prior to the first treatment with the trial drug. Concurrent treatment with biphosphonates is allowed </s>   Previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply with the protocol </s>   Active alcohol or drug abuse </s>   Other malignancy within the past 5 years [SECONDARY] Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. </s>   Women with breast density  25% (scattered fibroglandular densities or greater) are eligible. </s>   Prior Treatment </s>   Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. </s>   Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. </s>   Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. </s>   Vitamin D Use </s>   Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. </s>   Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. </s>   Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. </s>   Patients with a history of breast implants or breast reduction are not eligible. </s>   Patients with two or more bone fractures in the past five years are not eligible. </s>   Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. </s>   Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. </s>   Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. </s>   Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. </s>   Required initial laboratory values - Calcium < 10.5 mg/dL",0,"  Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) | Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. |   Women with breast density  25% (scattered fibroglandular densities or greater) are eligible. |   Prior Treatment |   Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. |   Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. |   Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. |   Vitamin D Use |   Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. |   Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. |   Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. |   Patients with a history of breast implants or breast reduction are not eligible. |   Patients with two or more bone fractures in the past five years are not eligible. |   Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. |   Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. |   Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. |   Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. |   Required initial laboratory values - Calcium < 10.5 mg/dL"
0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f,0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f,a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis,[PRIMARY] Adverse Events 1: </s>   Total: 20/167 (11.98%) </s>   Cardiac failure acute 0/167 (0.00%) </s>   Diarrhoea 5/167 (2.99%) </s>   Colitis 2/167 (1.20%) </s>   Enterocolitis 1/167 (0.60%) </s>   Enterocolitis haemorrhagic 1/167 (0.60%) </s>   Stomatitis 1/167 (0.60%) </s>   Impaired healing 1/167 (0.60%) </s>   Sudden death 1/167 (0.60%) </s>   Postoperative wound infection 2/167 (1.20%) </s>   Erysipelas 2/167 (1.20%) </s>   Bacterial diarrhoea 1/167 (0.60%) </s> Adverse Events 2: </s>   Total: 4/167 (2.40%) </s>   Cardiac failure acute 1/167 (0.60%) </s>   Diarrhoea 0/167 (0.00%) </s>   Colitis 0/167 (0.00%) </s>   Enterocolitis 0/167 (0.00%) </s>   Enterocolitis haemorrhagic 0/167 (0.00%) </s>   Stomatitis 0/167 (0.00%) </s>   Impaired healing 0/167 (0.00%) </s>   Sudden death 0/167 (0.00%) </s>   Postoperative wound infection 1/167 (0.60%) </s>   Erysipelas 0/167 (0.00%) </s>   Bacterial diarrhoea 0/167 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 112/458 (24.45%) </s>   Febrile neutropenia 8/458 (1.75%) </s>   Neutropenia 6/458 (1.31%) </s>   Anaemia 3/458 (0.66%) </s>   Thrombocytopenia 3/458 (0.66%) </s>   Pancytopenia 2/458 (0.44%) </s>   Myocardial infarction 0/458 (0.00%) </s>   Pericardial effusion 0/458 (0.00%) </s>   Tachycardia 0/458 (0.00%) </s>   Acute myocardial infarction 1/458 (0.22%) </s>   Atrial fibrillation 0/458 (0.00%) </s> Adverse Events 2: </s>   Total: 39/221 (17.65%) </s>   Febrile neutropenia 5/221 (2.26%) </s>   Neutropenia 1/221 (0.45%) </s>   Anaemia 2/221 (0.90%) </s>   Thrombocytopenia 0/221 (0.00%) </s>   Pancytopenia 0/221 (0.00%) </s>   Myocardial infarction 2/221 (0.90%) </s>   Pericardial effusion 2/221 (0.90%) </s>   Tachycardia 2/221 (0.90%) </s>   Acute myocardial infarction 0/221 (0.00%) </s>   Atrial fibrillation 1/221 (0.45%),0,  Enterocolitis 1/167 (0.60%) |   Enterocolitis 0/167 (0.00%) | Adverse Events 1: |   Total: 112/458 (24.45%) |   Febrile neutropenia 8/458 (1.75%) |   Neutropenia 6/458 (1.31%) |   Anaemia 3/458 (0.66%) |   Thrombocytopenia 3/458 (0.66%) |   Pancytopenia 2/458 (0.44%) |   Myocardial infarction 0/458 (0.00%) |   Pericardial effusion 0/458 (0.00%) |   Tachycardia 0/458 (0.00%) |   Acute myocardial infarction 1/458 (0.22%) |   Atrial fibrillation 0/458 (0.00%) | Adverse Events 2: |   Total: 39/221 (17.65%) |   Febrile neutropenia 5/221 (2.26%) |   Neutropenia 1/221 (0.45%) |   Anaemia 2/221 (0.90%) |   Thrombocytopenia 0/221 (0.00%) |   Pancytopenia 0/221 (0.00%) |   Myocardial infarction 2/221 (0.90%) |   Pericardial effusion 2/221 (0.90%) |   Tachycardia 2/221 (0.90%) |   Acute myocardial infarction 0/221 (0.00%) |   Atrial fibrillation 1/221 (0.45%)
cc1f712a-2116-4e40-9810-f315e3fa5ff8,cc1f712a-2116-4e40-9810-f315e3fa5ff8,the primary trial does not report the PFS or objective response rate of its patient cohort,[PRIMARY] Outcome Measurement:  </s>   Local Control Using Ipsilateral Breast Tumor Recurrence Rates </s>   [Not Specified] </s>   Time frame: 2 years after treatment completion </s> Results 1:  </s>   Arm/Group Title: Accelerated Partial Breast Brachytherapy </s>   Arm/Group Description: Each patient will receive accelerated partial breast brachytherapy with multiple plane implant. </s>   Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions. </s>   Overall Number of Participants Analyzed: 151 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  .7,1,Outcome Measurement:  |   Local Control Using Ipsilateral Breast Tumor Recurrence Rates |   [Not Specified] |   Time frame: 2 years after treatment completion
904061c0-14fa-4f13-9118-9a41e24fa8eb,904061c0-14fa-4f13-9118-9a41e24fa8eb,Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer </s>   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 </s>   Participants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study </s>   Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer </s>   Radiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor (AI), or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancer </s>   Measurable disease via Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1 </s>   Consent to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or a minimum of 20 (25 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue for oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing </s>   A valid cobas PIK3CA mutation result by central testing is required </s>   Adequate hematologic and end-organ function within 28 days prior to treatment initiation </s> Exclusion Criteria: </s>   Human epidermal growth factor receptor 2 (HER2)-positive disease by local laboratory testing (immunohistochemistry 3 positive [IHC 3+] staining or in situ hybridization positive) </s>   Prior treatment with fulvestrant </s>   Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor </s>   Prior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1 </s>   Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1 </s>   All acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the Investigator </s>   Prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer </s>   Concurrent hormone replacement therapy </s>   Known untreated or active central nervous system (CNS) metastases </s>   Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications </s>   History of inflammatory bowel disease or active bowel inflammation </s>   Clinically significant cardiac or pulmonary dysfunction </s>   Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus",0,"  Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor"
43ee7645-ce1e-42d5-9a74-3e379f6f367b,43ee7645-ce1e-42d5-9a74-3e379f6f367b,only patients with a HER2-positive status can take part in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Signed informed consent form. </s>    18 years of age. </s>   Histologically confirmed carcinoma of the breast with measurable or non-measurable metastatic disease that has progressed (patients with a history of brain metastasis are eligible for study participation [USA only], as long as their brain metastases have been treated and they have no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone). </s>   Progression of disease during or following administration of one (non-investigational) chemotherapy regimen administered in the first-line setting. </s>   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. </s>   For women of childbearing potential, use of an effective means of non-hormonal contraception. </s>   Life expectancy  3 months. </s>   Willingness and capacity to comply with study and follow-up procedures. </s> Exclusion Criteria: </s>   Prior hormonal therapy only as treatment for metastatic disease without chemotherapy. Patients must have received chemotherapy for their metastatic disease in the first-line setting. Hormone therapy alone is not allowed. </s>   For subjects who have received prior anthracycline-based therapy, documentation of left ventricular ejection fraction < 50% by either multiple gated acquisition (MUGA) or echocardiogram (ECHO). </s>   Treatment with more than one prior cytotoxic regimen for metastatic breast cancer (MBC). </s>   HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study). </s>   Unknown estrogen receptor (ER) and progesterone receptor (PR) status. </s>   Radiation therapy other than for palliation or brain metastasis, biologic therapy, or chemotherapy for MBC within 21 days prior to Day 0 (Day 1 of Cycle 1 of treatment). </s>   Prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) pathway-targeted therapy. </s>   Untreated brain metastasis. </s>   Inadequately controlled hypertension. </s>   Unstable angina. </s>   New York Heart Association Grade II or greater congestive heart failure (CHF). </s>   History of myocardial infarction within 6 months prior to Day 0 (the day of the first bevacizumab/placebo infusion). </s>   History of stroke or transient ischemic attack within 6 months prior to Day 0. </s>   Clinically significant peripheral vascular disease. </s>   Evidence of bleeding diathesis or coagulopathy. </s>   Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major elective surgical procedure during the study. </s>   Minor surgical procedures, fine-needle aspirations, or core biopsies within 7 days prior to Day 0. </s>   History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0. </s>   Serious, non-healing wound, ulcer, or bone fracture. </s>   History of anaphylactic reaction to monoclonal antibody therapy not controlled with treatment premedication. </s>   History of other malignancies within 5 years of Day 0, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. </s>   inadequate organ function. </s>   Pregnancy (positive serum pregnancy test) or lactation. </s>   Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications.",0,"  HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study)."
0cef8c8e-7986-46c7-a597-c5733a9899c0,0cef8c8e-7986-46c7-a597-c5733a9899c0,"the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months","[PRIMARY] Outcome Measurement:  </s>   Progression-Free Survival (PFS) </s>   Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions </s>   Time frame: every 8 weeks until progressive disease, expected average of 18 months </s> Results 1:  </s>   Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus </s>   Arm/Group Description: Systemic Therapy </s>   Overall Number of Participants Analyzed: 56 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  9.1        (6.8 to 10.8) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel/Bevacizumab/Placebo </s>   Arm/Group Description: Systemic Therapy </s>   Overall Number of Participants Analyzed: 57 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.1        (5.6 to 10.8)",0,"Outcome Measurement:  |   Progression-Free Survival (PFS) |   Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |   Time frame: every 8 weeks until progressive disease, expected average of 18 months | Results 1:  |   Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus |   Arm/Group Description: Systemic Therapy |   Overall Number of Participants Analyzed: 56 |   Median (95% Confidence Interval) |   Unit of Measure: months  9.1        (6.8 to 10.8) | Results 2:  |   Arm/Group Title: Paclitaxel/Bevacizumab/Placebo |   Arm/Group Description: Systemic Therapy |   Overall Number of Participants Analyzed: 57 |   Median (95% Confidence Interval) |   Unit of Measure: months  7.1        (5.6 to 10.8)"
43ce26e5-03fa-4e9d-b0eb-6ea356295753,43ce26e5-03fa-4e9d-b0eb-6ea356295753,"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .","[PRIMARY] INTERVENTION 1:  </s>   HER2+ TC </s>   Participants with HER2+ breast cancer received treatment as follows: </s>   Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. </s>   Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. </s>   Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off. </s>   Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years. </s> INTERVENTION 2:  </s>   HER2+ C </s>   Participants with HER2+ breast cancer received treatment as follows: </s>   Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. </s>   Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. </s>   Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.",1,"INTERVENTION 1:  |   HER2+ TC |   Participants with HER2+ breast cancer received treatment as follows: |   Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. |   Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. |   Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off. |   Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years. | INTERVENTION 2:  |   HER2+ C |   Participants with HER2+ breast cancer received treatment as follows: |   Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. |   Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. |   Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off."
3facad41-0221-42f8-834d-470e65c4aad5,3facad41-0221-42f8-834d-470e65c4aad5,the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ,"[PRIMARY] Outcome Measurement:  </s>   Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. </s>   The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months. </s>   Time frame: up to 3 years </s> Results 1:  </s>   Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel </s>   Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ] </s>   Overall Number of Participants Analyzed: 26 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  14.3        (9.3 to 35)",0,"Outcome Measurement:  |   Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen."
9cbc00e9-3a2d-4471-a93e-72c95132fb6a,9cbc00e9-3a2d-4471-a93e-72c95132fb6a,The only case of congestive heart failure in the primary trial occurred in cohort 1,[PRIMARY] Adverse Events 1: </s>   Total: 1/35 (2.86%) </s>   congestive heart failure *1/35 (2.86%) </s> Adverse Events 2: </s>   Total: 0/40 (0.00%) </s>   congestive heart failure *0/40 (0.00%),1,Adverse Events 1: |   Total: 1/35 (2.86%) |   congestive heart failure *1/35 (2.86%) | Adverse Events 2: |   Total: 0/40 (0.00%) |   congestive heart failure *0/40 (0.00%)
8b91cab9-d858-45f3-bf8d-3d6fc55b4818,8b91cab9-d858-45f3-bf8d-3d6fc55b4818,The the primary trial results section reports two different measurements,"[PRIMARY] Outcome Measurement:  </s>   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods </s>   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. </s>   Time frame: Baseline </s> Results 1:  </s>   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) </s>   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. </s>   Overall Number of Participants Analyzed: 92 </s>   Measure Type: Number </s>   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 </s>   Proportion of SNs (PICG) detected by ICG method: 0.95",1,"Outcome Measurement:  |   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods |   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. |   Time frame: Baseline | Results 1:  |   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) |   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. |   Overall Number of Participants Analyzed: 92 |   Measure Type: Number |   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 |   Proportion of SNs (PICG) detected by ICG method: 0.95"
4a75574c-fa86-4e62-a210-81c7b98a3807,4a75574c-fa86-4e62-a210-81c7b98a3807,T4 N2 M4 patients are eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically confirmed stage I, II, or III breast cancer </s>   T1-3, N0-2, M0 </s>   Patients with sentinel node biopsy positive disease must have undergone axillary dissection </s>   Tumor must be confined to the breast without detected metastases elsewhere </s>   T4 disease with minimal dermal invasion allowed </s>   No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer </s>   No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign </s>   No distant metastases </s>   No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT </s>   Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned </s>   Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery </s>   Negative surgical margins </s>   Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy </s>   Known HER2 status by immunohistochemistry or fluorescence in situ hybridization </s>   Hormone receptor status: </s>   Estrogen and progesterone receptor negative </s>   Less than 10% positive tumor cells by immunohistochemistry </s>   PATIENT CHARACTERISTICS: </s>   Age: </s> Not specified </s>   Sex: </s>   Not specified </s>   Menopausal status: </s>   Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR </s>   Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over) </s> Performance status: </s>   Not specified </s>   Life expectancy: </s>   Not specified </s>   Hematopoietic: </s>   WBC greater than 3,000/mm3 </s>   Platelet count greater than 100,000/mm3 </s>   Hepatic: </s>   See Disease Characteristics </s>   Bilirubin less than 2.0 mg/dL </s>   ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L </s>   Renal: </s>   Creatinine less than 1.2 mg/dL </s>   Other: </s>   Not pregnant or lactating within the past 6 months </s>   Fertile patients must use effective barrier contraception </s>   No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma </s>   No psychiatric or addictive disorders that would preclude study </s>   No non-malignant systemic disease that would preclude study </s>   PRIOR CONCURRENT THERAPY: </s>   Biologic therapy: </s>   Prior trastuzumab (Herceptin) allowed </s>   Chemotherapy: </s>   See Disease Characteristics </s>   No prior adjuvant or neoadjuvant chemotherapy for breast cancer </s>   Endocrine therapy: </s>   No prior endocrine therapy for breast cancer or prevention </s>   No prior tamoxifen or raloxifene for breast cancer </s>   Radiotherapy: </s>   No prior radiotherapy for breast cancer except primary irradiation </s>   Surgery: </s>   See Disease Characteristics </s>   Other: </s>   No prior preventative therapy for breast cancer",0,"  T1-3, N0-2, M0"
d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7,d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7,"The the primary trial results section reports two different measurements, for all 3 cohorts.","[PRIMARY] Outcome Measurement:  </s>   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods </s>   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. </s>   Time frame: Baseline </s> Results 1:  </s>   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) </s>   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. </s>   Overall Number of Participants Analyzed: 92 </s>   Measure Type: Number </s>   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 </s>   Proportion of SNs (PICG) detected by ICG method: 0.95",0,"Outcome Measurement:  |   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods |   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. |   Time frame: Baseline | Results 1:  |   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) |   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. |   Overall Number of Participants Analyzed: 92 |   Measure Type: Number |   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 |   Proportion of SNs (PICG) detected by ICG method: 0.95"
b0b61978-57db-4a1c-812c-509e8b05f2dc,b0b61978-57db-4a1c-812c-509e8b05f2dc,"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have","[PRIMARY] INTERVENTION 1:  </s>   Nivolumab + Daratumumab (TNBC) </s>   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) </s> INTERVENTION 2:  </s>   Nivolumab + Daratumumab (NSCLC) </s>   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",1,"INTERVENTION 1:  |   Nivolumab + Daratumumab (TNBC) |   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) | INTERVENTION 2:  |   Nivolumab + Daratumumab (NSCLC) |   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)"
24b85b44-b9e6-4c28-b3aa-1bd97102b7f1,24b85b44-b9e6-4c28-b3aa-1bd97102b7f1,Patients must have a palpable carcinoma to be included in the primary trial,"[PRIMARY] Inclusion Criteria Phase 1 </s>   Age greater than/equal to 18 years </s>   Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ </s>   Patient desire to undergo breast surgery </s>   3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. The cancer enhances on breast MRI imaging. </s>   Inclusion Criteria Phase 2 </s>   Age greater than/equal to 18 years </s>   Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ </s>   The tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter. </s>   . Determination by the surgeon that the neoplasm is non-palpable.A patient with a palpable hematoma from core biopsy, but a non-palpable neoplasm, will be eligible for study </s>   Patient desire to undergo breast conserving surgery </s>   Patients will have provided informed consent to participate, documented by their signature on the study consent form.The process of informed consent will be documented in the medical record and a copy of the signed consent form will be given to the patient. </s>   Exclusion Criteria (Phases 1 and 2) </s>   Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip or metallic foreign body in or near eyes </s>   Severe claustrophobia </s>   Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0) </s>   History of median sternotomy </s>   Pregnancy (Patient attestation that they are not pregnant will be acceptable, as per standard, as per standard policy for MRIs at DHMC). </s>   Multicentric breast cancer, defined as two or more tumors in different quadrants of the breast. An eligibility worksheet will be completed for each patient prior to enrollment and will be signed and dated by the surgeon investigator",1,  Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
fbb62216-2cf2-4813-ad41-12a86940610f,fbb62216-2cf2-4813-ad41-12a86940610f,Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 59/199 (29.65%) </s>   Anaemia 7/199 (3.52%) </s>   Thrombocytopenia 2/199 (1.01%) </s>   Acute myocardial infarction 0/199 (0.00%) </s>   Atrial fibrillation 1/199 (0.50%) </s>   Cardiac arrest 1/199 (0.50%) </s>   Cardiac failure 1/199 (0.50%) </s>   Cardiopulmonary failure 1/199 (0.50%) </s>   Left ventricular failure 1/199 (0.50%) </s>   Supraventricular tachycardia 0/199 (0.00%) </s>   Ventricular tachycardia 1/199 (0.50%) </s> Adverse Events 2: </s>   Total: 16/36 (44.44%) </s>   Anaemia 2/36 (5.56%) </s>   Thrombocytopenia 1/36 (2.78%) </s>   Acute myocardial infarction 1/36 (2.78%) </s>   Atrial fibrillation 0/36 (0.00%) </s>   Cardiac arrest 0/36 (0.00%) </s>   Cardiac failure 0/36 (0.00%) </s>   Cardiopulmonary failure 0/36 (0.00%) </s>   Left ventricular failure 0/36 (0.00%) </s>   Supraventricular tachycardia 1/36 (2.78%) </s>   Ventricular tachycardia 0/36 (0.00%),1,Adverse Events 1: |   Total: 59/199 (29.65%) |   Anaemia 7/199 (3.52%) |   Thrombocytopenia 2/199 (1.01%) |   Acute myocardial infarction 0/199 (0.00%) |   Atrial fibrillation 1/199 (0.50%) |   Cardiac arrest 1/199 (0.50%) |   Cardiac failure 1/199 (0.50%) |   Cardiopulmonary failure 1/199 (0.50%) |   Left ventricular failure 1/199 (0.50%) |   Supraventricular tachycardia 0/199 (0.00%) |   Ventricular tachycardia 1/199 (0.50%) | Adverse Events 2: |   Total: 16/36 (44.44%) |   Anaemia 2/36 (5.56%) |   Thrombocytopenia 1/36 (2.78%) |   Acute myocardial infarction 1/36 (2.78%) |   Atrial fibrillation 0/36 (0.00%) |   Cardiac arrest 0/36 (0.00%) |   Cardiac failure 0/36 (0.00%) |   Cardiopulmonary failure 0/36 (0.00%) |   Left ventricular failure 0/36 (0.00%) |   Supraventricular tachycardia 1/36 (2.78%) |   Ventricular tachycardia 0/36 (0.00%)
961a956e-fece-4baa-a2ad-d3a5320bd9d2,961a956e-fece-4baa-a2ad-d3a5320bd9d2,The shortest PFS in cohort 1 of the primary trial was less than 3 weeks,"[PRIMARY] Outcome Measurement:  </s>   Progression Free Survival </s>   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. </s>   Assessment period was from the day of randomisation until the first observation of lesion progression or death </s>   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, </s> Results 1:  </s>   Arm/Group Title: NK105 </s>   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.4        (7.0 to 9.9) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel </s>   Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.5        (6.9 to 11.5)",0,"Outcome Measurement:  |   Progression Free Survival |   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. |   Assessment period was from the day of randomisation until the first observation of lesion progression or death |   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, | Results 1:  |   Arm/Group Title: NK105 |   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle |   Overall Number of Participants Analyzed: 211 |   Median (95% Confidence Interval) |   Unit of Measure: months  8.4        (7.0 to 9.9)"
97fd111c-6969-43ab-93af-b3dff09960e5,97fd111c-6969-43ab-93af-b3dff09960e5,The adverse events section in the primary trial is reports the incidence rate of 12 different Aes,[PRIMARY] Adverse Events 1: </s>   Total: 0/0,0,Adverse Events 1: |   Total: 0/0
eb1bfb08-eba0-4130-b328-00f56c0f84a6,eb1bfb08-eba0-4130-b328-00f56c0f84a6,Diarrhoea is the most common adverse event in the primary trial and the secondary trial,[PRIMARY] Adverse Events 1: </s>   Total: 17/65 (26.15%) </s>   Febrile neutropenia 3/65 (4.62%) </s>   Neutropenia 2/65 (3.08%) </s>   Pancytopenia 1/65 (1.54%) </s>   Thrombocytopenia 1/65 (1.54%) </s>   Cardiac arrest 2/65 (3.08%) </s>   Myocardial infarction 1/65 (1.54%) </s>   Diarrhoea 5/65 (7.69%) </s>   Stomatitis 1/65 (1.54%) </s>   Vomiting 2/65 (3.08%) </s>   Fatigue 1/65 (1.54%) </s>   Jaundice 1/65 (1.54%) </s>   Neutropenic infection 2/65 (3.08%) [SECONDARY] Adverse Events 1: </s>   Total: 173/472 (36.65%) </s>   Anaemia 6/472 (1.27%) </s>   Febrile neutropenia 4/472 (0.85%) </s>   Iron deficiency anaemia 1/472 (0.21%) </s>   Leukopenia 2/472 (0.42%) </s>   Neutropenia 2/472 (0.42%) </s>   Thrombocytopenia 4/472 (0.85%) </s>   Acute myocardial infarction 1/472 (0.21%) </s>   Aortic valve incompetence 0/472 (0.00%) </s>   Atrial fibrillation 2/472 (0.42%) </s>   Cardiac arrest 1/472 (0.21%) </s> Adverse Events 2: </s>   Total: 40/238 (16.81%) </s>   Anaemia 0/238 (0.00%) </s>   Febrile neutropenia 1/238 (0.42%) </s>   Iron deficiency anaemia 0/238 (0.00%) </s>   Leukopenia 0/238 (0.00%) </s>   Neutropenia 2/238 (0.84%) </s>   Thrombocytopenia 0/238 (0.00%) </s>   Acute myocardial infarction 0/238 (0.00%) </s>   Aortic valve incompetence 1/238 (0.42%) </s>   Atrial fibrillation 0/238 (0.00%) </s>   Cardiac arrest 0/238 (0.00%),0,Adverse Events 1: |   Total: 17/65 (26.15%) |   Febrile neutropenia 3/65 (4.62%) |   Neutropenia 2/65 (3.08%) |   Pancytopenia 1/65 (1.54%) |   Thrombocytopenia 1/65 (1.54%) |   Cardiac arrest 2/65 (3.08%) |   Myocardial infarction 1/65 (1.54%) |   Diarrhoea 5/65 (7.69%) |   Stomatitis 1/65 (1.54%) |   Vomiting 2/65 (3.08%) |   Fatigue 1/65 (1.54%) |   Jaundice 1/65 (1.54%) |   Neutropenic infection 2/65 (3.08%) | Adverse Events 1: |   Total: 173/472 (36.65%) |   Anaemia 6/472 (1.27%) |   Febrile neutropenia 4/472 (0.85%) |   Iron deficiency anaemia 1/472 (0.21%) |   Leukopenia 2/472 (0.42%) |   Neutropenia 2/472 (0.42%) |   Thrombocytopenia 4/472 (0.85%) |   Acute myocardial infarction 1/472 (0.21%) |   Aortic valve incompetence 0/472 (0.00%) |   Atrial fibrillation 2/472 (0.42%) |   Cardiac arrest 1/472 (0.21%) | Adverse Events 2: |   Total: 40/238 (16.81%) |   Anaemia 0/238 (0.00%) |   Febrile neutropenia 1/238 (0.42%) |   Iron deficiency anaemia 0/238 (0.00%) |   Leukopenia 0/238 (0.00%) |   Neutropenia 2/238 (0.84%) |   Thrombocytopenia 0/238 (0.00%) |   Acute myocardial infarction 0/238 (0.00%) |   Aortic valve incompetence 1/238 (0.42%) |   Atrial fibrillation 0/238 (0.00%) |   Cardiac arrest 0/238 (0.00%)
b1219e71-fbf5-4bba-8a93-a27ae444e3e1,b1219e71-fbf5-4bba-8a93-a27ae444e3e1,"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer","[PRIMARY] Inclusion Criteria: </s>   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women </s> Exclusion Criteria: </s>   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).",1,"Inclusion Criteria: |   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women | Exclusion Criteria: |   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed)."
f10f3b84-e039-4a02-a98b-86d149d9a16f,f10f3b84-e039-4a02-a98b-86d149d9a16f,ongoing flucytosine treatments are not permitted for participants of the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Biopsy-diagnosed breast cancer with metastasis in multiple organs </s>   Performance Status (World Health Organization :WHO) 0-2 </s>   Functions below are maintained in major organs: </s>   Leukocyte count: 4,000/mm3 to 12,000/mm3 </s>   Neutrophil count: >2,000/mm3 or more </s>   Platelet count: <100,000/mm3 or more </s>   Hemoglobin: >9.5 g/dL </s>   Total bilirubin: >1.5 mg/dL </s>   AST(GOT): within twice a normal upper value in an institution </s>   AST(GPT): within twice a normal upper value in an institution </s>   BUN: < 25 mg/dL </s>   Creatinine: within a normal upper value in the institution </s>   24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula) </s>   Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 </s>   Written informed consent will be obtained for patients for entering this study </s> Exclusion Criteria: </s>   Patients with synchronous multiple cancers </s>   Complicated with infection </s>   Fever from suspected infection </s>   Metastasis to the central nerve system </s>   A history of ischemic cardiac diseases </s>   Active gastrointestinal ulcer </s>   Severe nerve disorder </s>   Women who are potentially pregnant, pregnant, or breast-feeding </s>   Severe drug allergy </s>   Severe suppression of the bone marrow </s>   Severe renal disorder </s>   Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy) </s>   Being treated with flucytosine </s>   Complicated with the infection onset which a study doctor assesses to be inappropriate for this study",1,  Being treated with flucytosine
0ddb07ae-6e70-436d-8723-f609e59c57da,0ddb07ae-6e70-436d-8723-f609e59c57da,the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight,[PRIMARY] INTERVENTION 1:  </s>   Pralatrexate </s>   Study drug 190 mg/m^2 for 2 to 4 weeks.,0,INTERVENTION 1:  |   Pralatrexate |   Study drug 190 mg/m^2 for 2 to 4 weeks.
c10eea1a-5768-442d-ae07-20b4f8f4b583,c10eea1a-5768-442d-ae07-20b4f8f4b583,Only patients with triple negative breast cancer are eligible for the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Archival tumor samples must be obtained from primary and/or metastatic sites </s>   Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1) expression </s>   HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies </s>   Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC </s>   Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent) </s>   Progression must have occurred during or after most recent treatment for locally advanced/metastatic BC or within 6 months after completing adjuvant therapy </s>   Participants must have measurable disease that is evaluable as per RECIST v1.1 </s>   Eastern Cooperative Oncology Group Performance Status of 0 or 1 </s>   Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause </s>   Use of highly effective method of contraception as defined by the protocol </s> Exclusion Criteria: </s>   Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents </s>   Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteria </s>   Radiation therapy within 2 weeks prior to Cycle 1, Day 1 </s>   History of exposure to the cumulative doses of anthracyclines </s>   History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence </s>   Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites </s>   Participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia </s>   Current severe, uncontrolled systemic disease </s>   Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment </s>   Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus </s>   Need for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids) </s>   Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than (>) 2 weeks prior to randomization </s>   Participants with known central nervous system disease </s>   Leptomeningeal disease </s>   History of autoimmune disease </s>   Prior allogeneic stem cell or solid organ transplantation </s>   Active tuberculosis </s>   Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study </s>   Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization </s>   Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial </s>   Participants who are breastfeeding, or intending to become pregnant during the study",0,  HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies
2ef186d0-b4ab-44de-b785-a63e9e95851a,2ef186d0-b4ab-44de-b785-a63e9e95851a,most participants in the secondary trial and the primary trial did not suffer from Enterocolitis,[PRIMARY] Adverse Events 1: </s>   Total: 20/167 (11.98%) </s>   Cardiac failure acute 0/167 (0.00%) </s>   Diarrhoea 5/167 (2.99%) </s>   Colitis 2/167 (1.20%) </s>   Enterocolitis 1/167 (0.60%) </s>   Enterocolitis haemorrhagic 1/167 (0.60%) </s>   Stomatitis 1/167 (0.60%) </s>   Impaired healing 1/167 (0.60%) </s>   Sudden death 1/167 (0.60%) </s>   Postoperative wound infection 2/167 (1.20%) </s>   Erysipelas 2/167 (1.20%) </s>   Bacterial diarrhoea 1/167 (0.60%) </s> Adverse Events 2: </s>   Total: 4/167 (2.40%) </s>   Cardiac failure acute 1/167 (0.60%) </s>   Diarrhoea 0/167 (0.00%) </s>   Colitis 0/167 (0.00%) </s>   Enterocolitis 0/167 (0.00%) </s>   Enterocolitis haemorrhagic 0/167 (0.00%) </s>   Stomatitis 0/167 (0.00%) </s>   Impaired healing 0/167 (0.00%) </s>   Sudden death 0/167 (0.00%) </s>   Postoperative wound infection 1/167 (0.60%) </s>   Erysipelas 0/167 (0.00%) </s>   Bacterial diarrhoea 0/167 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 112/458 (24.45%) </s>   Febrile neutropenia 8/458 (1.75%) </s>   Neutropenia 6/458 (1.31%) </s>   Anaemia 3/458 (0.66%) </s>   Thrombocytopenia 3/458 (0.66%) </s>   Pancytopenia 2/458 (0.44%) </s>   Myocardial infarction 0/458 (0.00%) </s>   Pericardial effusion 0/458 (0.00%) </s>   Tachycardia 0/458 (0.00%) </s>   Acute myocardial infarction 1/458 (0.22%) </s>   Atrial fibrillation 0/458 (0.00%) </s> Adverse Events 2: </s>   Total: 39/221 (17.65%) </s>   Febrile neutropenia 5/221 (2.26%) </s>   Neutropenia 1/221 (0.45%) </s>   Anaemia 2/221 (0.90%) </s>   Thrombocytopenia 0/221 (0.00%) </s>   Pancytopenia 0/221 (0.00%) </s>   Myocardial infarction 2/221 (0.90%) </s>   Pericardial effusion 2/221 (0.90%) </s>   Tachycardia 2/221 (0.90%) </s>   Acute myocardial infarction 0/221 (0.00%) </s>   Atrial fibrillation 1/221 (0.45%),1,  Enterocolitis 1/167 (0.60%) |   Enterocolitis 0/167 (0.00%) | Adverse Events 1: |   Total: 112/458 (24.45%) |   Febrile neutropenia 8/458 (1.75%) |   Neutropenia 6/458 (1.31%) |   Anaemia 3/458 (0.66%) |   Thrombocytopenia 3/458 (0.66%) |   Pancytopenia 2/458 (0.44%) |   Myocardial infarction 0/458 (0.00%) |   Pericardial effusion 0/458 (0.00%) |   Tachycardia 0/458 (0.00%) |   Acute myocardial infarction 1/458 (0.22%) |   Atrial fibrillation 0/458 (0.00%) | Adverse Events 2: |   Total: 39/221 (17.65%) |   Febrile neutropenia 5/221 (2.26%) |   Neutropenia 1/221 (0.45%) |   Anaemia 2/221 (0.90%) |   Thrombocytopenia 0/221 (0.00%) |   Pancytopenia 0/221 (0.00%) |   Myocardial infarction 2/221 (0.90%) |   Pericardial effusion 2/221 (0.90%) |   Tachycardia 2/221 (0.90%) |   Acute myocardial infarction 0/221 (0.00%) |   Atrial fibrillation 1/221 (0.45%)
fef5aedb-21c0-4130-b8a3-cb1df5017c7a,fef5aedb-21c0-4130-b8a3-cb1df5017c7a,The adverse events section in the primary trial is empty,[PRIMARY] Adverse Events 1: </s>   Total: 0/0,1,Adverse Events 1: |   Total: 0/0
2655c892-216e-4b96-a8f2-6f64403215c5,2655c892-216e-4b96-a8f2-6f64403215c5,there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 4/65 (6.15%) </s>   Thrombocytopenia * 0/65 (0.00%) </s>   Anaemia * 20/65 (0.00%) </s>   Febrile neutropenia * 20/65 (0.00%) </s>   Leukopenia * 20/65 (0.00%) </s>   Neutropenia * 20/65 (0.00%) </s>   Pericardial effusion * 20/65 (0.00%) </s>   Tachycardia * 20/65 (0.00%) </s>   Nausea * 0/65 (0.00%) </s>   Vomiting * 21/65 (1.54%) </s>   Constipation * 20/65 (0.00%) </s>   Abdominal pain * 20/65 (0.00%) </s> Adverse Events 2: </s>   Total: 33/134 (24.63%) </s>   Thrombocytopenia * 10/134 (7.46%) </s>   Anaemia * 29/134 (6.72%) </s>   Febrile neutropenia * 21/134 (0.75%) </s>   Leukopenia * 21/134 (0.75%) </s>   Neutropenia * 21/134 (0.75%) </s>   Pericardial effusion * 21/134 (0.75%) </s>   Tachycardia * 21/134 (0.75%) </s>   Nausea * 5/134 (3.73%) </s>   Vomiting * 23/134 (2.24%) </s>   Constipation * 22/134 (1.49%) </s>   Abdominal pain * 21/134 (0.75%),0,Adverse Events 1: |   Total: 4/65 (6.15%) |   Thrombocytopenia * 0/65 (0.00%) |   Anaemia * 20/65 (0.00%) |   Febrile neutropenia * 20/65 (0.00%) |   Leukopenia * 20/65 (0.00%) |   Neutropenia * 20/65 (0.00%) |   Pericardial effusion * 20/65 (0.00%) |   Tachycardia * 20/65 (0.00%) |   Nausea * 0/65 (0.00%) |   Vomiting * 21/65 (1.54%) |   Constipation * 20/65 (0.00%) |   Abdominal pain * 20/65 (0.00%)
2825d63b-8f22-4fb8-829f-9567845251c6,2825d63b-8f22-4fb8-829f-9567845251c6,adults and children can take part in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Metastatic breast cancer (Stage IV) </s>   Histologically confirmed estrogen receptor positive disease </s>   Female </s>   Serum 25(OH) <30 ng/ml </s>   Age  18 years </s>   Pre or post-menopausal </s>   ECOG Performance status 0-2 </s>   Adequate organ function as defined as GFR> 30 mls/min and serum calcium  10.4 mg/dl </s>   Any race/ethnicity </s>   English speaking </s>   No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician </s>   Willingness to sign a written informed consent and complete questionnaires </s>   Cease ingestion of vitamin D supplementation not study related </s> Exclusion Criteria: </s>   Women with Stage I-III breast cancer </s>   Serum 25(OH)D levels  30 ng/ml </s>   Untreated CNS involvement </s>   History of kidney stones </s>   History of renal failure </s>   History of hyperparathyroidism </s>   History of hypersensitivity to vitamin D </s>   Non-English speaking </s>   Currently pregnant or lactating, or anticipating pregnancy </s>   Unwilling to cease ingestion of calcium supplements (>1000 mg/d) </s>   Unwilling or unable to complete informed consent or study questionnaires </s>   Psychiatric or other clinical conditions that preclude study compliance </s>   Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities",0,  Age  18 years
6b35bc10-f591-4b84-abac-40a74be949fa,6b35bc10-f591-4b84-abac-40a74be949fa,Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer </s>   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 </s>   Participants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study </s>   Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer </s>   Radiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor (AI), or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancer </s>   Measurable disease via Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1 </s>   Consent to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or a minimum of 20 (25 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue for oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing </s>   A valid cobas PIK3CA mutation result by central testing is required </s>   Adequate hematologic and end-organ function within 28 days prior to treatment initiation </s> Exclusion Criteria: </s>   Human epidermal growth factor receptor 2 (HER2)-positive disease by local laboratory testing (immunohistochemistry 3 positive [IHC 3+] staining or in situ hybridization positive) </s>   Prior treatment with fulvestrant </s>   Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor </s>   Prior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1 </s>   Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1 </s>   All acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the Investigator </s>   Prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer </s>   Concurrent hormone replacement therapy </s>   Known untreated or active central nervous system (CNS) metastases </s>   Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications </s>   History of inflammatory bowel disease or active bowel inflammation </s>   Clinically significant cardiac or pulmonary dysfunction </s>   Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus",1,"  Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor"
a5baab2c-9c32-4301-a574-4ba5a0c2eb00,a5baab2c-9c32-4301-a574-4ba5a0c2eb00,Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Women with a history of breast cancer (currently without malignant disease) </s>   Bothersome hot flashes (defined by their occurrence  28 times per week and of sufficient severity to make the patient desire therapeutic intervention) </s>   Presence of hot flashes for  30 days prior to study registration </s>   Willingness to provide the biologic specimens as required by the protocol </s>   Hormone receptor status not specified </s>   PATIENT CHARACTERISTICS: </s>   Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy </s>   Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL </s>   No women of childbearing potential or who are premenopausal </s>   Creatinine clearance > 30 mL/min </s>   Ability to complete questionnaire(s) by themselves or with assistance </s>   ECOG performance status 0 or 1 </s>   No history of allergic or other adverse reaction to magnesium </s>   No diabetes </s>   No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse) </s>   No patients who have diarrhea where magnesium might make it worse (per provider discretion) </s>   PRIOR CONCURRENT THERAPY: </s>   None of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for  28 days and must not be expected to stop the medication during the study period): </s>   Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed) </s>   Androgens </s>   Estrogens (any delivery route) </s>   Progestational agents </s>   No prior use of magnesium for hot flashes </s>   No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started > 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period) </s>   No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day) </s>   Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels </s>   No current ( 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed) [SECONDARY] Inclusion Criteria: </s>   female patients, >=18 years of age, with locally advanced breast cancer. </s> Exclusion Criteria: </s>   previous therapy for any invasive malignancy.",0,"  Presence of hot flashes for  30 days prior to study registration | Inclusion Criteria: |   female patients, >=18 years of age, with locally advanced breast cancer. | Exclusion Criteria: |   previous therapy for any invasive malignancy."
70677d5f-7022-404c-8410-d1f89366d92f,70677d5f-7022-404c-8410-d1f89366d92f,the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.,"[PRIMARY] Outcome Measurement:  </s>   Number of Patients With Pathological Complete Response Rate </s>   Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. </s>   Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization) </s> Results 1:  </s>   Arm/Group Title: Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) </s>   Arm/Group Description: Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6). </s>   Overall Number of Participants Analyzed: 98 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  35  35.7% </s> Results 2:  </s>   Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) </s>   Arm/Group Description: Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab </s>   Overall Number of Participants Analyzed: 113 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  24  21.2% [SECONDARY] Outcome Measurement:  </s>   Disease Free Survival. </s>   Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years </s>   Time frame: 8 years </s> Results 1:  </s>   Arm/Group Title: Arm 1: Clodronate </s>   Arm/Group Description: Patient receives 2 tablets once daily for 3 years. </s>   clodronate: 1600 mg PO daily </s>   Overall Number of Participants Analyzed: 1655 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  81.0 </s> Results 2:  </s>   Arm/Group Title: Arm 2: Placebo </s>   Arm/Group Description: Patient receives 2 tablets once daily for 3 years. </s>   placebo: 2 pills PO daily </s>   Overall Number of Participants Analyzed: 1656 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  79.6",0,"Outcome Measurement:  |   Number of Patients With Pathological Complete Response Rate |   Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. |   Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization) | Outcome Measurement:  |   Disease Free Survival. |   Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years |   Time frame: 8 years"
f46a7d27-a94f-4389-a1a0-4a8f5177b354,f46a7d27-a94f-4389-a1a0-4a8f5177b354,None of the individual Aes recorded in the primary trial affect more than than one patient,[PRIMARY] Adverse Events 1: </s>   Total: 18/100 (18.00%) </s>   Anaemia * 4/100 (4.00%) </s>   Febrile neutropenia * 3/100 (3.00%) </s>   Neutropenia * 1/100 (1.00%) </s>   Pancytopenia * 0/100 (0.00%) </s>   Thrombocytopenia * 1/100 (1.00%) </s>   Acute coronary syndrome * 1/100 (1.00%) </s>   Stress cardiomyopathy * 0/100 (0.00%) </s>   Abdominal pain * 0/100 (0.00%) </s>   Abdominal pain upper * 0/100 (0.00%) </s>   Ascites * 1/100 (1.00%) </s> Adverse Events 2: </s>   Total: 45/152 (29.61%) </s>   Anaemia * 0/152 (0.00%) </s>   Febrile neutropenia * 3/152 (1.97%) </s>   Neutropenia * 1/152 (0.66%) </s>   Pancytopenia * 1/152 (0.66%) </s>   Thrombocytopenia * 0/152 (0.00%) </s>   Acute coronary syndrome * 0/152 (0.00%) </s>   Stress cardiomyopathy * 1/152 (0.66%) </s>   Abdominal pain * 2/152 (1.32%) </s>   Abdominal pain upper * 2/152 (1.32%) </s>   Ascites * 0/152 (0.00%),0,Adverse Events 1: |   Total: 18/100 (18.00%) |   Anaemia * 4/100 (4.00%) |   Febrile neutropenia * 3/100 (3.00%) |   Neutropenia * 1/100 (1.00%) |   Pancytopenia * 0/100 (0.00%) |   Thrombocytopenia * 1/100 (1.00%) |   Acute coronary syndrome * 1/100 (1.00%) |   Stress cardiomyopathy * 0/100 (0.00%) |   Abdominal pain * 0/100 (0.00%) |   Abdominal pain upper * 0/100 (0.00%) |   Ascites * 1/100 (1.00%)
fe876bb0-7ce3-4197-81ad-920f1f77938e,fe876bb0-7ce3-4197-81ad-920f1f77938e,there is a minimal difference between the results from the two the primary trial cohorts,"[PRIMARY] Outcome Measurement:  </s>   Event-free Survival </s>   Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. </s>   Time frame: 5 years </s> Results 1:  </s>   Arm/Group Title: Exemestane </s>   Arm/Group Description: Patients receive oral exemestane (25 mg) once daily for 5 years. </s>   exemestane: Given orally </s>   Overall Number of Participants Analyzed: 3789 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  88        (87 to 89) </s> Results 2:  </s>   Arm/Group Title: Anastrozole </s>   Arm/Group Description: Patients receive oral anastrozole (1 mg) once daily for 5 years. </s>   anastrozole: Given orally </s>   Overall Number of Participants Analyzed: 3787 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  89        (88 to 90)",1,"Outcome Measurement:  |   Event-free Survival |   Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. |   Time frame: 5 years | Results 1:  |   Arm/Group Title: Exemestane |   Arm/Group Description: Patients receive oral exemestane (25 mg) once daily for 5 years. |   exemestane: Given orally |   Overall Number of Participants Analyzed: 3789 |   Measure Type: Number |   Unit of Measure: percentage of participants  88        (87 to 89) | Results 2:  |   Arm/Group Title: Anastrozole |   Arm/Group Description: Patients receive oral anastrozole (1 mg) once daily for 5 years. |   anastrozole: Given orally |   Overall Number of Participants Analyzed: 3787 |   Measure Type: Number |   Unit of Measure: percentage of participants  89        (88 to 90)"
f45ff82d-e0f5-456a-9d78-ddc2dc6ab929,f45ff82d-e0f5-456a-9d78-ddc2dc6ab929,"to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.","[PRIMARY] Inclusion Criteria: </s>   Written informed consent </s>   Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk criteria according to St. Gallen consensus criteria. </s>   Histologically proven breast cancer. Interval between surgery and registration is less than 60 days. </s>   Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin. </s>   Patients without proven metastatic disease. </s>   Estrogen and progesterone receptors performed on the primary tumour prior to randomization. </s>   Age between 18 years and 70 years. </s>   Karnofsky performance status index > 80 %. </s>   Adequate hepatic, renal and heart functions. </s>   Adequate hematology levels. </s>   Negative pregnancy test </s> Exclusion Criteria: </s>   Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy). </s>   Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy. </s>   Prior radiation therapy for breast cancer. </s>   Bilateral invasive breast cancer. </s>   Pregnant, or lactating patients. </s>   Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment . </s>   Any T4 or N1-3 or M1 breast cancer. </s>   Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria. </s>   Other serious illness or medical condition </s>   Past or current history of neoplasm other than breast carcinoma. </s>   Ipsilateral ductal carcinoma in-situ (DCIS) of the breast. </s>   Lobular carcinoma in-situ (LCIS) of the breast. </s>   Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose </s>   Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry. </s>   Definite contraindications for the use of corticosteroids. </s>   Concurrent treatment with other experimental drugs. </s>   Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry. </s>   Concurrent treatment with any other anti-cancer therapy. </s> Male patients.",0,"  Age between 18 years and 70 years. |   Karnofsky performance status index > 80 %. |   Adequate hepatic, renal and heart functions. |   Adequate hematology levels."
4f705481-5dd0-414c-b375-c56e8c235b42,4f705481-5dd0-414c-b375-c56e8c235b42,The most common adverse event in the primary trial was skin infection,"[PRIMARY] Adverse Events 1: </s>   Total: 14/41 (34.15%) </s>   Anemia 1/41 (2.44%) </s>   Febrile neutropenia 1/41 (2.44%) </s>   Eye disorders - Other, Visual disturbance 1/41 (2.44%) </s>   Abdominal pain 1/41 (2.44%) </s>   Constipation 1/41 (2.44%) </s>   Nausea 1/41 (2.44%) </s>   Fever 1/41 (2.44%) </s>   Pain 1/41 (2.44%) </s>   Skin infection 2/41 (4.88%) </s>   Alkaline phosphatase increased 1/41 (2.44%) </s>   Aspartate aminotransferase increased 1/41 (2.44%)",1,"Adverse Events 1: |   Total: 14/41 (34.15%) |   Anemia 1/41 (2.44%) |   Febrile neutropenia 1/41 (2.44%) |   Eye disorders - Other, Visual disturbance 1/41 (2.44%) |   Abdominal pain 1/41 (2.44%) |   Constipation 1/41 (2.44%) |   Nausea 1/41 (2.44%) |   Fever 1/41 (2.44%) |   Pain 1/41 (2.44%) |   Skin infection 2/41 (4.88%) |   Alkaline phosphatase increased 1/41 (2.44%) |   Aspartate aminotransferase increased 1/41 (2.44%)"
614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2,614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2,"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",[PRIMARY] Adverse Events 1: </s>   Total: 11/56 (19.64%) </s>   Febrile Neutropenia * 3/56 (5.36%) </s>   Neutropenia * 1/56 (1.79%) </s>   Pancytopenia * 1/56 (1.79%) </s>   Atrial Fibrillation * 1/56 (1.79%) </s>   Coronary Artery Disease * 1/56 (1.79%) </s>   Constipation * 1/56 (1.79%) </s>   Chest Pain * 1/56 (1.79%) </s>   Non-Cardiac Chest Pain * 1/56 (1.79%) </s>   Edema due to Cardiac Disease * 1/56 (1.79%) </s>   Cellulitis * 1/56 (1.79%),0,Adverse Events 1: |   Total: 11/56 (19.64%) |   Febrile Neutropenia * 3/56 (5.36%) |   Neutropenia * 1/56 (1.79%) |   Pancytopenia * 1/56 (1.79%) |   Atrial Fibrillation * 1/56 (1.79%) |   Coronary Artery Disease * 1/56 (1.79%) |   Constipation * 1/56 (1.79%) |   Chest Pain * 1/56 (1.79%) |   Non-Cardiac Chest Pain * 1/56 (1.79%) |   Edema due to Cardiac Disease * 1/56 (1.79%) |   Cellulitis * 1/56 (1.79%)
c09fa61c-967a-40ae-96b0-c87b7cde237b,c09fa61c-967a-40ae-96b0-c87b7cde237b,None of the individual Aes recorded in the primary trial affect more than 10% of the population.,[PRIMARY] Adverse Events 1: </s>   Total: 18/100 (18.00%) </s>   Anaemia * 4/100 (4.00%) </s>   Febrile neutropenia * 3/100 (3.00%) </s>   Neutropenia * 1/100 (1.00%) </s>   Pancytopenia * 0/100 (0.00%) </s>   Thrombocytopenia * 1/100 (1.00%) </s>   Acute coronary syndrome * 1/100 (1.00%) </s>   Stress cardiomyopathy * 0/100 (0.00%) </s>   Abdominal pain * 0/100 (0.00%) </s>   Abdominal pain upper * 0/100 (0.00%) </s>   Ascites * 1/100 (1.00%) </s> Adverse Events 2: </s>   Total: 45/152 (29.61%) </s>   Anaemia * 0/152 (0.00%) </s>   Febrile neutropenia * 3/152 (1.97%) </s>   Neutropenia * 1/152 (0.66%) </s>   Pancytopenia * 1/152 (0.66%) </s>   Thrombocytopenia * 0/152 (0.00%) </s>   Acute coronary syndrome * 0/152 (0.00%) </s>   Stress cardiomyopathy * 1/152 (0.66%) </s>   Abdominal pain * 2/152 (1.32%) </s>   Abdominal pain upper * 2/152 (1.32%) </s>   Ascites * 0/152 (0.00%),1,Adverse Events 1: |   Total: 18/100 (18.00%) |   Anaemia * 4/100 (4.00%) |   Febrile neutropenia * 3/100 (3.00%) |   Neutropenia * 1/100 (1.00%) |   Pancytopenia * 0/100 (0.00%) |   Thrombocytopenia * 1/100 (1.00%) |   Acute coronary syndrome * 1/100 (1.00%) |   Stress cardiomyopathy * 0/100 (0.00%) |   Abdominal pain * 0/100 (0.00%) |   Abdominal pain upper * 0/100 (0.00%) |   Ascites * 1/100 (1.00%)
4309860d-042d-45a4-8a0a-a9fdd075247a,4309860d-042d-45a4-8a0a-a9fdd075247a,Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion,"[PRIMARY] INTERVENTION 1:  </s>   NKTR-102 </s>   In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. </s> INTERVENTION 2:  </s>   Treatment of Physician's Choice (TPC) </s>   In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.",0,"INTERVENTION 1:  |   NKTR-102 |   In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. | INTERVENTION 2:  |   Treatment of Physician's Choice (TPC) |   In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel."
f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85,f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85,the primary trial and the secondary trial use identical outcome measurements,"[PRIMARY] Outcome Measurement:  </s>   Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants </s>   Number of participants experiencing CR, PR or SD as defined by Response Evaluation Criteria In Solid Tumors (RECIST). Response is anyone who experiences SD, CR or PR in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. No symptoms or evidence of residual invasive tumor, including no residual tumor in axillary lymph nodes. PR: 50%/> decrease for minimum 4 weeks in measurable lesion determined by product of perpendicular diameters of lesion. Every lesion should not regress to qualify as PR; however, if lesion progresses or if new lesions appear, response cannot be classified as PR. Minor Response [MR]: Decreases in tumor masses insufficient to qualify as partial remission, i.e. <50%. SD: Between MR & PD. PD: Increase 25% measured lesion from baseline. New lesions constitutes increasing disease. Mixed responses consid </s>   Time frame: 6 months </s> Results 1:  </s>   Arm/Group Title: Dovitinib </s>   Arm/Group Description: Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle. </s>   Overall Number of Participants Analyzed: 19 </s>   Measure Type: Number </s>   Unit of Measure: participants  Complete Response (CR): 0 </s>   Partial Response (PR): 0 </s>   Stable Disease (SD): 1 [SECONDARY] Outcome Measurement:  </s>   Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants) </s>   pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes. </s>   Time frame: Surgery visit (at approximately Weeks 14 to 19) </s> Results 1:  </s>   Arm/Group Title: Ipatasertib + Paclitaxel </s>   Arm/Group Description: Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). </s>   Overall Number of Participants Analyzed: 76 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  17.1        (9.82 to 27.25) </s> Results 2:  </s>   Arm/Group Title: Placebo + Paclitaxel </s>   Arm/Group Description: Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses). </s>   Overall Number of Participants Analyzed: 75 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  13.3        (6.58 to 22.86)",0,"Outcome Measurement:  |   Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants |   Number of participants experiencing CR, PR or SD as defined by Response Evaluation Criteria In Solid Tumors (RECIST). Response is anyone who experiences SD, CR or PR in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. No symptoms or evidence of residual invasive tumor, including no residual tumor in axillary lymph nodes. PR: 50%/> decrease for minimum 4 weeks in measurable lesion determined by product of perpendicular diameters of lesion. Every lesion should not regress to qualify as PR; however, if lesion progresses or if new lesions appear, response cannot be classified as PR. Minor Response [MR]: Decreases in tumor masses insufficient to qualify as partial remission, i.e. <50%. SD: Between MR & PD. PD: Increase 25% measured lesion from baseline. New lesions constitutes increasing disease. Mixed responses consid |   Time frame: 6 months | Outcome Measurement:  |   Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants) |   pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes. |   Time frame: Surgery visit (at approximately Weeks 14 to 19)"
59cd7909-00c3-4c23-9a08-a42dbc8eabdd,59cd7909-00c3-4c23-9a08-a42dbc8eabdd,"Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression","[PRIMARY] INTERVENTION 1:  </s>   Abraxane, Avastin and Gemcitabine </s>   Each treatment cycle is 28 days. Participants will be treated until disease progression: </s>   Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; </s>   Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; </s>   Avastin: 10 mg/kg IV on days 1 and 15 of each cycle.",1,"INTERVENTION 1:  |   Abraxane, Avastin and Gemcitabine |   Each treatment cycle is 28 days. Participants will be treated until disease progression: |   Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; |   Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; |   Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
e6a4e9a6-56b8-4a30-9743-eb02688c090f,e6a4e9a6-56b8-4a30-9743-eb02688c090f,"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm","[PRIMARY] Inclusion Criteria: </s>   Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria. </s>   Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules </s>   Subjects must be of female gender and >= 18 years of age </s>   Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics: </s>   node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR </s>   node-negative AND at least one of the following features: </s>   Tumor >2 cm or </s>   Tumor >1 cm and </s>   Negative estrogen receptor/progesterone receptor (ER/PR) or </s>   Malignancy Grade 2-3 or </s>   Presence of peritumoral vascular invasion or </s>   Age <35 years </s>   HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using </s>   immunohistochemistry </s>   Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s]) </s>   Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55% </s>   Easter Cooperative Oncology Group (ECOG)-performance status of 0-1 </s>   Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN) </s>   Adequate renal function: calculated creatinine clearance >=50 ml/min </s>   Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN </s>   Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations </s>   Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening </s>   Subjects must be able to provide written informed consent </s> Exclusion Criteria: </s>   Subject who meets any of the following exclusion criteria will be disqualified from participation in the study: </s>   Clinical or radiological evidence of metastatic disease </s>   Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization </s>   Clinically significant pericardial effusion </s>   Serious cardiac illness including, but not confined to </s>   history of documented congestive heart failure </s>   history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy </s>   history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication </s>   serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias </s>   clinically significant valvular disease </s>   poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg) </s>   Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC) </s>   Pregnancy, or intending to become pregnant during the study </s>   Nursing (breastfeeding) or intending to be nursing during the study </s>   Any of the following clinical conditions: </s>   Chronic obstructive pulmonary disease, requiring chronic treatment </s>   Clinically significant active infections </s>   A history of a psychological illness of condition, preventing the subject to understand the requirements of the study </s>   Unstable regulation of diabetes mellitus </s>   A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study </s>   Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study </s>   Usage of any investigational product within 30 days prior to enrollment </s>   Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study. </s>   Allergy to or sensitivity to the study drug or its excipients",1,"  node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR |   node-negative AND at least one of the following features: |   Tumor >2 cm or |   Tumor >1 cm and"
82a3e542-f784-44d7-90f6-34d7e969283c,82a3e542-f784-44d7-90f6-34d7e969283c,the primary trial participants receive more than one type of medication during the study,[PRIMARY] INTERVENTION 1:  </s>   Avastin (Bevacizumab) Plus Hormone </s>   All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.,1,INTERVENTION 1:  |   Avastin (Bevacizumab) Plus Hormone |   All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.
fb360514-14be-45ab-8b74-ea5a7eb181d7,fb360514-14be-45ab-8b74-ea5a7eb181d7,the primary trial and the secondary trial do not report adverse events,[PRIMARY] Adverse Events 1: </s>   Total: 0/23 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 0/655 (0.00%) </s> Adverse Events 2: </s>   Total: 0/580 (0.00%),1,Adverse Events 1: |   Total: 0/23 (0.00%) | Adverse Events 1: |   Total: 0/655 (0.00%) | Adverse Events 2: |   Total: 0/580 (0.00%)
7137dec6-5c98-4156-8035-7bbaaf0b649d,7137dec6-5c98-4156-8035-7bbaaf0b649d,ECOG score < 2 is necessary to be eligible for the primary trial,"[PRIMARY] Inclusion criteria: </s>   Histologically confirmed diagnosis of HER2-overexpression breast cancer </s>   Stage IV metastatic disease </s>   Must have progressed on one prior trastuzumab treatment </s>   no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line) </s>   Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer </s>   Must have (archived) tumour tissue sample available for central re-assessment of HER2-status </s>   At least one measurable lesion according to RECIST 1.1. </s>   Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 . </s> Exclusion criteria: </s>   Prior treatment with Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor(EGFR/HER2)-targeted small molecules or antibodies other than trastuzumab </s>   Prior treatment with vinorelbine </s>   Known pre-existing interstitial lung disease </s>   Active brain metastases </s>   History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation. </s>   Cardiac left ventricular function with resting ejection fraction of less than 50%. </s>   Patients unable to comply with the protocol. </s>   Any contraindications for therapy with vinorelbine or trastuzumab. </s>   Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs. </s>   Use of any investigational drug within 4 weeks of randomisation. </s>   Inadequate hepatic, renal and haematologic organ function",1,  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 .
015dd869-db90-45a9-a951-9dc7dc2b2e01,015dd869-db90-45a9-a951-9dc7dc2b2e01,patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial,[PRIMARY] Inclusion Criteria: </s>   Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel). </s>   Less than 3 different chemotherapy treatments for metastatic disease. </s>   Prior treatment with hormonal and/or radiation therapy. </s>   Must have disease that can be measured. </s>   Must be able to take care of self needs for example personal hygiene </s> Exclusion Criteria: </s>   Must not be pregnant or breast-feeding. </s>   Cancer that has spread to the brain. </s>   Treatment with Gemcitabine or Pemetrexed </s>   Unable to take folic acid or Vitamin B12 </s>   Treatment for another cancer within the last 5 years,0,  Cancer that has spread to the brain.
3a4003f6-ff1c-43d8-be48-f767266b2cf5,3a4003f6-ff1c-43d8-be48-f767266b2cf5,the secondary trial and the primary trial do not have the same inclusion and exclusion conditions,"[PRIMARY] Inclusion Criteria: </s>   Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC. </s>   For the phase I portion, patients with any ER/PR/HER2 disease status, no longer eligible for hormonal therapy or HER2-targeted therapy, will be eligible. </s>   For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status. Patients with any ER/PR disease status are eligible. </s>   A paraffin-embedded tissue block or unstained slides from prior surgery must be available. </s>   Evidence of recurrent or progressive locally advanced or metastatic breast cancer. </s>   Presence of: </s>   For the phase I portion: at least one evaluable or measurable metastatic lesion , </s>   For the phase II portion: at least one measurable metastatic lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable. Minimum indicator lesion size: > or = to 10 mm measured by spiral CT or > or = to 20 mm measured by conventional techniques. </s>   Prior therapies: </s>   For the phase I portion: Any number of prior endocrine or biologic therapies is permitted . In addition, patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. </s>   For the phase II portion: 0-2 prior therapies for metastatic disease are allowed. </s>   Prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be permitted. Prior therapy with bevacizumab will be allowed. All previous chemotherapy, radiotherapy and intravenous biphosphonates must have been discontinued at least 3 weeks prior to study entry, 3 weeks also for trastuzumab and bevacizumab. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTC (Version 3) Grade 1. </s>   Endocrine therapy with an aromatase inhibitor, SERM (ie, tamoxifen) or fulvestrant is permitted, however it must be discontinued before enrolling in the study. </s>   ECOG performance status of 0 or 1. </s>   Age > or = to 18 years old. Adequate Organ Function </s>   Total bilirubin  1.5 times the institutional Upper Limit of Normal (ULN) </s>   Hepatic enzymes (AST, ALT )  2.5 times the institutional ULN </s>   Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN) </s>   Serum Creatinine  1.5 time the institutional ULN </s>   Neutrophil count, Platelets, both Grade 0-1 </s>   PT (INR) and PTT Grade 0-1, except for patients on Coumadin or low molecular weight heparin </s>   Ability to take oral medication (dasatinib must be swallowed whole) </s>   Concomitant Medications: </s>   Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy </s>   Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia. Concomitant Medications, any of the following should be considered for exclusion: </s>   Patient agrees to discontinue QT-prolonging agents strongly associated with Torsades de Pointes including: (patients must discontinue drug  7 days prior to starting dasatinib) such as: </s>   quinidine, procainamide, disopyramide </s>   amiodarone, sotalol, ibutilide, dofetilide </s>   erythromycin, clarithromycin </s>   chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide </s>   cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. </s>   The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not recommended. The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. </s>   Patient may not be receiving any potent CYP3A4 inhibitors. These are prohibited (patients must discontinue drug 7 days prior to starting dasatinib) and include: </s>   itraconazole, ketoconazole, miconazole, coriconazole </s>   amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir </s>   ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid </s>   ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin </s>   Women of childbearing potential (WOCBP) must have: </s>   A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration </s>   Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped </s>   Pregnant or nursing women may not participate. Patients of reproductive potential may not participate unless they have agreed to use an effective method of contraception and to continue contraception for 30 days from the date of the last study drug administration. Postmenopausal woman must be amenorrheic for at least 12 months to be considered of non-childbearing potential. </s>   Signed written informed consent including a HIPAA form according to institutional guidelines. </s> Exclusion Criteria: </s>   Life expectancy < 3 months. </s>   Prior severe allergic reaction to paclitaxel therapy. </s>   Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4). </s>   Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment. </s>   Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be discontinued > or = to 3 weeks from the start of protocol treatment. </s>   Concurrent medical condition which may increase the risk of toxicity. </s>   Patients may not have any clinically significant cardiovascular disease including the following: </s>   myocardial infarction or ventricular tachyarrhythmia within 6 months </s>   prolonged QTc >480 msec (Fridericia correction) </s>   ejection fraction less than institutional normal </s>   major conduction abnormality (unless a cardiac pacemaker is present) </s>   Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation. The patient may be referred to a cardiologist at the discretion of the principal investigator. Patients with underlying cardiopulmonary dysfunction should be excluded from the study. </s>   Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration </s>   History of significant bleeding disorder unrelated to cancer, including: </s>   Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) </s>   Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII antibodies) </s>   Ongoing or recent ( 3 months) significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk. </s>   Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. </s>   History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake. </s>   Presence of uncontrolled gastrointestinal malabsorption syndrome. </s>   Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial. </s>   Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might allowed for pre-existing non-target lesions with approval from the principal investigator of the trial. </s>   Patients with > Grade 1 neuropathy will be excluded form this trial. [SECONDARY] Inclusion criteria: </s>   Signed Informed Consent </s>   ErbB2(HER2)overexpressing breast cancer. </s>   Brain lesion(s) which are progressing. </s>   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). </s>   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. </s>   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. </s>   Able to swallow an oral medication. </s>   Adequate kidney and liver function. </s>   Adequate bone marrow function. </s> Exclusion criteria: </s>   Pregnant or lactating females. </s>   Conditions that would effect the absorption of an oral drug. </s>   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. </s>   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. </s>   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.",1,"Inclusion Criteria: |   Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC. |   For the phase I portion, patients with any ER/PR/HER2 disease status, no longer eligible for hormonal therapy or HER2-targeted therapy, will be eligible. |   For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status. Patients with any ER/PR disease status are eligible. |   A paraffin-embedded tissue block or unstained slides from prior surgery must be available. |   Evidence of recurrent or progressive locally advanced or metastatic breast cancer. |   Presence of: |   For the phase I portion: at least one evaluable or measurable metastatic lesion , |   For the phase II portion: at least one measurable metastatic lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable. Minimum indicator lesion size: > or = to 10 mm measured by spiral CT or > or = to 20 mm measured by conventional techniques. |   Prior therapies: |   For the phase I portion: Any number of prior endocrine or biologic therapies is permitted . In addition, patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. |   For the phase II portion: 0-2 prior therapies for metastatic disease are allowed. |   Prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be permitted. Prior therapy with bevacizumab will be allowed. All previous chemotherapy, radiotherapy and intravenous biphosphonates must have been discontinued at least 3 weeks prior to study entry, 3 weeks also for trastuzumab and bevacizumab. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTC (Version 3) Grade 1. |   Endocrine therapy with an aromatase inhibitor, SERM (ie, tamoxifen) or fulvestrant is permitted, however it must be discontinued before enrolling in the study. |   ECOG performance status of 0 or 1. |   Age > or = to 18 years old. Adequate Organ Function |   Total bilirubin  1.5 times the institutional Upper Limit of Normal (ULN) |   Hepatic enzymes (AST, ALT )  2.5 times the institutional ULN |   Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN) |   Serum Creatinine  1.5 time the institutional ULN |   Neutrophil count, Platelets, both Grade 0-1 |   PT (INR) and PTT Grade 0-1, except for patients on Coumadin or low molecular weight heparin |   Ability to take oral medication (dasatinib must be swallowed whole) |   Concomitant Medications: |   Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy |   Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia. Concomitant Medications, any of the following should be considered for exclusion: |   Patient agrees to discontinue QT-prolonging agents strongly associated with Torsades de Pointes including: (patients must discontinue drug  7 days prior to starting dasatinib) such as: |   quinidine, procainamide, disopyramide |   amiodarone, sotalol, ibutilide, dofetilide |   erythromycin, clarithromycin |   chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide |   cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. |   The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not recommended. The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. |   Patient may not be receiving any potent CYP3A4 inhibitors. These are prohibited (patients must discontinue drug 7 days prior to starting dasatinib) and include: |   itraconazole, ketoconazole, miconazole, coriconazole |   amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir |   ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid |   ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin |   Women of childbearing potential (WOCBP) must have: |   A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration |   Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped |   Pregnant or nursing women may not participate. Patients of reproductive potential may not participate unless they have agreed to use an effective method of contraception and to continue contraception for 30 days from the date of the last study drug administration. Postmenopausal woman must be amenorrheic for at least 12 months to be considered of non-childbearing potential. |   Signed written informed consent including a HIPAA form according to institutional guidelines. | Exclusion Criteria: |   Life expectancy < 3 months. |   Prior severe allergic reaction to paclitaxel therapy. |   Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4). |   Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment. |   Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be discontinued > or = to 3 weeks from the start of protocol treatment. |   Concurrent medical condition which may increase the risk of toxicity. |   Patients may not have any clinically significant cardiovascular disease including the following: |   myocardial infarction or ventricular tachyarrhythmia within 6 months |   prolonged QTc >480 msec (Fridericia correction) |   ejection fraction less than institutional normal |   major conduction abnormality (unless a cardiac pacemaker is present) |   Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation. The patient may be referred to a cardiologist at the discretion of the principal investigator. Patients with underlying cardiopulmonary dysfunction should be excluded from the study. |   Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration |   History of significant bleeding disorder unrelated to cancer, including: |   Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) |   Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII antibodies) |   Ongoing or recent ( 3 months) significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk. |   Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. |   History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake. |   Presence of uncontrolled gastrointestinal malabsorption syndrome. |   Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial. |   Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might allowed for pre-existing non-target lesions with approval from the principal investigator of the trial. |   Patients with > Grade 1 neuropathy will be excluded form this trial. | Inclusion criteria: |   Signed Informed Consent |   ErbB2(HER2)overexpressing breast cancer. |   Brain lesion(s) which are progressing. |   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). |   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. |   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. |   Able to swallow an oral medication. |   Adequate kidney and liver function. |   Adequate bone marrow function. | Exclusion criteria: |   Pregnant or lactating females. |   Conditions that would effect the absorption of an oral drug. |   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. |   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. |   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent."
47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7,47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7,"at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months","[PRIMARY] Outcome Measurement:  </s>   Progression-Free Survival (PFS) </s>   Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions </s>   Time frame: every 8 weeks until progressive disease, expected average of 18 months </s> Results 1:  </s>   Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus </s>   Arm/Group Description: Systemic Therapy </s>   Overall Number of Participants Analyzed: 56 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  9.1        (6.8 to 10.8) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel/Bevacizumab/Placebo </s>   Arm/Group Description: Systemic Therapy </s>   Overall Number of Participants Analyzed: 57 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.1        (5.6 to 10.8)",1,"Outcome Measurement:  |   Progression-Free Survival (PFS) |   Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |   Time frame: every 8 weeks until progressive disease, expected average of 18 months | Results 1:  |   Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus |   Arm/Group Description: Systemic Therapy |   Overall Number of Participants Analyzed: 56 |   Median (95% Confidence Interval) |   Unit of Measure: months  9.1        (6.8 to 10.8) | Results 2:  |   Arm/Group Title: Paclitaxel/Bevacizumab/Placebo |   Arm/Group Description: Systemic Therapy |   Overall Number of Participants Analyzed: 57 |   Median (95% Confidence Interval) |   Unit of Measure: months  7.1        (5.6 to 10.8)"
f3cb9150-32c6-4877-9a87-4fac45a24948,f3cb9150-32c6-4877-9a87-4fac45a24948,"Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial","[PRIMARY] Adverse Events 1: </s>   Total: 0/34 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 6/62 (9.68%) </s>   Musculoskeletal * 1/62 (1.61%) </s>   Mood Alteration: Depression * 1/62 (1.61%) </s>   renal - Other * 1/62 (1.61%) </s>   Obstruction, GU: Uterus * 1/62 (1.61%) </s>   Sexual * 0/62 (0.00%) </s>   Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) </s>   Ulceration * 1/62 (1.61%) </s> Adverse Events 2: </s>   Total: 1/64 (1.56%) </s>   Musculoskeletal * 0/64 (0.00%) </s>   Mood Alteration: Depression * 0/64 (0.00%) </s>   renal - Other * 0/64 (0.00%) </s>   Obstruction, GU: Uterus * 0/64 (0.00%) </s>   Sexual * 1/64 (1.56%) </s>   Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) </s>   Ulceration * 0/64 (0.00%)",0,"Adverse Events 1: |   Total: 0/34 (0.00%) | Adverse Events 1: |   Total: 6/62 (9.68%) |   Musculoskeletal * 1/62 (1.61%) |   Mood Alteration: Depression * 1/62 (1.61%) |   renal - Other * 1/62 (1.61%) |   Obstruction, GU: Uterus * 1/62 (1.61%) |   Sexual * 0/62 (0.00%) |   Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) |   Ulceration * 1/62 (1.61%) | Adverse Events 2: |   Total: 1/64 (1.56%) |   Musculoskeletal * 0/64 (0.00%) |   Mood Alteration: Depression * 0/64 (0.00%) |   renal - Other * 0/64 (0.00%) |   Obstruction, GU: Uterus * 0/64 (0.00%) |   Sexual * 1/64 (1.56%) |   Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) |   Ulceration * 0/64 (0.00%)"
9d8b26d6-d574-4717-88b6-77458bc683f3,9d8b26d6-d574-4717-88b6-77458bc683f3,Syncope was the most common adverse event recorded in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 5/55 (9.09%) </s>   Infection 2/55 (3.64%) </s>   Pain * 1/55 (1.82%) </s>   Muscle Weakness * 1/55 (1.82%) </s>   Dyspnea 1/55 (1.82%),0,Adverse Events 1: |   Total: 5/55 (9.09%) |   Infection 2/55 (3.64%) |   Pain * 1/55 (1.82%) |   Muscle Weakness * 1/55 (1.82%) |   Dyspnea 1/55 (1.82%)
51be7c95-8da4-419c-950c-91ebdd2c3fe5,51be7c95-8da4-419c-950c-91ebdd2c3fe5,All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial,"[PRIMARY] INTERVENTION 1:  </s>   BKM120 and Paclitaxel </s>   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel </s> INTERVENTION 2:  </s>   Placebo and Paclitaxel </s>   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel [SECONDARY] INTERVENTION 1:  </s>   Active Breathing Coordinator </s>   Patients breathe through the ABC device </s>   Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.",0,"INTERVENTION 1:  |   BKM120 and Paclitaxel |   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel | INTERVENTION 2:  |   Placebo and Paclitaxel |   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel | INTERVENTION 1:  |   Active Breathing Coordinator |   Patients breathe through the ABC device |   Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms."
07042b0f-d422-49c3-8d53-81319927a4b3,07042b0f-d422-49c3-8d53-81319927a4b3,"all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial","[PRIMARY] Inclusion Criteria: </s>   Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging </s>   Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned. </s>   Patients must have completed definitive resection of primary tumor with adequate excision of gross disease. </s>   For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy. </s>   Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy. </s>   LVEF > institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment. </s>   ECOG performance status 0-1 </s> Exclusion Criteria: </s>   Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment </s>   Patients with metastatic disease are ineligible. </s>   Known HIV infection </s>   Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding </s>   Uncontrolled intercurrent illness </s>   Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment </s>   History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab </s>   Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded </s>   History of bleeding diathesis or coagulopathy </s>   History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites) </s>   Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer </s>   Patients with large or rapidly accumulating pleural or abdominal effusions </s>   Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR </s>   Chronic therapy with full dose aspirin (< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed </s>   Patients may not receive other investigational agents while on study [SECONDARY] Inclusion Criteria: </s>   For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com </s>   Patients with metastatic or advanced solid tumors </s>   Women with histologically or cytologically confirmed triple negative breast carcinoma </s>   Participants with histologically or cytologically confirmed pancreatic adenocarcinoma </s>   Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) </s> Exclusion Criteria: </s>   Active brain metastases or leptomeningeal metastases. </s>   Any serious or uncontrolled medical disorder </s>   Prior malignancy active within the previous 3 years </s>   Other protocol defined inclusion/exclusion criteria could apply",1,"  Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging | Inclusion Criteria: |   For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com |   Patients with metastatic or advanced solid tumors |   Women with histologically or cytologically confirmed triple negative breast carcinoma |   Participants with histologically or cytologically confirmed pancreatic adenocarcinoma |   Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) | Exclusion Criteria: |   Active brain metastases or leptomeningeal metastases. |   Any serious or uncontrolled medical disorder |   Prior malignancy active within the previous 3 years |   Other protocol defined inclusion/exclusion criteria could apply"
32361e21-ee57-4c34-9390-833ba5048a10,32361e21-ee57-4c34-9390-833ba5048a10,the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally,"[PRIMARY] INTERVENTION 1:  </s>   Fulvestrant + Everolimus </s>   Fulvestrant + Everolimus </s>   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.",0,"INTERVENTION 1:  |   Fulvestrant + Everolimus |   Fulvestrant + Everolimus |   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
88668508-dfd4-4a39-91cd-cf1654a6dfc4,88668508-dfd4-4a39-91cd-cf1654a6dfc4,"the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",[PRIMARY] Outcome Measurement:  </s>   Local Control Using Ipsilateral Breast Tumor Recurrence Rates </s>   [Not Specified] </s>   Time frame: 2 years after treatment completion </s> Results 1:  </s>   Arm/Group Title: Accelerated Partial Breast Brachytherapy </s>   Arm/Group Description: Each patient will receive accelerated partial breast brachytherapy with multiple plane implant. </s>   Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions. </s>   Overall Number of Participants Analyzed: 151 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  .7,0,Outcome Measurement:  |   Local Control Using Ipsilateral Breast Tumor Recurrence Rates |   [Not Specified] |   Time frame: 2 years after treatment completion
dca4c9f7-bb2a-4f73-b390-93b7ced87c73,dca4c9f7-bb2a-4f73-b390-93b7ced87c73,The results from the secondary trial and the primary trial are non-comparable,"[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Complete Pathologic Response. </s>   Pathologic complete response (pCR): Absence of invasive breast cancer in the breast (mastectomy or lumpectomy) specimen at the time of definitive surgery. Presence of in situ cancer alone will be considered a pCR. </s>   Although clinical examination is the primary method of determining response, radiologic assessments (mammogram, ultrasound ± MRI) may be used to confirm response/non-response. </s>   Time frame: assess at 8 weeks </s> Results 1:  </s>   Arm/Group Title: Trastuzumab and Abraxane Followed Trastuzumab and Vinorelbine </s>   Arm/Group Description: Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta  ) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52. </s>   Overall Number of Participants Analyzed: 27 </s>   Measure Type: Number </s>   Unit of Measure: participants  13 [SECONDARY] Outcome Measurement:  </s>   Change in Masood Score </s>   Change in the semi-quantitative score assigned by the designated cytopathologist. </s>   Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4. </s>   Time frame: Baseline to 6 months </s> Results 1:  </s>   Arm/Group Title: Placebo </s>   Arm/Group Description: Placebo </s>   Placebo: matched tablet dialy </s>   Overall Number of Participants Analyzed: 84 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  -1.1         (1.9) </s> Results 2:  </s>   Arm/Group Title: Arzoxifene </s>   Arm/Group Description: LY353381, 20 mg daily </s>   arzoxifene: one tablet daily </s>   Overall Number of Participants Analyzed: 82 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  -0.8         (2.1)",1,"Outcome Measurement:  |   Number of Participants With Complete Pathologic Response. |   Pathologic complete response (pCR): Absence of invasive breast cancer in the breast (mastectomy or lumpectomy) specimen at the time of definitive surgery. Presence of in situ cancer alone will be considered a pCR. |   Although clinical examination is the primary method of determining response, radiologic assessments (mammogram, ultrasound ± MRI) may be used to confirm response/non-response. |   Time frame: assess at 8 weeks | Outcome Measurement:  |   Change in Masood Score |   Change in the semi-quantitative score assigned by the designated cytopathologist. |   Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4. |   Time frame: Baseline to 6 months"
e7604382-09cd-43b4-998f-a51b33f25c5a,e7604382-09cd-43b4-998f-a51b33f25c5a,the primary trial and the secondary trial participants do not receive any medication orally,[PRIMARY] INTERVENTION 1:  </s>   Intraductal Arm </s>   Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. [SECONDARY] INTERVENTION 1:  </s>   Cetuximab </s>   Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II. </s>   cetuximab: Given IV </s> INTERVENTION 2:  </s>   Cetuximab and Carboplatin After Cetuximab Alone </s>   Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab + carboplatin,1,INTERVENTION 1:  |   Intraductal Arm |   Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. | INTERVENTION 1:  |   Cetuximab |   Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II. |   cetuximab: Given IV | INTERVENTION 2:  |   Cetuximab and Carboplatin After Cetuximab Alone |   Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab + carboplatin
75affd49-4905-4d43-9a5c-ef795281bac4,75affd49-4905-4d43-9a5c-ef795281bac4,neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.,"[PRIMARY] Outcome Measurement:  </s>   Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment </s>   ORR is defined as the percentage of patients who exhibit a Complete Response (CR) or Partial Response (PR). Complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. Partial Response is at least a 50% reduction of all measurable lesions as measured by the product of the perpendicular diameters of the greatest dimensions of tumor size, with no new lesions appearing for at least four weeks. </s>   Time frame: 18 Months </s> Results 1:  </s>   Arm/Group Title: Arm A -Liposomal Doxorubicin Then Docetaxel </s>   Arm/Group Description: Liposomal doxorubicin (Arm A) </s>   Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle. </s>   Patients demonstrating progression on Liposomal Doxorubicin were eligible for cross over to treatment on Docetaxel, provided the patient still met the eligibility laboratory and performance status criteria. </s>   Overall Number of Participants Analyzed: 42 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  28        (16 to 42) </s> Results 2:  </s>   Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin </s>   Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. This dosing schedule will define one cycle. </s>   Patients demonstrating progression on Docetaxel were eligible for cross over to treatment on Liposomal Doxorubicin, provided the patient still met the eligibility laboratory and performance status criteria. </s>   Overall Number of Participants Analyzed: 44 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  31        (18 to 45)",1,"Outcome Measurement:  |   Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment |   ORR is defined as the percentage of patients who exhibit a Complete Response (CR) or Partial Response (PR). Complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. Partial Response is at least a 50% reduction of all measurable lesions as measured by the product of the perpendicular diameters of the greatest dimensions of tumor size, with no new lesions appearing for at least four weeks. |   Time frame: 18 Months | Results 1:  |   Arm/Group Title: Arm A -Liposomal Doxorubicin Then Docetaxel |   Arm/Group Description: Liposomal doxorubicin (Arm A) |   Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle. |   Patients demonstrating progression on Liposomal Doxorubicin were eligible for cross over to treatment on Docetaxel, provided the patient still met the eligibility laboratory and performance status criteria. |   Overall Number of Participants Analyzed: 42 |   Measure Type: Number |   Unit of Measure: percentage of patients  28        (16 to 42) | Results 2:  |   Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin |   Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. This dosing schedule will define one cycle. |   Patients demonstrating progression on Docetaxel were eligible for cross over to treatment on Liposomal Doxorubicin, provided the patient still met the eligibility laboratory and performance status criteria. |   Overall Number of Participants Analyzed: 44 |   Measure Type: Number |   Unit of Measure: percentage of patients  31        (18 to 45)"
2e76c74a-b6dd-47d8-a674-c1e80b0a3a65,2e76c74a-b6dd-47d8-a674-c1e80b0a3a65,"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.","[PRIMARY] Inclusion Criteria: </s>   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women </s> Exclusion Criteria: </s>   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).",0,"Inclusion Criteria: |   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women | Exclusion Criteria: |   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed)."
8c6314f7-34f5-42a7-ba66-b95d050a6315,8c6314f7-34f5-42a7-ba66-b95d050a6315,The shortest PFS in cohort 1 of the primary trial was 1.4 months below average,"[PRIMARY] Outcome Measurement:  </s>   Progression Free Survival </s>   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. </s>   Assessment period was from the day of randomisation until the first observation of lesion progression or death </s>   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, </s> Results 1:  </s>   Arm/Group Title: NK105 </s>   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.4        (7.0 to 9.9) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel </s>   Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.5        (6.9 to 11.5)",1,"Outcome Measurement:  |   Progression Free Survival |   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. |   Assessment period was from the day of randomisation until the first observation of lesion progression or death |   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, | Results 1:  |   Arm/Group Title: NK105 |   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle |   Overall Number of Participants Analyzed: 211 |   Median (95% Confidence Interval) |   Unit of Measure: months  8.4        (7.0 to 9.9)"
f114846e-79d8-4712-add0-bb34b65d418f,f114846e-79d8-4712-add0-bb34b65d418f,there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.,"[PRIMARY] Outcome Measurement:  </s>   Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) </s>   Number of patients event-free </s>   Time frame: 12 month period following randomisation </s> Results 1:  </s>   Arm/Group Title: Fulvestrant + Anastrozole </s>   Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg </s>   Overall Number of Participants Analyzed: 6 </s>   Measure Type: Number </s>   Unit of Measure: Participants  6 </s> Results 2:  </s>   Arm/Group Title: Anastrozole </s>   Arm/Group Description: anastrozole 1 mg </s>   Overall Number of Participants Analyzed: 7 </s>   Measure Type: Number </s>   Unit of Measure: Participants  7",0,"Outcome Measurement:  |   Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) |   Number of patients event-free |   Time frame: 12 month period following randomisation | Results 1:  |   Arm/Group Title: Fulvestrant + Anastrozole |   Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg |   Overall Number of Participants Analyzed: 6 |   Measure Type: Number |   Unit of Measure: Participants  6 | Results 2:  |   Arm/Group Title: Anastrozole |   Arm/Group Description: anastrozole 1 mg |   Overall Number of Participants Analyzed: 7 |   Measure Type: Number |   Unit of Measure: Participants  7"
812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe,812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe,the primary trial reports the changes in the number of lesions for patients in its cohorts.,"[PRIMARY] Outcome Measurement:  </s>   Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 </s>   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment. </s>   Time frame: Baseline up to end of Cycle 2 (Day 42) </s> Results 1:  </s>   Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim </s>   Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]). </s>   Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care. </s>   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met. </s>   Overall Number of Participants Analyzed: 17 </s>   Mean (Standard Deviation) </s>   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08) </s> Results 2:  </s>   Arm/Group Title: Ixabepilone </s>   Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. </s>   Dosage determined by calculating participant's body surface area (40 mg/m^2). </s>   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met. </s>   Overall Number of Participants Analyzed: 11 </s>   Mean (Standard Deviation) </s>   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)",0,"Outcome Measurement:  |   Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 |   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment."
b1d28450-fc7d-496a-9c7c-bf711b28f8e4,b1d28450-fc7d-496a-9c7c-bf711b28f8e4,all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy,"[PRIMARY] Inclusion Criteria: </s>   Adult Women ( 18 years old). </s>   Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease. </s>   Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease. </s>   HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive). </s>   Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued > 12 months prior to randomization. </s>   Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment. </s>   Documentation of negative pregnancy test. </s>   Organ functions at time of inclusion. </s> Exclusion Criteria: </s>   Prior mTOR inhibitors for the treatment of cancer. </s>   Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. </s>   Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc). </s>   Radiotherapy to  25% of the bone marrow within 4 weeks prior to randomization </s>   History of central nervous system metastasis. </s>   Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract. </s>   Serious peripheral neuropathy. </s>   Cardiac disease or dysfunction. </s>   Uncontrolled hypertension. </s> HIV. </s> Pregnant,",0,  Documentation of negative pregnancy test. |   Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.
c7dc582a-4a58-4cb5-b980-b2d2b6a128c3,c7dc582a-4a58-4cb5-b980-b2d2b6a128c3,no cardiac or neural adverse events were recorded in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 2/30 (6.67%) </s>   Dry Eyes  [1]1/30 (3.33%) </s>   Diarrhea  [2]1/30 (3.33%),1,Adverse Events 1: |   Total: 2/30 (6.67%) |   Dry Eyes  [1]1/30 (3.33%) |   Diarrhea  [2]1/30 (3.33%)
a805f174-2707-4302-a195-05153ea8523e,a805f174-2707-4302-a195-05153ea8523e,Only adults can take part in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Metastatic breast cancer (Stage IV) </s>   Histologically confirmed estrogen receptor positive disease </s>   Female </s>   Serum 25(OH) <30 ng/ml </s>   Age  18 years </s>   Pre or post-menopausal </s>   ECOG Performance status 0-2 </s>   Adequate organ function as defined as GFR> 30 mls/min and serum calcium  10.4 mg/dl </s>   Any race/ethnicity </s>   English speaking </s>   No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician </s>   Willingness to sign a written informed consent and complete questionnaires </s>   Cease ingestion of vitamin D supplementation not study related </s> Exclusion Criteria: </s>   Women with Stage I-III breast cancer </s>   Serum 25(OH)D levels  30 ng/ml </s>   Untreated CNS involvement </s>   History of kidney stones </s>   History of renal failure </s>   History of hyperparathyroidism </s>   History of hypersensitivity to vitamin D </s>   Non-English speaking </s>   Currently pregnant or lactating, or anticipating pregnancy </s>   Unwilling to cease ingestion of calcium supplements (>1000 mg/d) </s>   Unwilling or unable to complete informed consent or study questionnaires </s>   Psychiatric or other clinical conditions that preclude study compliance </s>   Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities",1,  Age  18 years
e4aeb013-7713-4b73-acbd-f8379cc6a494,e4aeb013-7713-4b73-acbd-f8379cc6a494,there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1,[PRIMARY] Adverse Events 1: </s>   Total: 5/101 (4.95%) </s>   BILATERAL CATARACTS * 0/101 (0.00%) </s>   APPENDICITIS * 2/101 (1.98%) </s>   ISCHEMIC COLITIS * 1/101 (0.99%) </s>   SLIPPED DISK * 0/101 (0.00%) </s>   RIGHT BIMALLEOLAR ANKLE FRACTURE * 0/101 (0.00%) </s>   ACUTE MYELOID LEUKEMIA * 0/101 (0.00%) </s>   BREAST CANCER * 0/101 (0.00%) </s>   PRIMARY DCIS IN BREAST * 0/101 (0.00%) </s>   OVARIAN CYST * 1/101 (0.99%) </s> Adverse Events 2: </s>   Total: 9/98 (9.18%) </s>   BILATERAL CATARACTS * 1/98 (1.02%) </s>   APPENDICITIS * 0/98 (0.00%) </s>   ISCHEMIC COLITIS * 0/98 (0.00%) </s>   SLIPPED DISK * 1/98 (1.02%) </s>   RIGHT BIMALLEOLAR ANKLE FRACTURE * 1/98 (1.02%) </s>   ACUTE MYELOID LEUKEMIA * 1/98 (1.02%) </s>   BREAST CANCER * 1/98 (1.02%) </s>   PRIMARY DCIS IN BREAST * 1/98 (1.02%) </s>   OVARIAN CYST * 1/98 (1.02%),1,  SLIPPED DISK * 0/101 (0.00%) |   SLIPPED DISK * 1/98 (1.02%)
b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3,b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3,"All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months","[PRIMARY] Outcome Measurement:  </s>   Centrally Assessed Progression Free Survival </s>   Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months. </s>   Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut. </s> Results 1:  </s>   Arm/Group Title: Neratinib Plus Capecitabine </s>   Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. </s>   Overall Number of Participants Analyzed: 307 </s>   Mean (95% Confidence Interval) </s>   Unit of Measure: months  8.8        (7.8 to 9.8) </s> Results 2:  </s>   Arm/Group Title: Lapatinib Plus Capecitabine </s>   Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. </s>   Overall Number of Participants Analyzed: 314 </s>   Mean (95% Confidence Interval) </s>   Unit of Measure: months  6.6        (5.9 to 7.4)",1,"Outcome Measurement:  |   Centrally Assessed Progression Free Survival |   Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months. |   Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut. | Results 1:  |   Arm/Group Title: Neratinib Plus Capecitabine |   Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. |   Overall Number of Participants Analyzed: 307 |   Mean (95% Confidence Interval) |   Unit of Measure: months  8.8        (7.8 to 9.8)"
2729a321-709b-4392-9604-dd7237bedb17,2729a321-709b-4392-9604-dd7237bedb17,the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.,"[PRIMARY] Outcome Measurement:  </s>   Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer </s>   The percentage of patients alive and cancer-free. </s>   Time frame: 5 years </s> Results 1:  </s>   Arm/Group Title: Group 1: TAC X 6 </s>   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel. </s>   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles </s>   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles </s>   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles </s>   Overall Number of Participants Analyzed: 1610 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) </s> Results 2:  </s>   Arm/Group Title: Group 2: AC X 4 Then P X 4 </s>   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel </s>   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles </s>   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles </s>   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles </s>   Overall Number of Participants Analyzed: 1618 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)",1,"Outcome Measurement:  |   Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer |   The percentage of patients alive and cancer-free. |   Time frame: 5 years | Results 1:  |   Arm/Group Title: Group 1: TAC X 6 |   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel. |   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles |   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles |   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles |   Overall Number of Participants Analyzed: 1610 |   Measure Type: Number |   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) | Results 2:  |   Arm/Group Title: Group 2: AC X 4 Then P X 4 |   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel |   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles |   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles |   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles |   Overall Number of Participants Analyzed: 1618 |   Measure Type: Number |   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)"
8e9611fc-89f8-44cb-af09-8d71a13ca082,8e9611fc-89f8-44cb-af09-8d71a13ca082,Cohort 1 and 2 of the primary trial do not receive the same intervention,"[PRIMARY] INTERVENTION 1:  </s>   NKTR-102 </s>   In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. </s> INTERVENTION 2:  </s>   Treatment of Physician's Choice (TPC) </s>   In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.",1,"INTERVENTION 1:  |   NKTR-102 |   In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. | INTERVENTION 2:  |   Treatment of Physician's Choice (TPC) |   In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel."
b9491012-49ba-4eb1-8230-1966f54ea012,b9491012-49ba-4eb1-8230-1966f54ea012,Patients with Extracranial metastases can be eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain </s>   Extracranial metastases allowed </s>   Must have demonstrated progression of brain metastases after prior treatment for brain metastases, including any of the following: </s>   External beam radiotherapy </s>   Brachytherapy </s>   Stereotactic radiosurgery </s>   Surgery </s>   Chemotherapy </s>   Treatments with investigational drugs, biologics, or devices </s>   Disease progression in the CNS must meet  1 of the following criteria: </s>   New lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI) </s>   Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI) </s>   New or progressive lesions that do not meet measurable disease definition allowed </s>   Leptomeningeal disease allowed if concurrent progression or parenchymal brain metastases </s>   Not a candidate for surgical resection and/or further stereotactic radiosurgery </s>   Hormone receptor status not specified </s>   PATIENT CHARACTERISTICS: </s>   Menopausal status not specified </s>   ECOG performance status 0-2 </s>   Life expectancy  1 month </s>   Hemoglobin  10 g/dL (transfusion allowed) </s>   ANC  1,500/mm³ </s>   Granulocyte count  1,500/mm³ </s>   Platelet count  100,000/mm³ </s>   Creatinine  1.5 mg/dL </s>   Total bilirubin  1.5 times upper limit of normal (ULN) </s>   AST and ALT  3 times ULN </s>   Must be able to swallow and retain oral medications </s>   No other active malignancy except for any of the following: </s>   Curatively treated basal or squamous cell carcinoma of the skin </s>   Carcinoma in situ of the cervix </s>   Other malignancies considered disease-free </s>   Not pregnant or nursing </s>   Negative pregnancy test </s>   Fertile patients must use effective contraception </s>   No history of immediate or delayed-type hypersensitivity reaction to gadolinium contrast agents or other contraindication to gadolinium contrast </s>   No other known contraindication to MRI including, but not limited to, any of the following: </s>   Cardiac pacemaker </s>   Implanted cardiac defibrillator </s>   Brain aneurysm clips </s>   Cochlear implant </s>   Ocular foreign body </s>   Shrapnel </s>   No active or uncontrolled infection </s>   PRIOR CONCURRENT THERAPY: </s>   See Disease Characteristics </s>   Recovered from the side effects of prior chemotherapy, surgery, or radiotherapy for extracranial disease or brain metastases </s>   Concurrent trastuzumab, bisphosphonate, and/or corticosteroid therapy allowed </s>   At least 1 week since prior or on current stable dose of corticosteroid therapy </s>   Patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication </s>   Concurrent coumadin allowed </s>   No prophylactic use of filgrastim (G-CSF) during first course of treatment",1,  Extracranial metastases allowed
62e449ad-16b3-479d-94a5-ffc435b5e99c,62e449ad-16b3-479d-94a5-ffc435b5e99c,patients with a Malignant brain tumour diagnosis are excluded from the primary trial,[PRIMARY] Inclusion Criteria: </s>   Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel). </s>   Less than 3 different chemotherapy treatments for metastatic disease. </s>   Prior treatment with hormonal and/or radiation therapy. </s>   Must have disease that can be measured. </s>   Must be able to take care of self needs for example personal hygiene </s> Exclusion Criteria: </s>   Must not be pregnant or breast-feeding. </s>   Cancer that has spread to the brain. </s>   Treatment with Gemcitabine or Pemetrexed </s>   Unable to take folic acid or Vitamin B12 </s>   Treatment for another cancer within the last 5 years,1,  Cancer that has spread to the brain.
565d7982-aa9a-4c01-987c-1d67bc9c212d,565d7982-aa9a-4c01-987c-1d67bc9c212d,"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry","[PRIMARY] Inclusion Criteria: </s>   Biopsy-diagnosed breast cancer with metastasis in multiple organs </s>   Performance Status (World Health Organization :WHO) 0-2 </s>   Functions below are maintained in major organs: </s>   Leukocyte count: 4,000/mm3 to 12,000/mm3 </s>   Neutrophil count: >2,000/mm3 or more </s>   Platelet count: <100,000/mm3 or more </s>   Hemoglobin: >9.5 g/dL </s>   Total bilirubin: >1.5 mg/dL </s>   AST(GOT): within twice a normal upper value in an institution </s>   AST(GPT): within twice a normal upper value in an institution </s>   BUN: < 25 mg/dL </s>   Creatinine: within a normal upper value in the institution </s>   24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula) </s>   Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85 </s>   Written informed consent will be obtained for patients for entering this study </s> Exclusion Criteria: </s>   Patients with synchronous multiple cancers </s>   Complicated with infection </s>   Fever from suspected infection </s>   Metastasis to the central nerve system </s>   A history of ischemic cardiac diseases </s>   Active gastrointestinal ulcer </s>   Severe nerve disorder </s>   Women who are potentially pregnant, pregnant, or breast-feeding </s>   Severe drug allergy </s>   Severe suppression of the bone marrow </s>   Severe renal disorder </s>   Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy) </s>   Being treated with flucytosine </s>   Complicated with the infection onset which a study doctor assesses to be inappropriate for this study",0,  Being treated with flucytosine
7271e0db-bb82-423f-ad95-5ffa84fab97e,7271e0db-bb82-423f-ad95-5ffa84fab97e,There are more cases of Urosepsis in the primary trial than in the secondary trial,[PRIMARY] Adverse Events 1: </s>   Total: 3/12 (25.00%) </s>   Atrial fibrillation 0/12 (0.00%) </s>   Cardiac ischemia/infarction  [1]0/12 (0.00%) </s>   Congestive Heart Failure  [2]0/12 (0.00%) </s>   Diverticulitis 0/12 (0.00%) </s>   Cholecystitis 0/12 (0.00%) </s>   Hyperbilirubinemia 0/12 (0.00%) </s>   Urosepsis 2/12 (16.67%) </s>   Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) </s>   Rash  [3]0/12 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 18/65 (27.69%) </s>   Anaemia 5/65 (7.69%) </s>   Febrile neutropenia 1/65 (1.54%) </s>   Leukocytosis 0/65 (0.00%) </s>   Neutropenia 4/65 (6.15%) </s>   Thrombocytopenia 6/65 (9.23%) </s>   Cardiac failure congestive 0/65 (0.00%) </s>   Epigastric discomfort 0/65 (0.00%) </s>   Nausea 1/65 (1.54%) </s>   Vomiting 3/65 (4.62%) </s>   Condition aggravated 0/65 (0.00%) </s>   Medical device complication 0/65 (0.00%) </s> Adverse Events 2: </s>   Total: 22/66 (33.33%) </s>   Anaemia 1/66 (1.52%) </s>   Febrile neutropenia 2/66 (3.03%) </s>   Leukocytosis 1/66 (1.52%) </s>   Neutropenia 2/66 (3.03%) </s>   Thrombocytopenia 0/66 (0.00%) </s>   Cardiac failure congestive 1/66 (1.52%) </s>   Epigastric discomfort 1/66 (1.52%) </s>   Nausea 0/66 (0.00%) </s>   Vomiting 1/66 (1.52%) </s>   Condition aggravated 1/66 (1.52%) </s>   Medical device complication 1/66 (1.52%),1,Adverse Events 1: |   Urosepsis 2/12 (16.67%) | Adverse Events 1: |   Total: 18/65 (27.69%) |   Anaemia 5/65 (7.69%) |   Febrile neutropenia 1/65 (1.54%) |   Leukocytosis 0/65 (0.00%) |   Neutropenia 4/65 (6.15%) |   Thrombocytopenia 6/65 (9.23%) |   Cardiac failure congestive 0/65 (0.00%) |   Epigastric discomfort 0/65 (0.00%) |   Nausea 1/65 (1.54%) |   Vomiting 3/65 (4.62%) |   Condition aggravated 0/65 (0.00%) |   Medical device complication 0/65 (0.00%) | Adverse Events 2: |   Total: 22/66 (33.33%) |   Anaemia 1/66 (1.52%) |   Febrile neutropenia 2/66 (3.03%) |   Leukocytosis 1/66 (1.52%) |   Neutropenia 2/66 (3.03%) |   Thrombocytopenia 0/66 (0.00%) |   Cardiac failure congestive 1/66 (1.52%) |   Epigastric discomfort 1/66 (1.52%) |   Nausea 0/66 (0.00%) |   Vomiting 1/66 (1.52%) |   Condition aggravated 1/66 (1.52%) |   Medical device complication 1/66 (1.52%)
6402e13a-7cfb-4774-b7f9-80ecb79fda2a,6402e13a-7cfb-4774-b7f9-80ecb79fda2a,the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.,"[PRIMARY] INTERVENTION 1:  </s>   Positron Emission Mammography </s>   Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm). [SECONDARY] INTERVENTION 1:  </s>   Exemestane </s>   Patients receive oral exemestane (25 mg) once daily for 5 years. </s>   exemestane: Given orally </s> INTERVENTION 2:  </s>   Anastrozole </s>   Patients receive oral anastrozole (1 mg) once daily for 5 years. </s>   anastrozole: Given orally",1,"INTERVENTION 1:  |   Positron Emission Mammography |   Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm). | INTERVENTION 1:  |   Exemestane |   Patients receive oral exemestane (25 mg) once daily for 5 years. |   exemestane: Given orally | INTERVENTION 2:  |   Anastrozole |   Patients receive oral anastrozole (1 mg) once daily for 5 years. |   anastrozole: Given orally"
734423d5-4b47-4448-ab98-811015d626f0,734423d5-4b47-4448-ab98-811015d626f0,There were multiple patients which suffered Neutropenia in both cohorts of the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 3/39 (7.69%) </s>   Neutropenia  1/39 (2.56%) </s>   Bilateral Pulmonary Thromboembolism  0/39 (0.00%) </s>   Fever  1/39 (2.56%) </s>   Empyema associated with a permanent thoracic catheter  1/39 (2.56%) </s> Adverse Events 2: </s>   Total: 3/21 (14.29%) </s>   Neutropenia  1/21 (4.76%) </s>   Bilateral Pulmonary Thromboembolism  1/21 (4.76%) </s>   Fever  1/21 (4.76%) </s>   Empyema associated with a permanent thoracic catheter  0/21 (0.00%),0,Adverse Events 1: |   Total: 3/39 (7.69%) |   Neutropenia  1/39 (2.56%) | Adverse Events 2: |   Total: 3/21 (14.29%) |   Neutropenia  1/21 (4.76%)
e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd,e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd,"All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole","[PRIMARY] INTERVENTION 1:  </s>   Arm A - Flaxseed & Active Anastrazole </s>   25 mg flaxseed per day and 1 mg anastrozole pill per day </s>   Anastrozole: 1 mg per day </s>   flaxseed: 25 g per day ground </s> INTERVENTION 2:  </s>   Arm B - Flaxseed </s>   Flaxseed 25 mg per day and 1 placebo pill per day </s>   flaxseed: 25 g per day ground [SECONDARY] INTERVENTION 1:  </s>   Phase 1 - Cohort A </s>   Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer </s>   Anastrozole </s> AZD0530",0,"INTERVENTION 1:  |   Arm A - Flaxseed & Active Anastrazole |   25 mg flaxseed per day and 1 mg anastrozole pill per day |   Anastrozole: 1 mg per day |   flaxseed: 25 g per day ground | INTERVENTION 2:  |   Arm B - Flaxseed |   Flaxseed 25 mg per day and 1 placebo pill per day |   flaxseed: 25 g per day ground | INTERVENTION 1:  |   Phase 1 - Cohort A |   Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer |   Anastrozole | AZD0530"
32ed503c-1cfd-44f6-b8bb-23d9d175d73d,32ed503c-1cfd-44f6-b8bb-23d9d175d73d,Patients must be able to undergo a PET scan to participate in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy </s>   Locally advanced breast cancer, not stage IV, and with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam) </s>   No obvious contraindications for primary chemotherapy </s>   Residual tumor planned to be removed surgically following completion of neoadjuvant therapy </s>   Able to lie still for 1.5 hours for PET scanning </s>   Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) </s>   Leukocytes >= 3,000/ul </s>   Absolute neutrophil count >= 1,500/ul </s>   Platelets >= 100,000/ul </s>   Total bilirubin within normal institutional limits </s>   Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times the institutional upper limit of normal </s>   Creatinine within normal institutional limits OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal </s>   If female, postmenopausal for a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care (SOC) pregnancy test, and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation </s>   Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines </s> Exclusion Criteria: </s>   Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy </s>   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements </s>   Medically unstable </s>   Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours </s>   History of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine </s>   Pregnant or nursing </s>   Previous malignancy, other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, from which the patient has been disease free for less than 5 years </s>   Currently on hormone therapy as the primary systemic neoadjuvant therapy",1,  Able to lie still for 1.5 hours for PET scanning
175044aa-72b1-405d-8506-30002f5098e4,175044aa-72b1-405d-8506-30002f5098e4,"There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",[PRIMARY] Adverse Events 1: </s>   Total: 0,0,Adverse Events 1: |   Total: 0
045ad91e-44fa-42cc-ac22-a7aab26a9009,045ad91e-44fa-42cc-ac22-a7aab26a9009,"the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",[PRIMARY] INTERVENTION 1:  </s>   Avastin (Bevacizumab) Plus Hormone </s>   All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.,0,INTERVENTION 1:  |   Avastin (Bevacizumab) Plus Hormone |   All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.
00822101-fa21-4a26-bf45-3b1f535da005,00822101-fa21-4a26-bf45-3b1f535da005,a patient with a HER2-positive status can not take part in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Signed informed consent form. </s>    18 years of age. </s>   Histologically confirmed carcinoma of the breast with measurable or non-measurable metastatic disease that has progressed (patients with a history of brain metastasis are eligible for study participation [USA only], as long as their brain metastases have been treated and they have no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone). </s>   Progression of disease during or following administration of one (non-investigational) chemotherapy regimen administered in the first-line setting. </s>   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. </s>   For women of childbearing potential, use of an effective means of non-hormonal contraception. </s>   Life expectancy  3 months. </s>   Willingness and capacity to comply with study and follow-up procedures. </s> Exclusion Criteria: </s>   Prior hormonal therapy only as treatment for metastatic disease without chemotherapy. Patients must have received chemotherapy for their metastatic disease in the first-line setting. Hormone therapy alone is not allowed. </s>   For subjects who have received prior anthracycline-based therapy, documentation of left ventricular ejection fraction < 50% by either multiple gated acquisition (MUGA) or echocardiogram (ECHO). </s>   Treatment with more than one prior cytotoxic regimen for metastatic breast cancer (MBC). </s>   HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study). </s>   Unknown estrogen receptor (ER) and progesterone receptor (PR) status. </s>   Radiation therapy other than for palliation or brain metastasis, biologic therapy, or chemotherapy for MBC within 21 days prior to Day 0 (Day 1 of Cycle 1 of treatment). </s>   Prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) pathway-targeted therapy. </s>   Untreated brain metastasis. </s>   Inadequately controlled hypertension. </s>   Unstable angina. </s>   New York Heart Association Grade II or greater congestive heart failure (CHF). </s>   History of myocardial infarction within 6 months prior to Day 0 (the day of the first bevacizumab/placebo infusion). </s>   History of stroke or transient ischemic attack within 6 months prior to Day 0. </s>   Clinically significant peripheral vascular disease. </s>   Evidence of bleeding diathesis or coagulopathy. </s>   Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major elective surgical procedure during the study. </s>   Minor surgical procedures, fine-needle aspirations, or core biopsies within 7 days prior to Day 0. </s>   History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0. </s>   Serious, non-healing wound, ulcer, or bone fracture. </s>   History of anaphylactic reaction to monoclonal antibody therapy not controlled with treatment premedication. </s>   History of other malignancies within 5 years of Day 0, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. </s>   inadequate organ function. </s>   Pregnancy (positive serum pregnancy test) or lactation. </s>   Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications.",1,"  HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study)."
06f798d1-2956-4903-83e9-58a41fa425f7,06f798d1-2956-4903-83e9-58a41fa425f7,the primary trial and the secondary trial do not record any cardiac or infection related adverse events,[PRIMARY] Adverse Events 1: </s>   Total: 0/655 (0.00%) </s> Adverse Events 2: </s>   Total: 0/580 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 0/15 (0.00%) </s> Adverse Events 2: </s>   Total: 0/16 (0.00%),1,Adverse Events 1: |   Total: 0/655 (0.00%) | Adverse Events 2: |   Total: 0/580 (0.00%) | Adverse Events 1: |   Total: 0/15 (0.00%) | Adverse Events 2: |   Total: 0/16 (0.00%)
8648c7df-582a-42a9-9330-414b2430ac56,8648c7df-582a-42a9-9330-414b2430ac56,"none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events","[PRIMARY] Adverse Events 1: </s>   Total: 340/1612 (21.09%) </s>   Anemia 10/1612 (0.62%) </s>   Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%) </s>   Febrile neutropenia 7/1612 (0.43%) </s>   Cardiac disorders - Other, specify 6/1612 (0.37%) </s>   Conduction disorder 2/1612 (0.12%) </s>   Myocardial infarction 6/1612 (0.37%) </s>   Palpitations 1/1612 (0.06%) </s>   Pericardial effusion 0/1612 (0.00%) </s>   Sinus bradycardia 2/1612 (0.12%) </s> Adverse Events 2: </s>   Total: 350/1623 (21.57%) </s>   Anemia 8/1623 (0.49%) </s>   Blood and lymphatic system disorders - Other, specify 3/1623 (0.18%) </s>   Febrile neutropenia 4/1623 (0.25%) </s>   Cardiac disorders - Other, specify 2/1623 (0.12%) </s>   Conduction disorder 1/1623 (0.06%) </s>   Myocardial infarction 4/1623 (0.25%) </s>   Palpitations 0/1623 (0.00%) </s>   Pericardial effusion 2/1623 (0.12%) </s>   Sinus bradycardia 0/1623 (0.00%)",0,"Adverse Events 1: |   Total: 340/1612 (21.09%) |   Anemia 10/1612 (0.62%) |   Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%) |   Febrile neutropenia 7/1612 (0.43%) |   Cardiac disorders - Other, specify 6/1612 (0.37%) |   Conduction disorder 2/1612 (0.12%) |   Myocardial infarction 6/1612 (0.37%) |   Palpitations 1/1612 (0.06%) |   Pericardial effusion 0/1612 (0.00%) |   Sinus bradycardia 2/1612 (0.12%) | Adverse Events 2: |   Total: 350/1623 (21.57%) |   Anemia 8/1623 (0.49%) |   Blood and lymphatic system disorders - Other, specify 3/1623 (0.18%) |   Febrile neutropenia 4/1623 (0.25%) |   Cardiac disorders - Other, specify 2/1623 (0.12%) |   Conduction disorder 1/1623 (0.06%) |   Myocardial infarction 4/1623 (0.25%) |   Palpitations 0/1623 (0.00%) |   Pericardial effusion 2/1623 (0.12%) |   Sinus bradycardia 0/1623 (0.00%)"
89f610a7-9e81-43a4-8c1e-5503233b2be1,89f610a7-9e81-43a4-8c1e-5503233b2be1,Breast cancer patients must have documented stable disease to participate in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Pathologically confirmed diagnosis of breast cancer with documented progressive disease. </s>   Patients with stable brain metastases are eligible for this trial. </s>   At least one prior chemotherapy regimen for metastatic breast cancer. Prior treatment must be discontinued at least 2 weeks before treatment start. </s>   Concomitant therapy with bisphosphonates is allowed. </s>   Stable dose coumadin anticoagulation is allowed, providing that anticoagulation can be safely held to an International Normalized Ratio (INR) within normal range for the purpose of tumor biopsy. Low molecular weight heparin (LMWH is the preferred method of anticoagulation. </s>   Prothrombin time (PT)/International Normalized Ratio (INR) and partial thromboplastin time (PTT) within institutional normal limits within two weeks before initial biopsy. </s>   Measurable disease, as defined by RECIST guidelines or evaluable disease. Bone metastases must be evaluable. </s>   Disease amenable to core biopsy. Patients with pulmonary metastases as their only site of disease may enroll on this trial and will not undergo biopsy. </s>   For Phase I: patients with human epidermal growth factor receptor 2 (HER2) overexpressing disease must have been previously treated with trastuzumab. Patients with HER2 overexpressing disease are not eligible for the Phase II trial. </s>   Age eighteen years or older. </s>   Eastern Cooperative Oncology Group (ECOG) performance status </= 2. </s>   Life expectancy of >/= 12 weeks. </s>   Patients with < grade 1 peripheral neuropathy are eligible for this trial. </s>   Adequate bone marrow reserve: Absolute Neutrophil Count (ANC) >/= 1000, platelets >/= 100,000. </s>   Adequate renal function: serum creatinine </= 1.5x upper limit of normal (ULN) OR calculated creatinine clearance  50 ml/min. </s>   Sodium, potassium, and chloride levels within institutional normal limits. </s>   Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x ULN, and total bilirubin </= 1.5x upper limit of normal. In patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be </= 5 times the ULN. </s>   At baseline: Ejection fraction (EF)  50%, no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point - patients may be eligible for study if the drug can be changed to another agent with less risk (such as changing from citalopram to an alternate antidepressant). </s>   Able to take oral medications and maintain hydration. </s>   Ability to give written informed consent and willingness to comply with the requirements of the protocol </s>   Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drug </s>   Specific inclusion criteria for Phase II </s>  Patients enrolling on the phase II portion of this trial must have ER, progesterone receptors (PR) and HER2 negative disease defined as less than 10% staining for ER and PR, and HER2 not amplified byFluorescent in situ hybridization (FISH), 0-1% by Immunohistochemistry (IHC), or 2+ by IHC and no evidence of amplification by FISH. </s> Exclusion Criteria: </s>   Treatment with another chemotherapy or hormonal therapy within the past 2 weeks. </s>   Treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks. </s>   Concurrent treatment with radiotherapy. </s>   Ongoing treatment with any other investigational therapy. </s>   Prior treatment with eribulin </s>   Severe, concurrent illness including congestive heart failure, significant cardiac disease and uncontrolled hypertension, that would likely prevent the patient from being able to comply with the study protocol. </s>   Inadequate bone marrow, renal, or hepatic function as defined above, or an active coagulopathy that precludes tissue biopsy. </s>   Pregnant or lactating women and women of child-bearing potential who are not using an effective method of birth control. Women of childbearing potential must undergo a serum pregnancy test within seven days of starting the study drug.",0,  Pathologically confirmed diagnosis of breast cancer with documented progressive disease.
b0046821-ba27-4a90-8869-cb708b843aa4,b0046821-ba27-4a90-8869-cb708b843aa4,"All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed","[PRIMARY] INTERVENTION 1:  </s>   Arm A - Flaxseed & Active Anastrazole </s>   25 mg flaxseed per day and 1 mg anastrozole pill per day </s>   Anastrozole: 1 mg per day </s>   flaxseed: 25 g per day ground </s> INTERVENTION 2:  </s>   Arm B - Flaxseed </s>   Flaxseed 25 mg per day and 1 placebo pill per day </s>   flaxseed: 25 g per day ground [SECONDARY] INTERVENTION 1:  </s>   Phase 1 - Cohort A </s>   Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer </s>   Anastrozole </s> AZD0530",1,"INTERVENTION 1:  |   Arm A - Flaxseed & Active Anastrazole |   25 mg flaxseed per day and 1 mg anastrozole pill per day |   Anastrozole: 1 mg per day |   flaxseed: 25 g per day ground | INTERVENTION 2:  |   Arm B - Flaxseed |   Flaxseed 25 mg per day and 1 placebo pill per day |   flaxseed: 25 g per day ground | INTERVENTION 1:  |   Phase 1 - Cohort A |   Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer |   Anastrozole | AZD0530"
d1b217ae-76f3-4ba6-958e-5b2558703ba4,d1b217ae-76f3-4ba6-958e-5b2558703ba4,"several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",[PRIMARY] Adverse Events 1: </s>   Total: 1/35 (2.86%) </s>   congestive heart failure *1/35 (2.86%) </s> Adverse Events 2: </s>   Total: 0/40 (0.00%) </s>   congestive heart failure *0/40 (0.00%),0,Adverse Events 1: |   Total: 1/35 (2.86%) |   congestive heart failure *1/35 (2.86%) | Adverse Events 2: |   Total: 0/40 (0.00%) |   congestive heart failure *0/40 (0.00%)
8ddf8b88-6e06-4c71-9e28-45f73a637af0,8ddf8b88-6e06-4c71-9e28-45f73a637af0,"the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.","[PRIMARY] INTERVENTION 1:  </s>   Positron Emission Mammography </s>   Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm). [SECONDARY] INTERVENTION 1:  </s>   Exemestane </s>   Patients receive oral exemestane (25 mg) once daily for 5 years. </s>   exemestane: Given orally </s> INTERVENTION 2:  </s>   Anastrozole </s>   Patients receive oral anastrozole (1 mg) once daily for 5 years. </s>   anastrozole: Given orally",0,"INTERVENTION 1:  |   Positron Emission Mammography |   Positron Emission Mammography: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm). | INTERVENTION 1:  |   Exemestane |   Patients receive oral exemestane (25 mg) once daily for 5 years. |   exemestane: Given orally | INTERVENTION 2:  |   Anastrozole |   Patients receive oral anastrozole (1 mg) once daily for 5 years. |   anastrozole: Given orally"
0ea29bd5-20be-40ea-8ad7-705d283d1d48,0ea29bd5-20be-40ea-8ad7-705d283d1d48,"the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer","[PRIMARY] Outcome Measurement:  </s>   Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer </s>   The percentage of patients alive and cancer-free. </s>   Time frame: 5 years </s> Results 1:  </s>   Arm/Group Title: Group 1: TAC X 6 </s>   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel. </s>   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles </s>   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles </s>   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles </s>   Overall Number of Participants Analyzed: 1610 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) </s> Results 2:  </s>   Arm/Group Title: Group 2: AC X 4 Then P X 4 </s>   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel </s>   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles </s>   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles </s>   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles </s>   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles </s>   Overall Number of Participants Analyzed: 1618 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)",0,"Outcome Measurement:  |   Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer |   The percentage of patients alive and cancer-free. |   Time frame: 5 years | Results 1:  |   Arm/Group Title: Group 1: TAC X 6 |   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel. |   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles |   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles |   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles |   Overall Number of Participants Analyzed: 1610 |   Measure Type: Number |   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) | Results 2:  |   Arm/Group Title: Group 2: AC X 4 Then P X 4 |   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel |   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles |   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles |   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles |   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles |   Overall Number of Participants Analyzed: 1618 |   Measure Type: Number |   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)"
e147796d-2edd-42d1-ac53-300fb8bd5eb6,e147796d-2edd-42d1-ac53-300fb8bd5eb6,80% of patients in the primary trial received a placebo intervention,"[PRIMARY] INTERVENTION 1:  </s>   Lapatinib 1500 mg </s>   Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. </s> INTERVENTION 2:  </s>   Placebo </s>   Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.",0,"INTERVENTION 1:  |   Lapatinib 1500 mg |   Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. | INTERVENTION 2:  |   Placebo |   Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal."
6b33b4ae-36f2-4a53-a954-6f246f6e023d,6b33b4ae-36f2-4a53-a954-6f246f6e023d,Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%),"[PRIMARY] Inclusion Criteria: </s>   For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly-effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the participant and/or partner </s>   Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection; participants with measurable and/or non-measurable disease are eligible </s>   Known and documented HER2-positive </s>   Known and documented LVEF of at least 50 percent (%) </s>   Adequate organ function </s>   A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than [<] 12 months of amenorrhea post-menopause, and women who have not undergone surgical sterilization [absence of ovaries and/or uterus]) within 7 days prior to the first dose of study treatment with the result available prior to first dosing </s> Exclusion Criteria: </s>   Previous systemic non-hormonal anti-cancer therapy for the metastatic or locally recurrent disease </s>   Pregnant or lactating women </s>   Current clinical or radiographic evidence of central nervous system (CNS) metastases </s>   Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment in the adjuvant or neo-adjuvant setting </s>   History of LVEF decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy",1,  Known and documented HER2-positive |   Known and documented LVEF of at least 50 percent (%)
06fad978-1dc3-46f5-b45f-5ac6577f28b9,06fad978-1dc3-46f5-b45f-5ac6577f28b9,Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Females with histologic or cytologic diagnosis of advanced breast cancer. Lesions should not be amenable to surgery or radiation of curative intent. </s>   Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale. </s>   One prior chemotherapy containing anthracyclines as (neo)adjuvant or palliative 1st-line treatment. </s>   One prior chemotherapy containing taxanes as (neo) adjuvant or palliative 1st-line treatment. </s>   Prior radiation therapy is allowed to less than 25% of the bone marrow. Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry. Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy. </s>   At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Positron emission tomography [PET] scans and ultrasounds may not be used. </s>   Antitumoral hormonal treatment must be discontinued prior to enrollment. </s>   Estimated life expectancy of at least 3 months. </s>   Participant compliance and geographic proximity that allow adequate follow-up. </s>   Adequate organ function </s>   Female participants of childbearing potential must test negative for pregnancy within 7 days of enrollment based on a urine and/or serum pregnancy test and agree to use a reliable method of birth control during and for 6 months following the last dose of study drug. </s>   Participants must sign an informed consent document. </s>   Female participants must be at least 18 years of age. </s> Exclusion Criteria: </s>   Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. </s>   Have previously completed or withdrawn from this study or any other study investigating Pemetrexed, Gemcitabine, Carboplatin or Vinorelbine </s>   Have received more than one line of chemotherapy in Metastatic Breast Cancer. Participants having received more than one combination of anthracycline plus taxane. </s>   Are pregnant or breast-feeding. </s>   Have serious concomitant systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to complete the study. </s>   Have a prior malignancy other than breast cancer, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. </s>   Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam), unless the Creatinine Clearance is greater than or equal to 80 ml/min. </s>   Have central nervous system (CNS) metastases. </s>   Have clinically relevant (by physical exam) third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study entry. </s>   Are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. </s>   Concurrent administration of any other antitumor therapy. [SECONDARY] Inclusion Criteria: </s>   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women </s> Exclusion Criteria: </s>   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).",0,"Inclusion Criteria: |   Females with histologic or cytologic diagnosis of advanced breast cancer. Lesions should not be amenable to surgery or radiation of curative intent. | Inclusion Criteria: |   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women"
878c09e7-3fd9-404e-921e-5b549e9578fb,878c09e7-3fd9-404e-921e-5b549e9578fb,"Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.","[PRIMARY] Outcome Measurement:  </s>   Severity of Adverse Events </s>   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. </s>   Time frame: From cycle 1 up to approximately 3 years </s> Results 1:  </s>   Arm/Group Title: Trastuzumab Emtansine </s>   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. </s>   Overall Number of Participants Analyzed: 70 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  Grade 1: 53  75.7% </s>   Grade 2: 40  57.1% </s>   Grade 3: 18  25.7% </s>   Grade 4: 2   2.9% </s>   Grade 5: 12  17.1%",1,"Outcome Measurement:  |   Severity of Adverse Events |   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. |   Time frame: From cycle 1 up to approximately 3 years | Results 1:  |   Arm/Group Title: Trastuzumab Emtansine |   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. |   Overall Number of Participants Analyzed: 70 |   Measure Type: Count of Participants |   Unit of Measure: Participants  Grade 1: 53  75.7% |   Grade 2: 40  57.1% |   Grade 3: 18  25.7% |   Grade 4: 2   2.9% |   Grade 5: 12  17.1%"
3a0c517d-9b9a-4497-9675-50ff12cd02b7,3a0c517d-9b9a-4497-9675-50ff12cd02b7,in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain,[PRIMARY] Adverse Events 1: </s>   Total: 70/219 (31.96%) </s>   Anaemia * 0/219 (0.00%) </s>   Febrile neutropenia * 26/219 (11.87%) </s>   Neutropenia * 7/219 (3.20%) </s>   Thrombocytopenia * 1/219 (0.46%) </s>   Cardiac failure * 2/219 (0.91%) </s>   Sinus tachycardia * 1/219 (0.46%) </s>   Left ventricular dysfunction * 2/219 (0.91%) </s>   Abdominal pain * 1/219 (0.46%) </s>   Abdominal pain upper * 1/219 (0.46%) </s>   Colitis * 3/219 (1.37%) </s> Adverse Events 2: </s>   Total: 30/223 (13.45%) </s>   Anaemia * 3/223 (1.35%) </s>   Febrile neutropenia * 3/223 (1.35%) </s>   Neutropenia * 0/223 (0.00%) </s>   Thrombocytopenia * 1/223 (0.45%) </s>   Cardiac failure * 1/223 (0.45%) </s>   Sinus tachycardia * 0/223 (0.00%) </s>   Left ventricular dysfunction * 0/223 (0.00%) </s>   Abdominal pain * 0/223 (0.00%) </s>   Abdominal pain upper * 0/223 (0.00%) </s>   Colitis * 0/223 (0.00%),1,  Left ventricular dysfunction * 2/219 (0.91%) |   Abdominal pain * 1/219 (0.46%)
9abb10d7-496e-44fd-915d-d86aedf6c9b6,9abb10d7-496e-44fd-915d-d86aedf6c9b6,Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%),"[PRIMARY] Inclusion Criteria: </s>   For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly-effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the participant and/or partner </s>   Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection; participants with measurable and/or non-measurable disease are eligible </s>   Known and documented HER2-positive </s>   Known and documented LVEF of at least 50 percent (%) </s>   Adequate organ function </s>   A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than [<] 12 months of amenorrhea post-menopause, and women who have not undergone surgical sterilization [absence of ovaries and/or uterus]) within 7 days prior to the first dose of study treatment with the result available prior to first dosing </s> Exclusion Criteria: </s>   Previous systemic non-hormonal anti-cancer therapy for the metastatic or locally recurrent disease </s>   Pregnant or lactating women </s>   Current clinical or radiographic evidence of central nervous system (CNS) metastases </s>   Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment in the adjuvant or neo-adjuvant setting </s>   History of LVEF decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy",0,  Known and documented HER2-positive |   Known and documented LVEF of at least 50 percent (%)
8460a212-8054-4bd2-b4e6-af1d137a2f79,8460a212-8054-4bd2-b4e6-af1d137a2f79,the primary trial and the secondary trial report their results using different units of measure,"[PRIMARY] Outcome Measurement:  </s>   Objective Response Rate </s>   The objective response rate (ORR) was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. </s>   Time frame: Evaluated every 6 weeks from the time of their first treatment, per RECIST 1.1. Duration of therapy will depend on individual response, evidence of disease progression and tolerance, up to 1 year </s> Results 1:  </s>   Arm/Group Title: Cisplatin + AZD1775 </s>   Arm/Group Description: Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later. </s>   AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days. </s>   At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3). </s>   Overall Number of Participants Analyzed: 34 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  26        (13 to 44) [SECONDARY] Outcome Measurement:  </s>   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods </s>   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. </s>   Time frame: Baseline </s> Results 1:  </s>   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) </s>   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. </s>   Overall Number of Participants Analyzed: 92 </s>   Measure Type: Number </s>   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 </s>   Proportion of SNs (PICG) detected by ICG method: 0.95",1,  Unit of Measure: percentage of participants  26        (13 to 44) |   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86
a3390ae6-d41d-4dc7-899e-de9534adfd6b,a3390ae6-d41d-4dc7-899e-de9534adfd6b,the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib,[PRIMARY] INTERVENTION 1:  </s>   Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 </s>   Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.,1,INTERVENTION 1:  |   Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 |   Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.
17bbea92-8f92-41f3-9b9d-cf6e62cf6798,17bbea92-8f92-41f3-9b9d-cf6e62cf6798,the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.,"[PRIMARY] Outcome Measurement:  </s>   Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel </s>   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle. </s>   Time frame: From first dose date through day 28 </s> Results 1:  </s>   Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m  </s>   Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle. </s>   Overall Number of Participants Analyzed: 3 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  0   0.0% </s> Results 2:  </s>   Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m  </s>   Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle. </s>   Overall Number of Participants Analyzed: 5 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  0   0.0%",1,"Outcome Measurement:  |   Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel |   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle. |   Time frame: From first dose date through day 28"
794269ca-e7ec-4a65-ace5-b0f24a8cdc15,794269ca-e7ec-4a65-ace5-b0f24a8cdc15,the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS,"[PRIMARY] Outcome Measurement:  </s>   Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) </s>   The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method. </s>   Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) </s> Results 1:  </s>   Arm/Group Title: Ixabepilone 40 mg/m^2 </s>   Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks </s>   Overall Number of Participants Analyzed: 40 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  30.0        (16.6 to 46.5) </s> Results 2:  </s>   Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 </s>   Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks </s>   Overall Number of Participants Analyzed: 39 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  35.9        (21.2 to 52.8) [SECONDARY] Outcome Measurement:  </s>   Progression Free Survival </s>   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. </s>   Assessment period was from the day of randomisation until the first observation of lesion progression or death </s>   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, </s> Results 1:  </s>   Arm/Group Title: NK105 </s>   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.4        (7.0 to 9.9) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel </s>   Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.5        (6.9 to 11.5)",1,"Outcome Measurement:  |   Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) |   The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method. |   Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) | Outcome Measurement:  |   Progression Free Survival |   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. |   Assessment period was from the day of randomisation until the first observation of lesion progression or death |   Time frame: Baseline, every 6 weeks of study treatment period, and end of study,"
4dfff980-6a2b-4f01-9194-6ec831d6fed7,4dfff980-6a2b-4f01-9194-6ec831d6fed7,Infections were the most common adverse events recorded in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 5/55 (9.09%) </s>   Infection 2/55 (3.64%) </s>   Pain * 1/55 (1.82%) </s>   Muscle Weakness * 1/55 (1.82%) </s>   Dyspnea 1/55 (1.82%),1,Adverse Events 1: |   Total: 5/55 (9.09%) |   Infection 2/55 (3.64%) |   Pain * 1/55 (1.82%) |   Muscle Weakness * 1/55 (1.82%) |   Dyspnea 1/55 (1.82%)
dc4c57b0-8c75-494e-81b0-3528df85ebff,dc4c57b0-8c75-494e-81b0-3528df85ebff,neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts,"[PRIMARY] Outcome Measurement:  </s>   LDex Change- </s>   Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. </s>   Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks. </s> Results 1:  </s>   Arm/Group Title: Laser Therapy Alone </s>   Arm/Group Description: therapist administered laser treatment </s>   laser: therapist administered laser </s>   Overall Number of Participants Analyzed: 15 </s>   Median (Inter-Quartile Range) </s>   Unit of Measure: LDex  28.0        (17 to 35) </s> Results 2:  </s>   Arm/Group Title: Mld Alone </s>   Arm/Group Description: therapist administered manual lymphatic drainage </s>   manual lymphatic drainage: therapist administered massage therapy </s>   Overall Number of Participants Analyzed: 16 </s>   Median (Inter-Quartile Range) </s>   Unit of Measure: LDex  17.8        (3 to 38) [SECONDARY] Outcome Measurement:  </s>   Overall Survival (OS) of Patients </s>   To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis. </s>   Time frame: Within 3 years from study start </s> Results 1:  </s>   Arm/Group Title: NKTR-102 </s>   Arm/Group Description: In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. </s>   Overall Number of Participants Analyzed: 92 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.8        (6.1 to 10.2) </s> Results 2:  </s>   Arm/Group Title: Treatment of Physician's Choice (TPC) </s>   Arm/Group Description: In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. </s>   Overall Number of Participants Analyzed: 86 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.5        (5.8 to 10.4)",0,Outcome Measurement:  |   LDex Change- |   Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. |   Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks. | Outcome Measurement:  |   Overall Survival (OS) of Patients |   To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis. |   Time frame: Within 3 years from study start
8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c,8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c,"the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ","[PRIMARY] Outcome Measurement:  </s>   Objective Response Rate (ORR) </s>   An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. </s>   Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization </s>   Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) </s> Results 1:  </s>   Arm/Group Title: Fulvestrant 250 mg </s>   Arm/Group Description: Fulvestrant 250 mg </s>   Overall Number of Participants Analyzed: 45 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  11.1 </s> Results 2:  </s>   Arm/Group Title: Fulvestrant 250 mg + Loading Dose </s>   Arm/Group Description: Fulvestrant 250 mg + Loading Dose </s>   Overall Number of Participants Analyzed: 51 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  17.6 [SECONDARY] Outcome Measurement:  </s>   Objective Response (OR) </s>   OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST). OR was primary endpoint only for Cohort B. </s>   Time frame: Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter. </s> Results 1:  </s>   Arm/Group Title: Cohort B </s>   Arm/Group Description: Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd </s>   Overall Number of Participants Analyzed: 21 </s>   Measure Type: Number </s>   Unit of Measure: Participants with OR  0",0,"Outcome Measurement:  |   Objective Response Rate (ORR) |   An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. |   Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization |   Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) | Outcome Measurement:  |   Objective Response (OR) |   OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST). OR was primary endpoint only for Cohort B. |   Time frame: Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter."
251a20d8-2555-4929-9d01-c02311bdc93f,251a20d8-2555-4929-9d01-c02311bdc93f,a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1,"[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Disease Progression (PD) or Death </s>   This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up. </s>   Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years) </s> Results 1:  </s>   Arm/Group Title: Fulvestrant and Dasatinib </s>   Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib. </s>   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. </s>   Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years </s>   Overall Number of Participants Analyzed: 50 </s>   Measure Type: Number </s>   Unit of Measure: participants  35 </s> Results 2:  </s>   Arm/Group Title: Fulvestrant </s>   Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only. </s>   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. </s>   Overall Number of Participants Analyzed: 49 </s>   Measure Type: Number </s>   Unit of Measure: participants  40",1,"Outcome Measurement:  |   Number of Participants With Disease Progression (PD) or Death |   This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up. |   Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years) | Results 1:  |   Arm/Group Title: Fulvestrant and Dasatinib |   Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib. |   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. |   Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years |   Overall Number of Participants Analyzed: 50 |   Measure Type: Number |   Unit of Measure: participants  35 | Results 2:  |   Arm/Group Title: Fulvestrant |   Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only. |   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. |   Overall Number of Participants Analyzed: 49 |   Measure Type: Number |   Unit of Measure: participants  40"
dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1,dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1,the secondary trial and the primary trial do not record the same metrics in their results section,"[PRIMARY] Outcome Measurement:  </s>   LDex Change- </s>   Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. </s>   Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks. </s> Results 1:  </s>   Arm/Group Title: Laser Therapy Alone </s>   Arm/Group Description: therapist administered laser treatment </s>   laser: therapist administered laser </s>   Overall Number of Participants Analyzed: 15 </s>   Median (Inter-Quartile Range) </s>   Unit of Measure: LDex  28.0        (17 to 35) </s> Results 2:  </s>   Arm/Group Title: Mld Alone </s>   Arm/Group Description: therapist administered manual lymphatic drainage </s>   manual lymphatic drainage: therapist administered massage therapy </s>   Overall Number of Participants Analyzed: 16 </s>   Median (Inter-Quartile Range) </s>   Unit of Measure: LDex  17.8        (3 to 38) [SECONDARY] Outcome Measurement:  </s>   Overall Survival (OS) of Patients </s>   To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis. </s>   Time frame: Within 3 years from study start </s> Results 1:  </s>   Arm/Group Title: NKTR-102 </s>   Arm/Group Description: In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. </s>   Overall Number of Participants Analyzed: 92 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.8        (6.1 to 10.2) </s> Results 2:  </s>   Arm/Group Title: Treatment of Physician's Choice (TPC) </s>   Arm/Group Description: In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. </s>   Overall Number of Participants Analyzed: 86 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.5        (5.8 to 10.4)",1,Outcome Measurement:  |   LDex Change- |   Bioimpedance measured by units of LDex. As extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. |   Time frame: Bioimpedance at baseline and end of treatment with the average number of treaments being 9 conducted over a median of up to 4 weeks. | Outcome Measurement:  |   Overall Survival (OS) of Patients |   To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis. |   Time frame: Within 3 years from study start
f0273b8c-460d-46fe-9c52-8ff4b08e439b,f0273b8c-460d-46fe-9c52-8ff4b08e439b,"eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial","[PRIMARY] Inclusion Criteria: </s>   women >=18 years of age; </s>   newly diagnosed; </s>   infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer. </s> Exclusion Criteria: </s>   evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes; </s>   previous systemic or local primary treatment.",1,Inclusion Criteria: |   women >=18 years of age;
bc2024fc-5b39-4fa6-badf-f034d6fe8bb8,bc2024fc-5b39-4fa6-badf-f034d6fe8bb8,Breast cancer patients must have documented progressive disease to participate in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Pathologically confirmed diagnosis of breast cancer with documented progressive disease. </s>   Patients with stable brain metastases are eligible for this trial. </s>   At least one prior chemotherapy regimen for metastatic breast cancer. Prior treatment must be discontinued at least 2 weeks before treatment start. </s>   Concomitant therapy with bisphosphonates is allowed. </s>   Stable dose coumadin anticoagulation is allowed, providing that anticoagulation can be safely held to an International Normalized Ratio (INR) within normal range for the purpose of tumor biopsy. Low molecular weight heparin (LMWH is the preferred method of anticoagulation. </s>   Prothrombin time (PT)/International Normalized Ratio (INR) and partial thromboplastin time (PTT) within institutional normal limits within two weeks before initial biopsy. </s>   Measurable disease, as defined by RECIST guidelines or evaluable disease. Bone metastases must be evaluable. </s>   Disease amenable to core biopsy. Patients with pulmonary metastases as their only site of disease may enroll on this trial and will not undergo biopsy. </s>   For Phase I: patients with human epidermal growth factor receptor 2 (HER2) overexpressing disease must have been previously treated with trastuzumab. Patients with HER2 overexpressing disease are not eligible for the Phase II trial. </s>   Age eighteen years or older. </s>   Eastern Cooperative Oncology Group (ECOG) performance status </= 2. </s>   Life expectancy of >/= 12 weeks. </s>   Patients with < grade 1 peripheral neuropathy are eligible for this trial. </s>   Adequate bone marrow reserve: Absolute Neutrophil Count (ANC) >/= 1000, platelets >/= 100,000. </s>   Adequate renal function: serum creatinine </= 1.5x upper limit of normal (ULN) OR calculated creatinine clearance  50 ml/min. </s>   Sodium, potassium, and chloride levels within institutional normal limits. </s>   Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x ULN, and total bilirubin </= 1.5x upper limit of normal. In patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be </= 5 times the ULN. </s>   At baseline: Ejection fraction (EF)  50%, no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point - patients may be eligible for study if the drug can be changed to another agent with less risk (such as changing from citalopram to an alternate antidepressant). </s>   Able to take oral medications and maintain hydration. </s>   Ability to give written informed consent and willingness to comply with the requirements of the protocol </s>   Women of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drug </s>   Specific inclusion criteria for Phase II </s>  Patients enrolling on the phase II portion of this trial must have ER, progesterone receptors (PR) and HER2 negative disease defined as less than 10% staining for ER and PR, and HER2 not amplified byFluorescent in situ hybridization (FISH), 0-1% by Immunohistochemistry (IHC), or 2+ by IHC and no evidence of amplification by FISH. </s> Exclusion Criteria: </s>   Treatment with another chemotherapy or hormonal therapy within the past 2 weeks. </s>   Treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks. </s>   Concurrent treatment with radiotherapy. </s>   Ongoing treatment with any other investigational therapy. </s>   Prior treatment with eribulin </s>   Severe, concurrent illness including congestive heart failure, significant cardiac disease and uncontrolled hypertension, that would likely prevent the patient from being able to comply with the study protocol. </s>   Inadequate bone marrow, renal, or hepatic function as defined above, or an active coagulopathy that precludes tissue biopsy. </s>   Pregnant or lactating women and women of child-bearing potential who are not using an effective method of birth control. Women of childbearing potential must undergo a serum pregnancy test within seven days of starting the study drug.",1,  Pathologically confirmed diagnosis of breast cancer with documented progressive disease.
c2217d42-e90c-4ffe-b084-e653b9ace4d5,c2217d42-e90c-4ffe-b084-e653b9ace4d5,"the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",[PRIMARY] Adverse Events 1: </s>   Total: 0/655 (0.00%) </s> Adverse Events 2: </s>   Total: 0/580 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 0/15 (0.00%) </s> Adverse Events 2: </s>   Total: 0/16 (0.00%),0,Adverse Events 1: |   Total: 0/655 (0.00%) | Adverse Events 2: |   Total: 0/580 (0.00%) | Adverse Events 1: |   Total: 0/15 (0.00%) | Adverse Events 2: |   Total: 0/16 (0.00%)
080da381-b5dd-46d3-99c4-18112da153c1,080da381-b5dd-46d3-99c4-18112da153c1,"There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",[PRIMARY] Adverse Events 1: </s>   Total: 0/0 </s> Adverse Events 2: </s>     [SECONDARY] Adverse Events 1: </s>   Total: 59/199 (29.65%) </s>   Anaemia 7/199 (3.52%) </s>   Thrombocytopenia 2/199 (1.01%) </s>   Acute myocardial infarction 0/199 (0.00%) </s>   Atrial fibrillation 1/199 (0.50%) </s>   Cardiac arrest 1/199 (0.50%) </s>   Cardiac failure 1/199 (0.50%) </s>   Cardiopulmonary failure 1/199 (0.50%) </s>   Left ventricular failure 1/199 (0.50%) </s>   Supraventricular tachycardia 0/199 (0.00%) </s>   Ventricular tachycardia 1/199 (0.50%) </s> Adverse Events 2: </s>   Total: 16/36 (44.44%) </s>   Anaemia 2/36 (5.56%) </s>   Thrombocytopenia 1/36 (2.78%) </s>   Acute myocardial infarction 1/36 (2.78%) </s>   Atrial fibrillation 0/36 (0.00%) </s>   Cardiac arrest 0/36 (0.00%) </s>   Cardiac failure 0/36 (0.00%) </s>   Cardiopulmonary failure 0/36 (0.00%) </s>   Left ventricular failure 0/36 (0.00%) </s>   Supraventricular tachycardia 1/36 (2.78%) </s>   Ventricular tachycardia 0/36 (0.00%),0,Adverse Events 1: |   Total: 0/0 | Adverse Events 2: |     | Adverse Events 1: |   Acute myocardial infarction 1/36 (2.78%) |   Cardiopulmonary failure 0/36 (0.00%) |   Supraventricular tachycardia 1/36 (2.78%)
c100a7cd-e3a2-4901-a3e0-12336f769c7b,c100a7cd-e3a2-4901-a3e0-12336f769c7b,"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16","[PRIMARY] Adverse Events 1: </s>   Total: 16/48 (33.33%) </s>   Febrile neutropenia grade 3 3/48 (6.25%) </s>   Neutropenia grade 3 1/48 (2.08%) </s>   Holocraneal cephalea 1/48 (2.08%) </s>   Hypersensibility reaction grade 3 2/48 (4.17%) </s>   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) </s>   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) </s>   Catheter - related infection grade 3 1/48 (2.08%) [SECONDARY] Adverse Events 1: </s>   Total: 21/519 (4.05%) </s>   Anaemia 1/519 (0.19%) </s>   Blood bilirubin 0/519 (0.00%) </s>   Leukopenia 0/519 (0.00%) </s>   Neutropenia 1/519 (0.19%) </s>   Arrhythmia 0/519 (0.00%) </s>   Carotid artery thrombosis 1/519 (0.19%) </s>   Ear infection 0/519 (0.00%) </s>   Conjunctivitis 0/519 (0.00%) </s>   Abdominal pain 1/519 (0.19%) </s>   Anal fissure 0/519 (0.00%) </s>   Constipation 0/519 (0.00%) </s>   Diarrhoea 1/519 (0.19%) </s> Adverse Events 2: </s>   Total: 119/532 (22.37%) </s>   Anaemia 1/532 (0.19%) </s>   Blood bilirubin 1/532 (0.19%) </s>   Leukopenia 1/532 (0.19%) </s>   Neutropenia 5/532 (0.94%) </s>   Arrhythmia 1/532 (0.19%) </s>   Carotid artery thrombosis 0/532 (0.00%) </s>   Ear infection 1/532 (0.19%) </s>   Conjunctivitis 1/532 (0.19%) </s>   Abdominal pain 1/532 (0.19%) </s>   Anal fissure 1/532 (0.19%) </s>   Constipation 1/532 (0.19%) </s>   Diarrhoea 6/532 (1.13%)",0,"Adverse Events 1: |   Total: 16/48 (33.33%) |   Febrile neutropenia grade 3 3/48 (6.25%) |   Neutropenia grade 3 1/48 (2.08%) |   Holocraneal cephalea 1/48 (2.08%) |   Hypersensibility reaction grade 3 2/48 (4.17%) |   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) |   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) |   Catheter - related infection grade 3 1/48 (2.08%) | Adverse Events 1: |   Conjunctivitis 0/519 (0.00%) | Adverse Events 2: |   Conjunctivitis 1/532 (0.19%)"
ec1e269e-470d-43d9-8f23-8a19a5c96fcc,ec1e269e-470d-43d9-8f23-8a19a5c96fcc,Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2,[PRIMARY] Adverse Events 1: </s>   Total: 59/199 (29.65%) </s>   Anaemia 7/199 (3.52%) </s>   Thrombocytopenia 2/199 (1.01%) </s>   Acute myocardial infarction 0/199 (0.00%) </s>   Atrial fibrillation 1/199 (0.50%) </s>   Cardiac arrest 1/199 (0.50%) </s>   Cardiac failure 1/199 (0.50%) </s>   Cardiopulmonary failure 1/199 (0.50%) </s>   Left ventricular failure 1/199 (0.50%) </s>   Supraventricular tachycardia 0/199 (0.00%) </s>   Ventricular tachycardia 1/199 (0.50%) </s> Adverse Events 2: </s>   Total: 16/36 (44.44%) </s>   Anaemia 2/36 (5.56%) </s>   Thrombocytopenia 1/36 (2.78%) </s>   Acute myocardial infarction 1/36 (2.78%) </s>   Atrial fibrillation 0/36 (0.00%) </s>   Cardiac arrest 0/36 (0.00%) </s>   Cardiac failure 0/36 (0.00%) </s>   Cardiopulmonary failure 0/36 (0.00%) </s>   Left ventricular failure 0/36 (0.00%) </s>   Supraventricular tachycardia 1/36 (2.78%) </s>   Ventricular tachycardia 0/36 (0.00%),0,Adverse Events 1: |   Total: 59/199 (29.65%) |   Anaemia 7/199 (3.52%) |   Thrombocytopenia 2/199 (1.01%) |   Acute myocardial infarction 0/199 (0.00%) |   Atrial fibrillation 1/199 (0.50%) |   Cardiac arrest 1/199 (0.50%) |   Cardiac failure 1/199 (0.50%) |   Cardiopulmonary failure 1/199 (0.50%) |   Left ventricular failure 1/199 (0.50%) |   Supraventricular tachycardia 0/199 (0.00%) |   Ventricular tachycardia 1/199 (0.50%) | Adverse Events 2: |   Total: 16/36 (44.44%) |   Anaemia 2/36 (5.56%) |   Thrombocytopenia 1/36 (2.78%) |   Acute myocardial infarction 1/36 (2.78%) |   Atrial fibrillation 0/36 (0.00%) |   Cardiac arrest 0/36 (0.00%) |   Cardiac failure 0/36 (0.00%) |   Cardiopulmonary failure 0/36 (0.00%) |   Left ventricular failure 0/36 (0.00%) |   Supraventricular tachycardia 1/36 (2.78%) |   Ventricular tachycardia 0/36 (0.00%)
21611c2a-e6eb-4012-a209-9b6781e1f260,21611c2a-e6eb-4012-a209-9b6781e1f260,There is no adverse events section in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 0,1,Adverse Events 1: |   Total: 0
d1b7105d-0b7d-4b10-92a7-d63243ff0629,d1b7105d-0b7d-4b10-92a7-d63243ff0629,"Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ","[PRIMARY] Inclusion criteria: </s> Inclusion Criteria: </s>   Female patients age 18 years or older </s>   Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant, irrespective of prior hormone therapy metastatic disease (stage IV); </s>   HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative) </s>   At least one measurable tumour lesion (RECIST); </s>   Availability of tumour samples </s>   Written informed consent that is consistent with ICH-GCP guidelines and local law </s>   Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 - 2. </s> Exclusion criteria: </s> Exclusion Criteria: </s>   Active infectious disease </s>   Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea </s>   Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol </s>   Active/symptomatic brain metastases </s>   Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) </s>   ANC less than 1500/mm3 platelet count less than 100 000/mm3 </s>   Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent) </s>   AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases </s>   Serum creatinine greater than 1.5 mg/dl (>132 and#61549 mol/L, SI unit equivalent) </s>   Patients who are sexually active and unwilling to use a medically acceptable method of contraception </s>   Pregnancy or breast-feeding </s>   Concomitant treatment with other investigational drugs or other anti-cancer-therapy during this study and/or during the past two/four weeks, prior to the first treatment with the trial drug. Concurrent treatment with biphosphonates is allowed </s>   Previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply with the protocol </s>   Active alcohol or drug abuse </s>   Other malignancy within the past 5 years [SECONDARY] Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. </s>   Women with breast density  25% (scattered fibroglandular densities or greater) are eligible. </s>   Prior Treatment </s>   Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. </s>   Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. </s>   Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. </s>   Vitamin D Use </s>   Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. </s>   Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. </s>   Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. </s>   Patients with a history of breast implants or breast reduction are not eligible. </s>   Patients with two or more bone fractures in the past five years are not eligible. </s>   Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. </s>   Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. </s>   Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. </s>   Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. </s>   Required initial laboratory values - Calcium < 10.5 mg/dL",1,"  Cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) | Premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months). Women with fewer than 4 menses in the last 6 months or who have had a hysterectomy with ovaries intact will be considered premenopausal if FSH level < 20. |   Women with breast density  25% (scattered fibroglandular densities or greater) are eligible. |   Prior Treatment |   Patients who are currently receiving hormone replacement therapy (estrogen or progesterone); or are taking tamoxifen or raloxifene are not eligible. Women who have taken these medications must have stopped for at least 4 months prior to study entry. |   Topical estrogen (eg, transdermal patches and vaginal estrogens) is allowed. |   Patients who are currently using hormonal contraception, should be taking it for at least 4 months prior to study entry. |   Vitamin D Use |   Patients who are taking regular vitamin D supplementation (above 400 IUs daily) and refuse or are unable to stop use are not eligible. Women who agree to stop will need to do so for at least 6 months prior to registration. |   Patients may not start vitamin D supplementation after registration (regardless of results of vitamin D testing) but they may continue vitamin D if they are already taking 400 IUs daily or less and have been taking vitamin D for at least 6 months prior to baseline mammogram. |   Patients with a history of breast cancer (including DCIS) or ovarian cancer are not eligible. |   Patients with a history of breast implants or breast reduction are not eligible. |   Patients with two or more bone fractures in the past five years are not eligible. |   Patients with a diagnosis of osteoporosis with physician recommendation for treatment of low bone mass are not eligible. |   Patients known to have hyperparathyroid disease or other serious disturbances of calcium metabolism requiring intervention in the past 5 years are not eligible. |   Patients with a history of kidney stones (unless documented not to have been a calcium stone) are not eligible. |   Patients participating in a concurrent breast cancer chemoprevention trial are not eligible. |   Required initial laboratory values - Calcium < 10.5 mg/dL"
7f3fe97e-68ee-470f-b06e-21cdddb67aa8,7f3fe97e-68ee-470f-b06e-21cdddb67aa8,"all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial","[PRIMARY] Inclusion Criteria: </s>   Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging </s>   Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned. </s>   Patients must have completed definitive resection of primary tumor with adequate excision of gross disease. </s>   For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy. </s>   Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy. </s>   LVEF > institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment. </s>   ECOG performance status 0-1 </s> Exclusion Criteria: </s>   Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment </s>   Patients with metastatic disease are ineligible. </s>   Known HIV infection </s>   Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding </s>   Uncontrolled intercurrent illness </s>   Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment </s>   History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab </s>   Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded </s>   History of bleeding diathesis or coagulopathy </s>   History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites) </s>   Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer </s>   Patients with large or rapidly accumulating pleural or abdominal effusions </s>   Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR </s>   Chronic therapy with full dose aspirin (< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed </s>   Patients may not receive other investigational agents while on study [SECONDARY] Inclusion Criteria: </s>   For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com </s>   Patients with metastatic or advanced solid tumors </s>   Women with histologically or cytologically confirmed triple negative breast carcinoma </s>   Participants with histologically or cytologically confirmed pancreatic adenocarcinoma </s>   Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) </s> Exclusion Criteria: </s>   Active brain metastases or leptomeningeal metastases. </s>   Any serious or uncontrolled medical disorder </s>   Prior malignancy active within the previous 3 years </s>   Other protocol defined inclusion/exclusion criteria could apply",0,"  Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging | Inclusion Criteria: |   For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com |   Patients with metastatic or advanced solid tumors |   Women with histologically or cytologically confirmed triple negative breast carcinoma |   Participants with histologically or cytologically confirmed pancreatic adenocarcinoma |   Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) | Exclusion Criteria: |   Active brain metastases or leptomeningeal metastases. |   Any serious or uncontrolled medical disorder |   Prior malignancy active within the previous 3 years |   Other protocol defined inclusion/exclusion criteria could apply"
ce8464bd-951e-44aa-97d9-10b917b055ce,ce8464bd-951e-44aa-97d9-10b917b055ce,there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1,[PRIMARY] Adverse Events 1: </s>   Total: 5/101 (4.95%) </s>   BILATERAL CATARACTS * 0/101 (0.00%) </s>   APPENDICITIS * 2/101 (1.98%) </s>   ISCHEMIC COLITIS * 1/101 (0.99%) </s>   SLIPPED DISK * 0/101 (0.00%) </s>   RIGHT BIMALLEOLAR ANKLE FRACTURE * 0/101 (0.00%) </s>   ACUTE MYELOID LEUKEMIA * 0/101 (0.00%) </s>   BREAST CANCER * 0/101 (0.00%) </s>   PRIMARY DCIS IN BREAST * 0/101 (0.00%) </s>   OVARIAN CYST * 1/101 (0.99%) </s> Adverse Events 2: </s>   Total: 9/98 (9.18%) </s>   BILATERAL CATARACTS * 1/98 (1.02%) </s>   APPENDICITIS * 0/98 (0.00%) </s>   ISCHEMIC COLITIS * 0/98 (0.00%) </s>   SLIPPED DISK * 1/98 (1.02%) </s>   RIGHT BIMALLEOLAR ANKLE FRACTURE * 1/98 (1.02%) </s>   ACUTE MYELOID LEUKEMIA * 1/98 (1.02%) </s>   BREAST CANCER * 1/98 (1.02%) </s>   PRIMARY DCIS IN BREAST * 1/98 (1.02%) </s>   OVARIAN CYST * 1/98 (1.02%),0,  SLIPPED DISK * 0/101 (0.00%) |   SLIPPED DISK * 1/98 (1.02%)
0131ebe3-746b-45a5-ba60-fdd326974fec,0131ebe3-746b-45a5-ba60-fdd326974fec,the primary trial and the secondary trial use comparable outcome measurements,"[PRIMARY] Outcome Measurement:  </s>   Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants </s>   Number of participants experiencing CR, PR or SD as defined by Response Evaluation Criteria In Solid Tumors (RECIST). Response is anyone who experiences SD, CR or PR in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. No symptoms or evidence of residual invasive tumor, including no residual tumor in axillary lymph nodes. PR: 50%/> decrease for minimum 4 weeks in measurable lesion determined by product of perpendicular diameters of lesion. Every lesion should not regress to qualify as PR; however, if lesion progresses or if new lesions appear, response cannot be classified as PR. Minor Response [MR]: Decreases in tumor masses insufficient to qualify as partial remission, i.e. <50%. SD: Between MR & PD. PD: Increase 25% measured lesion from baseline. New lesions constitutes increasing disease. Mixed responses consid </s>   Time frame: 6 months </s> Results 1:  </s>   Arm/Group Title: Dovitinib </s>   Arm/Group Description: Dovitinib 500 mg single oral dose for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle. </s>   Overall Number of Participants Analyzed: 19 </s>   Measure Type: Number </s>   Unit of Measure: participants  Complete Response (CR): 0 </s>   Partial Response (PR): 0 </s>   Stable Disease (SD): 1 [SECONDARY] Outcome Measurement:  </s>   Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants) </s>   pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes. </s>   Time frame: Surgery visit (at approximately Weeks 14 to 19) </s> Results 1:  </s>   Arm/Group Title: Ipatasertib + Paclitaxel </s>   Arm/Group Description: Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). </s>   Overall Number of Participants Analyzed: 76 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  17.1        (9.82 to 27.25) </s> Results 2:  </s>   Arm/Group Title: Placebo + Paclitaxel </s>   Arm/Group Description: Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses). </s>   Overall Number of Participants Analyzed: 75 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  13.3        (6.58 to 22.86)",1,"Outcome Measurement:  |   Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants |   Number of participants experiencing CR, PR or SD as defined by Response Evaluation Criteria In Solid Tumors (RECIST). Response is anyone who experiences SD, CR or PR in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. No symptoms or evidence of residual invasive tumor, including no residual tumor in axillary lymph nodes. PR: 50%/> decrease for minimum 4 weeks in measurable lesion determined by product of perpendicular diameters of lesion. Every lesion should not regress to qualify as PR; however, if lesion progresses or if new lesions appear, response cannot be classified as PR. Minor Response [MR]: Decreases in tumor masses insufficient to qualify as partial remission, i.e. <50%. SD: Between MR & PD. PD: Increase 25% measured lesion from baseline. New lesions constitutes increasing disease. Mixed responses consid |   Time frame: 6 months | Outcome Measurement:  |   Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in All Participants) |   pCR was defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System with the following determination for breast and axilla by local pathology laboratory evaluation: T0: no evidence of primary tumor; Tis: early cancer that has not spread to neighboring tissue and N0: no cancer found in the lymph nodes. |   Time frame: Surgery visit (at approximately Weeks 14 to 19)"
b1dd7632-ed92-40a9-9293-bce68619c658,b1dd7632-ed92-40a9-9293-bce68619c658,"Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible","[PRIMARY] Eligibility Criteria: </s>   Newly diagnosed with stage I-III cancer of the female breast </s>   No prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer </s>   * Patients with a history of other invasive malignancies are eligible as long as they have completed treatment and are 5 years post-diagnosis; patients with basal cell and squamous cell cancer of the skin are eligible </s>   Neoadjuvant therapy </s>   Patients scheduled to receive any type of radiation therapy to the breast or axilla are eligible; however, they must be registered to this study with pre-surgery measures taken prior to receiving neoadjuvant therapy </s>   Patients scheduled to receive neoadjuvant chemotherapy are also eligible; however, they must be registered to this study with pre-surgery measurements taken prior to receiving neoadjuvant therapy </s>   Patients receiving no neoadjuvant therapy are eligible </s>   May be enrolled on other treatment trials; however, patients enrolled on surgery trials where only one treatment arm is full axillary node dissection are not eligible; NOTE: Patients enrolled on American College of Surgeons Oncology Group (ACOSOG)-Z1071 are eligible to participate in this study; patients concurrently enrolled on this study and ACOSOG-Z1071, may not also be enrolled on the ACOSOG-Z1071 lymphedema sub-study </s>   No documented cardiac conduction disturbances, unstable angina, dementia, or any other chronic disease which, in the opinion of the treating physician, significantly increases mortality over the next 2 years </s>   No diagnosed lymphedema </s>   In order to be properly fitted for the elastic sleeve, eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the ranges for one of the six sleeve sizes </s>   Not currently homebound or dependent upon a walker or wheelchair for mobility </s>   Able to participate in a mild exercise program </s>   Willing to return to the study site for the duration of the study (18 months) </s>   Sentinel (SND) or full axillary node dissection (AND) (no minimum number of nodes required) </s>   Patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study; however, it should be documented appropriately on form C-1628 at the conclusion of study participation",0,Eligibility Criteria: |   Newly diagnosed with stage I-III cancer of the female breast
45ccd2c8-6e02-4f0f-a370-eed18d26e6dc,45ccd2c8-6e02-4f0f-a370-eed18d26e6dc,the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally,"[PRIMARY] INTERVENTION 1:  </s>   Fulvestrant + Everolimus </s>   Fulvestrant + Everolimus </s>   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.",1,"INTERVENTION 1:  |   Fulvestrant + Everolimus |   Fulvestrant + Everolimus |   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
4a15ec5e-4904-4f01-a0a2-c51e83c8c070,4a15ec5e-4904-4f01-a0a2-c51e83c8c070,the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort,"[PRIMARY] Outcome Measurement:  </s>   Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients </s>   The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm. </s>   Time frame: 4-7 weeks (prescribed course of radiation) </s> Results 1:  </s>   Arm/Group Title: Curcumin C3 Complex </s>   Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks). </s>   Overall Number of Participants Analyzed: 14 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  2.6         (0.994) </s> Results 2:  </s>   Arm/Group Title: Placebo </s>   Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks). </s>   Overall Number of Participants Analyzed: 16 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  3.4         (0.554)",1,"Outcome Measurement:  |   Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients |   The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm. |   Time frame: 4-7 weeks (prescribed course of radiation) | Results 1:  |   Arm/Group Title: Curcumin C3 Complex |   Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks). |   Overall Number of Participants Analyzed: 14 |   Mean (Standard Deviation) |   Unit of Measure: units on a scale  2.6         (0.994) | Results 2:  |   Arm/Group Title: Placebo |   Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks). |   Overall Number of Participants Analyzed: 16 |   Mean (Standard Deviation) |   Unit of Measure: units on a scale  3.4         (0.554)"
b9e29ea8-6847-40d4-b5c3-81c496101695,b9e29ea8-6847-40d4-b5c3-81c496101695,"All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months","[PRIMARY] Outcome Measurement:  </s>   Centrally Assessed Progression Free Survival </s>   Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months. </s>   Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut. </s> Results 1:  </s>   Arm/Group Title: Neratinib Plus Capecitabine </s>   Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. </s>   Overall Number of Participants Analyzed: 307 </s>   Mean (95% Confidence Interval) </s>   Unit of Measure: months  8.8        (7.8 to 9.8) </s> Results 2:  </s>   Arm/Group Title: Lapatinib Plus Capecitabine </s>   Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. </s>   Overall Number of Participants Analyzed: 314 </s>   Mean (95% Confidence Interval) </s>   Unit of Measure: months  6.6        (5.9 to 7.4)",0,"Outcome Measurement:  |   Centrally Assessed Progression Free Survival |   Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months. |   Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut. | Results 1:  |   Arm/Group Title: Neratinib Plus Capecitabine |   Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle. |   Overall Number of Participants Analyzed: 307 |   Mean (95% Confidence Interval) |   Unit of Measure: months  8.8        (7.8 to 9.8)"
2a2c16a7-f427-4fdb-8153-94aac304e4b8,2a2c16a7-f427-4fdb-8153-94aac304e4b8,"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles","[PRIMARY] INTERVENTION 1:  </s>   HER2+ TC </s>   Participants with HER2+ breast cancer received treatment as follows: </s>   Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. </s>   Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. </s>   Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off. </s>   Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years. </s> INTERVENTION 2:  </s>   HER2+ C </s>   Participants with HER2+ breast cancer received treatment as follows: </s>   Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. </s>   Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. </s>   Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.",0,"INTERVENTION 1:  |   HER2+ TC |   Participants with HER2+ breast cancer received treatment as follows: |   Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. |   Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. |   Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off. |   Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years. | INTERVENTION 2:  |   HER2+ C |   Participants with HER2+ breast cancer received treatment as follows: |   Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off. |   Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off. |   Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off."
618a3ae1-b22c-4c35-86a6-190c1b5b5d21,618a3ae1-b22c-4c35-86a6-190c1b5b5d21,Patients must have a Life expectancy of at least 1 year to enroll in the primary trial,"[PRIMARY] Inclusion criteria: </s>   Female patients  18 years of age. </s>   Written informed consent given. </s>   Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed. </s>   Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months. </s>   Eastern Cooperative Oncology Group (ECOG) performance status 2 . </s>   Life expectancy  1 year. </s> Exclusion criteria: </s>   More than 3 months since last infusion of Zoledronic Acid (Zometa®). </s>   Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry. </s>   Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 </s>   Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L). </s>   Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. </s>   Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants). </s>   Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide). </s>   History of non-compliance to medical regimens or potential unreliable behavior. </s>   Known sensitivity to study drug(s) or class of study drug(s). </s>   Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study </s>   Use of any other investigational agent in the last 30 days.",1,  Life expectancy  1 year.
e62f5a3f-0091-4980-9822-db8f4dc2502a,e62f5a3f-0091-4980-9822-db8f4dc2502a,"the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts","[PRIMARY] Outcome Measurement:  </s>   Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients </s>   The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm. </s>   Time frame: 4-7 weeks (prescribed course of radiation) </s> Results 1:  </s>   Arm/Group Title: Curcumin C3 Complex </s>   Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks). </s>   Overall Number of Participants Analyzed: 14 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  2.6         (0.994) </s> Results 2:  </s>   Arm/Group Title: Placebo </s>   Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks). </s>   Overall Number of Participants Analyzed: 16 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  3.4         (0.554)",0,"Outcome Measurement:  |   Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients |   The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm. |   Time frame: 4-7 weeks (prescribed course of radiation) | Results 1:  |   Arm/Group Title: Curcumin C3 Complex |   Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks). |   Overall Number of Participants Analyzed: 14 |   Mean (Standard Deviation) |   Unit of Measure: units on a scale  2.6         (0.994) | Results 2:  |   Arm/Group Title: Placebo |   Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks). |   Overall Number of Participants Analyzed: 16 |   Mean (Standard Deviation) |   Unit of Measure: units on a scale  3.4         (0.554)"
4a41ac73-538a-43e5-b7ce-8c8e2d56286e,4a41ac73-538a-43e5-b7ce-8c8e2d56286e,"Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.","[PRIMARY] Inclusion Criteria: </s>   No known soy intolerance </s>   At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following: </s>   Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following: </s>   Gail score >= 1.66% </s>   Gail score >= 0.1% for women age 20-29 years </s>   Gail score >= 1.0% for women age 30-39 years </s>   Estimated 5-year risk of developing breast cancer using the Claus model: </s>   Claus score >= 1.66% </s>   Claus score >= 0.1% for women age 20-29 years </s>   Claus score >= 1.0% for women age 30-39 years </s>   Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity </s>   History of lobular carcinoma in situ </s>   No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical </s>   No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago </s>   Pre- or postmenopausal </s>   ECOG performance status 0-1 </s>   Hemoglobin > 10.0 g/dL </s>   Platelet count > 100,000/mm^3 </s>   Absolute neutrophil count > 1,000/mm^3 </s>   Creatinine < 2.0 mg/dL </s>   SGPT < 82 U/L </s>   SGOT < 68 U/L </s>   Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator] </s>   Life expectancy > 2 years </s>   Not pregnant or nursing </s>   Negative pregnancy test </s>   Fertile patients must use effective barrier contraception </s>   Must be willing to keep a dietary diary </s>   No venous thrombosis within the past year </s>   No unrecognized or poorly controlled thyroid disease </s>   No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer </s>   No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained </s>   None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation: </s>   Oral contraceptives </s>   Soy supplements </s>   High soy-containing foods </s>   Fish oil supplements </s>   Multivitamins </s>   Vitamins C and E </s>   Daily aspirin or nonsteroidal </s>   Anti-inflammatory drugs </s>   No other concurrent investigational agents </s>   No concurrent warfarin or other blood thinners </s>   Female patient </s> Exclusion Criteria: </s>   Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously </s>   Currently pregnant, or planning to become pregnant during the study period </s>   History of venous thrombosis within past year </s>   Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained </s>   History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer </s>   Known soy intolerance </s>   Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled. </s>   Currently receiving any other investigational agents </s>   Currently on coumadin, or other blood thinners </s>   History of breast augmentation implants. </s>   Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study. [SECONDARY] Inclusion Criteria: </s>   Female aged  18 years. </s>   Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released. </s>   TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2. </s>   Patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment </s>   Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1. </s>   Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1. </s>   Life expectancy of at least three months. </s>   Patients must be able to swallow and retain oral medication (intact tablet). </s>   Able to undergo all screening assessments outlined in the protocol. </s>   Adequate organ function (defined by the following parameters): </s>   Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min. </s>   Serum hemoglobin  9 g/dL; absolute neutrophil count  1.5 x 109/L; platelets  100 x 109/L. </s>   Serum bilirubin  1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome </s>   Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST)  2.5 x UNL but  5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP)  UNL but i)  2.5 x UNL in case of liver metastases and ii)  5 UNL in case of bone metastases; albumin  2.5 g/dl. </s>   No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease. </s>   No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status. </s>   Dated and signed IEC/IRB-approved informed consent. </s> Exclusion Criteria: </s>   Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease. </s>   Less than four weeks since last radiotherapy (excluding palliative radiotherapy). </s>   Pregnancy or lactation or unwillingness to use adequate method of birth control. </s>   Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures. </s>   Active or uncontrolled infection. </s>   Malabsorption syndrome, disease significantly affecting gastrointestinal function. </s>   G>1 pre-existing peripheral neuropathy </s>   Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer </s>   Hypersensitivity to: </s>   paclitaxel </s>   ibuprofen or to more than one non-steroidal anti-inflammatory drug. </s>   medications belonging to the class of sulfonamides, with the exception of sulfanilamides (e.g., sulfamethoxazole).",0,"Exclusion Criteria: |   Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously | Exclusion Criteria: |   Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease. |   Less than four weeks since last radiotherapy (excluding palliative radiotherapy)."
75a65913-5655-4377-b441-ecdd4dd75175,75a65913-5655-4377-b441-ecdd4dd75175,Patients with stage 4 cancer are excluded from the primary trial,"[PRIMARY] Eligibility Criteria: </s>   Newly diagnosed with stage I-III cancer of the female breast </s>   No prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer </s>   * Patients with a history of other invasive malignancies are eligible as long as they have completed treatment and are 5 years post-diagnosis; patients with basal cell and squamous cell cancer of the skin are eligible </s>   Neoadjuvant therapy </s>   Patients scheduled to receive any type of radiation therapy to the breast or axilla are eligible; however, they must be registered to this study with pre-surgery measures taken prior to receiving neoadjuvant therapy </s>   Patients scheduled to receive neoadjuvant chemotherapy are also eligible; however, they must be registered to this study with pre-surgery measurements taken prior to receiving neoadjuvant therapy </s>   Patients receiving no neoadjuvant therapy are eligible </s>   May be enrolled on other treatment trials; however, patients enrolled on surgery trials where only one treatment arm is full axillary node dissection are not eligible; NOTE: Patients enrolled on American College of Surgeons Oncology Group (ACOSOG)-Z1071 are eligible to participate in this study; patients concurrently enrolled on this study and ACOSOG-Z1071, may not also be enrolled on the ACOSOG-Z1071 lymphedema sub-study </s>   No documented cardiac conduction disturbances, unstable angina, dementia, or any other chronic disease which, in the opinion of the treating physician, significantly increases mortality over the next 2 years </s>   No diagnosed lymphedema </s>   In order to be properly fitted for the elastic sleeve, eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the ranges for one of the six sleeve sizes </s>   Not currently homebound or dependent upon a walker or wheelchair for mobility </s>   Able to participate in a mild exercise program </s>   Willing to return to the study site for the duration of the study (18 months) </s>   Sentinel (SND) or full axillary node dissection (AND) (no minimum number of nodes required) </s>   Patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study; however, it should be documented appropriately on form C-1628 at the conclusion of study participation",1,Eligibility Criteria: |   Newly diagnosed with stage I-III cancer of the female breast
1329dec6-fb2c-4219-9db6-3fef9d94b316,1329dec6-fb2c-4219-9db6-3fef9d94b316,in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain,[PRIMARY] Adverse Events 1: </s>   Total: 70/219 (31.96%) </s>   Anaemia * 0/219 (0.00%) </s>   Febrile neutropenia * 26/219 (11.87%) </s>   Neutropenia * 7/219 (3.20%) </s>   Thrombocytopenia * 1/219 (0.46%) </s>   Cardiac failure * 2/219 (0.91%) </s>   Sinus tachycardia * 1/219 (0.46%) </s>   Left ventricular dysfunction * 2/219 (0.91%) </s>   Abdominal pain * 1/219 (0.46%) </s>   Abdominal pain upper * 1/219 (0.46%) </s>   Colitis * 3/219 (1.37%) </s> Adverse Events 2: </s>   Total: 30/223 (13.45%) </s>   Anaemia * 3/223 (1.35%) </s>   Febrile neutropenia * 3/223 (1.35%) </s>   Neutropenia * 0/223 (0.00%) </s>   Thrombocytopenia * 1/223 (0.45%) </s>   Cardiac failure * 1/223 (0.45%) </s>   Sinus tachycardia * 0/223 (0.00%) </s>   Left ventricular dysfunction * 0/223 (0.00%) </s>   Abdominal pain * 0/223 (0.00%) </s>   Abdominal pain upper * 0/223 (0.00%) </s>   Colitis * 0/223 (0.00%),0,  Left ventricular dysfunction * 2/219 (0.91%) |   Abdominal pain * 1/219 (0.46%)
29b2fa29-5a76-4877-95bb-1a8de7973d33,29b2fa29-5a76-4877-95bb-1a8de7973d33,Only 6/67 patients in cohort 1 of the primary trial suffered adverse events,[PRIMARY] Adverse Events 1: </s>   Total: 6 </s>   Atrial fibrillation 1/67 (1.49%) </s>   Ventricular fibrillation 1/67 (1.49%) </s>   Gastrointestinal perforation 1/67 (1.49%) </s>   Periproctitis 1/67 (1.49%) </s>   General physical health deterioration 1/67 (1.49%) </s>   Escherichia sepsis 1/67 (1.49%) </s>   Pneumonia 1/67 (1.49%) </s>   Tumour pain 1/67 (1.49%) </s>   Renal failure acute 1/67 (1.49%) </s>   Pleurisy 1/67 (1.49%),1,Adverse Events 1: |   Total: 6
7edba90d-076d-4f55-b9d6-a1765ceb48bd,7edba90d-076d-4f55-b9d6-a1765ceb48bd,the primary trial and the secondary trial participants do not receive any medication by IV,[PRIMARY] INTERVENTION 1:  </s>   Intraductal Arm </s>   Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. [SECONDARY] INTERVENTION 1:  </s>   Cetuximab </s>   Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II. </s>   cetuximab: Given IV </s> INTERVENTION 2:  </s>   Cetuximab and Carboplatin After Cetuximab Alone </s>   Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab + carboplatin,0,INTERVENTION 1:  |   Intraductal Arm |   Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. | INTERVENTION 1:  |   Cetuximab |   Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II. |   cetuximab: Given IV | INTERVENTION 2:  |   Cetuximab and Carboplatin After Cetuximab Alone |   Patients from Arm 1 who progressed on cetuximab alone who went on to receive cetuximab + carboplatin
ba9daeb9-796d-49ab-a30c-4d8acbdf4d37,ba9daeb9-796d-49ab-a30c-4d8acbdf4d37,"in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin","[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Disease Progression (PD) or Death </s>   This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up. </s>   Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years) </s> Results 1:  </s>   Arm/Group Title: Fulvestrant and Dasatinib </s>   Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib. </s>   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. </s>   Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years </s>   Overall Number of Participants Analyzed: 50 </s>   Measure Type: Number </s>   Unit of Measure: participants  35 </s> Results 2:  </s>   Arm/Group Title: Fulvestrant </s>   Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only. </s>   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. </s>   Overall Number of Participants Analyzed: 49 </s>   Measure Type: Number </s>   Unit of Measure: participants  40",0,"Outcome Measurement:  |   Number of Participants With Disease Progression (PD) or Death |   This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up. |   Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years) | Results 1:  |   Arm/Group Title: Fulvestrant and Dasatinib |   Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib. |   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. |   Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years |   Overall Number of Participants Analyzed: 50 |   Measure Type: Number |   Unit of Measure: participants  35 | Results 2:  |   Arm/Group Title: Fulvestrant |   Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only. |   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. |   Overall Number of Participants Analyzed: 49 |   Measure Type: Number |   Unit of Measure: participants  40"
1314146f-2869-4525-8034-7f732d238385,1314146f-2869-4525-8034-7f732d238385,none of the individual adverse events in the primary trial affect more than 100 patients.,"[PRIMARY] Adverse Events 1: </s>   Total: 340/1612 (21.09%) </s>   Anemia 10/1612 (0.62%) </s>   Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%) </s>   Febrile neutropenia 7/1612 (0.43%) </s>   Cardiac disorders - Other, specify 6/1612 (0.37%) </s>   Conduction disorder 2/1612 (0.12%) </s>   Myocardial infarction 6/1612 (0.37%) </s>   Palpitations 1/1612 (0.06%) </s>   Pericardial effusion 0/1612 (0.00%) </s>   Sinus bradycardia 2/1612 (0.12%) </s> Adverse Events 2: </s>   Total: 350/1623 (21.57%) </s>   Anemia 8/1623 (0.49%) </s>   Blood and lymphatic system disorders - Other, specify 3/1623 (0.18%) </s>   Febrile neutropenia 4/1623 (0.25%) </s>   Cardiac disorders - Other, specify 2/1623 (0.12%) </s>   Conduction disorder 1/1623 (0.06%) </s>   Myocardial infarction 4/1623 (0.25%) </s>   Palpitations 0/1623 (0.00%) </s>   Pericardial effusion 2/1623 (0.12%) </s>   Sinus bradycardia 0/1623 (0.00%)",1,"Adverse Events 1: |   Total: 340/1612 (21.09%) |   Anemia 10/1612 (0.62%) |   Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%) |   Febrile neutropenia 7/1612 (0.43%) |   Cardiac disorders - Other, specify 6/1612 (0.37%) |   Conduction disorder 2/1612 (0.12%) |   Myocardial infarction 6/1612 (0.37%) |   Palpitations 1/1612 (0.06%) |   Pericardial effusion 0/1612 (0.00%) |   Sinus bradycardia 2/1612 (0.12%) | Adverse Events 2: |   Total: 350/1623 (21.57%) |   Anemia 8/1623 (0.49%) |   Blood and lymphatic system disorders - Other, specify 3/1623 (0.18%) |   Febrile neutropenia 4/1623 (0.25%) |   Cardiac disorders - Other, specify 2/1623 (0.12%) |   Conduction disorder 1/1623 (0.06%) |   Myocardial infarction 4/1623 (0.25%) |   Palpitations 0/1623 (0.00%) |   Pericardial effusion 2/1623 (0.12%) |   Sinus bradycardia 0/1623 (0.00%)"
7c7418d2-32d7-4517-874b-eb3db24ea16a,7c7418d2-32d7-4517-874b-eb3db24ea16a,"to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.","[PRIMARY] Inclusion Criteria: </s>   Written informed consent </s>   Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk criteria according to St. Gallen consensus criteria. </s>   Histologically proven breast cancer. Interval between surgery and registration is less than 60 days. </s>   Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin. </s>   Patients without proven metastatic disease. </s>   Estrogen and progesterone receptors performed on the primary tumour prior to randomization. </s>   Age between 18 years and 70 years. </s>   Karnofsky performance status index > 80 %. </s>   Adequate hepatic, renal and heart functions. </s>   Adequate hematology levels. </s>   Negative pregnancy test </s> Exclusion Criteria: </s>   Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy). </s>   Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy. </s>   Prior radiation therapy for breast cancer. </s>   Bilateral invasive breast cancer. </s>   Pregnant, or lactating patients. </s>   Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment . </s>   Any T4 or N1-3 or M1 breast cancer. </s>   Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria. </s>   Other serious illness or medical condition </s>   Past or current history of neoplasm other than breast carcinoma. </s>   Ipsilateral ductal carcinoma in-situ (DCIS) of the breast. </s>   Lobular carcinoma in-situ (LCIS) of the breast. </s>   Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose </s>   Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry. </s>   Definite contraindications for the use of corticosteroids. </s>   Concurrent treatment with other experimental drugs. </s>   Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry. </s>   Concurrent treatment with any other anti-cancer therapy. </s> Male patients.",1,"  Age between 18 years and 70 years. |   Karnofsky performance status index > 80 %. |   Adequate hepatic, renal and heart functions. |   Adequate hematology levels."
1f6a14ae-e22b-4b40-b389-217570dbf38e,1f6a14ae-e22b-4b40-b389-217570dbf38e,50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ,"[PRIMARY] Outcome Measurement:  </s>   Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel </s>   DLT is an AE or laboratory abnormality related to AZD8931, starting during the DLT evaluation period and meeting any of the following criteria (further detail in protocol): Symptomatic ocular surface lesion; CTCAE grade 4 haematological AE; CTCAE grade 3 of febrile neutropenia / neutropenia / thrombocytopenia / hyperkalaemia / hyperglycaemia / hypotension / urological toxicity / ILD / pneumonitis; QTcF interval > 500 msec, two ECGs  30 minutes apart; Symptomatic congestive cardiac failure and a drop in LVEF; Decrease in LVEF of 20% to below the LLN; CS rash remaining CTCAE grade 3 for 5 days despite optimal treatment; CTCAE grade 3 nausea, vomiting or diarrhoea, despite optimal therapy; Other CTCAE grade 3 toxicity which, in the opinion of the investigator, is CS and related to AZD8931; Delay to the administration of paclitaxel on D1 of Cycle 2 by 7 days. Patients could have more than one DLT. </s>   Time frame: Weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant </s> Results 1:  </s>   Arm/Group Title: AZD8931 160 mg bd </s>   Arm/Group Description: Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle </s>   Overall Number of Participants Analyzed: 6 </s>   Measure Type: Number </s>   Unit of Measure: Number of Dose Limiting Toxicities  Total: 2 </s>   Eye disorders: Keratitis: 1 </s>   Eye disorders: Photophobia: 1 </s>   Gastrointestinal disorders: Diarrhoea: 1 </s>   Gastrointestinal disorders: Oesophagitis: 0 </s>   Infections and infestations: Rash pustular: 0 </s> Results 2:  </s>   Arm/Group Title: AZD8931 120 mg bd </s>   Arm/Group Description: Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle </s>   Overall Number of Participants Analyzed: 2 </s>   Measure Type: Number </s>   Unit of Measure: Number of Dose Limiting Toxicities  Total: 1 </s>   Eye disorders: Keratitis: 0 </s>   Eye disorders: Photophobia: 0 </s>   Gastrointestinal disorders: Diarrhoea: 1 </s>   Gastrointestinal disorders: Oesophagitis: 0 </s>   Infections and infestations: Rash pustular: 0",1,"Results 2:  |   Arm/Group Title: AZD8931 120 mg bd |   Arm/Group Description: Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle |   Overall Number of Participants Analyzed: 2 |   Measure Type: Number |   Unit of Measure: Number of Dose Limiting Toxicities  Total: 1 |   Eye disorders: Keratitis: 0 |   Eye disorders: Photophobia: 0 |   Gastrointestinal disorders: Diarrhoea: 1 |   Gastrointestinal disorders: Oesophagitis: 0 |   Infections and infestations: Rash pustular: 0"
5c1e360c-fd93-4dd4-b855-71ba416d34cb,5c1e360c-fd93-4dd4-b855-71ba416d34cb,patients must be able to receive medication orally to participate in the primary trial,"[PRIMARY] Inclusion criteria: </s>   Signed Informed Consent </s>   ErbB2(HER2)overexpressing breast cancer. </s>   Brain lesion(s) which are progressing. </s>   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). </s>   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. </s>   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. </s>   Able to swallow an oral medication. </s>   Adequate kidney and liver function. </s>   Adequate bone marrow function. </s> Exclusion criteria: </s>   Pregnant or lactating females. </s>   Conditions that would effect the absorption of an oral drug. </s>   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. </s>   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. </s>   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.",1,  Able to swallow an oral medication.
c7a953b0-ac96-4e0a-9c1d-98cf8af2861d,c7a953b0-ac96-4e0a-9c1d-98cf8af2861d,the primary trial and the secondary trial report the same types of adverse events,[PRIMARY] Adverse Events 1: </s>   Total: 0/23 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 0/655 (0.00%) </s> Adverse Events 2: </s>   Total: 0/580 (0.00%),0,Adverse Events 1: |   Total: 0/23 (0.00%) | Adverse Events 1: |   Total: 0/655 (0.00%) | Adverse Events 2: |   Total: 0/580 (0.00%)
48f516ff-abb4-4312-9b00-02f53fb16218,48f516ff-abb4-4312-9b00-02f53fb16218,under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response,"[PRIMARY] Outcome Measurement:  </s>   Pathologic Complete Response </s>   [Not Specified] </s>   Time frame: 22 weeks </s> Results 1:  </s>   Arm/Group Title: Intervention Arm </s>   Arm/Group Description: Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery </s>   nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks </s>   trastuzumab: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks </s>   Doxorubicin: 60 MG/M2 every two weeks for a total of 4 cycles </s>   cyclophosphamide: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above) </s>   Growth Factor Support: - All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. </s>   - Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician. </s>   Surgery: -After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy. </s>   -All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection. </s>   Overall Number of Participants Analyzed: 32 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  26",0,"Outcome Measurement:  |   Pathologic Complete Response |   [Not Specified] |   Time frame: 22 weeks | Results 1:  |   Arm/Group Title: Intervention Arm |   Arm/Group Description: Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery |   nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks |   trastuzumab: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks |   Doxorubicin: 60 MG/M2 every two weeks for a total of 4 cycles |   cyclophosphamide: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above) |   Growth Factor Support: - All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. |   - Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician. |   Surgery: -After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy. |   -All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection. |   Overall Number of Participants Analyzed: 32 |   Measure Type: Number |   Unit of Measure: percentage of participants  26"
978d19fc-e7f6-485e-b8bd-cfcde06441ab,978d19fc-e7f6-485e-b8bd-cfcde06441ab,T1 N0 M0 patients are eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically confirmed stage I, II, or III breast cancer </s>   T1-3, N0-2, M0 </s>   Patients with sentinel node biopsy positive disease must have undergone axillary dissection </s>   Tumor must be confined to the breast without detected metastases elsewhere </s>   T4 disease with minimal dermal invasion allowed </s>   No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer </s>   No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign </s>   No distant metastases </s>   No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT </s>   Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned </s>   Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery </s>   Negative surgical margins </s>   Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy </s>   Known HER2 status by immunohistochemistry or fluorescence in situ hybridization </s>   Hormone receptor status: </s>   Estrogen and progesterone receptor negative </s>   Less than 10% positive tumor cells by immunohistochemistry </s>   PATIENT CHARACTERISTICS: </s>   Age: </s> Not specified </s>   Sex: </s>   Not specified </s>   Menopausal status: </s>   Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR </s>   Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over) </s> Performance status: </s>   Not specified </s>   Life expectancy: </s>   Not specified </s>   Hematopoietic: </s>   WBC greater than 3,000/mm3 </s>   Platelet count greater than 100,000/mm3 </s>   Hepatic: </s>   See Disease Characteristics </s>   Bilirubin less than 2.0 mg/dL </s>   ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L </s>   Renal: </s>   Creatinine less than 1.2 mg/dL </s>   Other: </s>   Not pregnant or lactating within the past 6 months </s>   Fertile patients must use effective barrier contraception </s>   No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma </s>   No psychiatric or addictive disorders that would preclude study </s>   No non-malignant systemic disease that would preclude study </s>   PRIOR CONCURRENT THERAPY: </s>   Biologic therapy: </s>   Prior trastuzumab (Herceptin) allowed </s>   Chemotherapy: </s>   See Disease Characteristics </s>   No prior adjuvant or neoadjuvant chemotherapy for breast cancer </s>   Endocrine therapy: </s>   No prior endocrine therapy for breast cancer or prevention </s>   No prior tamoxifen or raloxifene for breast cancer </s>   Radiotherapy: </s>   No prior radiotherapy for breast cancer except primary irradiation </s>   Surgery: </s>   See Disease Characteristics </s>   Other: </s>   No prior preventative therapy for breast cancer",1,"  T1-3, N0-2, M0"
0a6d1b4c-244e-44e2-a229-62e4cbdfa979,0a6d1b4c-244e-44e2-a229-62e4cbdfa979,the results of the secondary trial and the primary trial are non-comparable,"[PRIMARY] Outcome Measurement:  </s>   Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks </s>   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. </s>   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity. </s>   The development of clinical fat necrosis. </s>   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically. </s>   The data is shown as the number of participants that experienced each of the specific toxicities. </s>   Time frame: 2 years </s> Results 1:  </s>   Arm/Group Title: Partial Breast Irradiation </s>   Arm/Group Description: Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks </s>   External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks </s>   Overall Number of Participants Analyzed: 53 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  Grade 3 or 4 Skin/ Subcutaneous toxicity: 0   0.0% </s>   Grade 3 or 4 Pulmonary Toxicity: 0   0.0% </s>   Fat Necrosis: 0   0.0% </s>   Rib fractures on ipsilateral treated side: 0   0.0% [SECONDARY] Outcome Measurement:  </s>   Overall Tumor Response </s>   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (""respond""), stay the same (""stable""), or worsen (""progression"") during treatment. </s>   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression </s> Results 1:  </s>   Arm/Group Title: Pemetrexed </s>   Arm/Group Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression </s>   Overall Number of Participants Analyzed: 35 </s>   Measure Type: Number </s>   Unit of Measure: participants  Complete Response: 1 </s>   Partial Response: 8 </s>   Stable Disease: 14 </s>   Progressive Disease: 9 </s>   Best Response Not Evaluable: 3",1,"Outcome Measurement:  |   Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks |   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. |   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity. |   The development of clinical fat necrosis. |   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically. |   The data is shown as the number of participants that experienced each of the specific toxicities. |   Time frame: 2 years | Outcome Measurement:  |   Overall Tumor Response |   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (""respond""), stay the same (""stable""), or worsen (""progression"") during treatment. |   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression"
9bcc31df-c1f6-4785-9235-f673213acf3a,9bcc31df-c1f6-4785-9235-f673213acf3a,both the primary trial cohorts receive identical doses of Docetaxel ,"[PRIMARY] INTERVENTION 1:  </s>   Docetaxel 100 mg/m^2 Plus Placebo </s>   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. </s> INTERVENTION 2:  </s>   Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg </s>   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.",1,"INTERVENTION 1:  |   Docetaxel 100 mg/m^2 Plus Placebo |   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. | INTERVENTION 2:  |   Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg |   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal."
63a0a9fc-80b9-450f-b2c6-7aee37ce26a9,63a0a9fc-80b9-450f-b2c6-7aee37ce26a9,neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention,[PRIMARY] INTERVENTION 1:  </s>   No Exercise </s>   Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week </s> INTERVENTION 2:  </s>   Exercise </s>   Exercise Arm: Exercise consisting of progressive walking and resistance band training </s>   Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise,0,INTERVENTION 1:  |   No Exercise |   Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week | INTERVENTION 2:  |   Exercise |   Exercise Arm: Exercise consisting of progressive walking and resistance band training |   Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise
75cf4ec2-9f2b-4d5b-8772-af247eaca07b,75cf4ec2-9f2b-4d5b-8772-af247eaca07b,Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically confirmed breast cancer </s>   Metastatic (stage IV) disease </s>   Measurable disease by RECIST criteria </s>   Irradiated lesions are not considered measurable disease </s>   Central nervous system (CNS) metastases allowed if disease is stable (no evidence of progression)  3 months after local therapy </s>   No lesions identifiable only by positron emission tomography (PET) scan </s>   HER2 nonoverexpressing disease by IHC (0 or 1) or non-gene amplified by Fluorescence In Situ Hybridization (FISH) </s>   HER2 2+ by IHC allowed </s>   Hormone receptor status: </s>   Estrogen receptor-negative and progesterone receptor-negative tumor </s>   Inclusion Criteria </s>   At least 18 years of age </s>   Metastatic breast cancer (Stage IV) with measurable disease by RECIST criteria </s>   No more than three prior chemotherapy regimens either in the adjuvant or metastatic setting. </s>   Histologically documented (either primary or metastatic site) breast cancer that is estrogen receptor- (ER-) negative, PR-negative, and HER-2 nonoverexpressing by immunohistochemistry (0,1) or non-gene amplified by FISH performed upon the primary tumor or metastatic lesion. HER-2 2+ by immunohistochemistry is usually negative by FISH, and this confirmatory test should be performed when possible, however may participate if fulfill other criteria. </s>   Completion of prior chemotherapy at least 3 weeks prior to study entry. </s>   Patients may have received therapy (ies) in the adjuvant or metastatic setting, however must have discontinued prior to entry. Patients may receive concurrent bisphosphonates, however if taking bisphosphonates, bone lesions may not be used for progression or response. </s>   Radiation therapy must be completed at least 2 weeks prior to study entry, and radiated lesions may not serve as measurable disease. </s>   Patients may have CNS metastases if stable (no evidence of progression) > 3 months after local therapy. </s>   Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and life expectancy of at least 6 months. </s>   Adequate organ function defined as:absolute neutrophil count (ANC) > 1500/mm3, plts > 100,000/mm3, creatinine clearance >50 mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x upper limit of normal (ULN) (or 5 x ULN in case of liver metastases); total bilirubin 1.5 mg/dL. </s>   Tissue block available for EGFR studies is recommended, although will not exclude patients from participating. </s>   Pregnant or lactating women will be excluded. Women of child bearing potential must have documented negative pregnancy test within two weeks of study entry and agree to acceptable birth control during the duration of the study therapy. </s>   Signed written informed consent. </s>   Exclusion Criteria </s>   Lesions identifiable only by PET. </s>   More than three prior chemotherapy regimens (including adjuvant). Sequential regimens such as doxorubicin and cyclophosphamide followed by paclitaxel (AC-paclitaxel) are considered one regimen. </s>   Prior therapy which specifically and directly targets the EGFR pathway with therapeutic intent. </s>   Prior platinum agent for metastatic disease. If platinum agent was used adjuvantly, the patient must have had at least 12 months disease-free interval prior to relapse. </s>   Prior severe infusion reaction to a monoclonal antibody. </s>   Major medical conditions that might affect study participation (uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection). </s>   Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy that is either symptomatic or asymptomatic but with decreased ejection fraction <45% </s>   Other significant comorbid condition which the investigator feels might compromise effective and safe participation in the study. </s>   Inability to comply with the requirements of the study.",1,DISEASE CHARACTERISTICS: |   Histologically confirmed breast cancer |   Metastatic (stage IV) disease
553f00ea-5197-4233-b1e0-e5727856b599,553f00ea-5197-4233-b1e0-e5727856b599,no cardiac or bowel-related adverse events were recorded in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 2/30 (6.67%) </s>   Dry Eyes  [1]1/30 (3.33%) </s>   Diarrhea  [2]1/30 (3.33%),0,Adverse Events 1: |   Total: 2/30 (6.67%) |   Dry Eyes  [1]1/30 (3.33%) |   Diarrhea  [2]1/30 (3.33%)
57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32,57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32,"There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial","[PRIMARY] Adverse Events 1: </s>   Total: 0/150 (0.00%) </s> Adverse Events 2: </s>   Total:  [SECONDARY] Adverse Events 1: </s>   Total: 14/41 (34.15%) </s>   Anemia 1/41 (2.44%) </s>   Febrile neutropenia 1/41 (2.44%) </s>   Eye disorders - Other, Visual disturbance 1/41 (2.44%) </s>   Abdominal pain 1/41 (2.44%) </s>   Constipation 1/41 (2.44%) </s>   Nausea 1/41 (2.44%) </s>   Fever 1/41 (2.44%) </s>   Pain 1/41 (2.44%) </s>   Skin infection 2/41 (4.88%) </s>   Alkaline phosphatase increased 1/41 (2.44%) </s>   Aspartate aminotransferase increased 1/41 (2.44%)",0,"Adverse Events 1: |   Total: 0/150 (0.00%) | Adverse Events 1: |   Total: 14/41 (34.15%) |   Anemia 1/41 (2.44%) |   Febrile neutropenia 1/41 (2.44%) |   Eye disorders - Other, Visual disturbance 1/41 (2.44%) |   Abdominal pain 1/41 (2.44%)"
215a5c4a-d90c-4500-8284-0679ce311734,215a5c4a-d90c-4500-8284-0679ce311734,patients must have HER2- breast cancer to participate in the primary trial,"[PRIMARY] Inclusion criteria: </s>   Signed Informed Consent </s>   ErbB2(HER2)overexpressing breast cancer. </s>   Brain lesion(s) which are progressing. </s>   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). </s>   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. </s>   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. </s>   Able to swallow an oral medication. </s>   Adequate kidney and liver function. </s>   Adequate bone marrow function. </s> Exclusion criteria: </s>   Pregnant or lactating females. </s>   Conditions that would effect the absorption of an oral drug. </s>   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. </s>   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. </s>   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.",0,  ErbB2(HER2)overexpressing breast cancer.
e9a4bd91-f58b-4234-9037-75e0699d1bbd,e9a4bd91-f58b-4234-9037-75e0699d1bbd,the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate,[PRIMARY] INTERVENTION 1:  </s>   Pralatrexate </s>   Study drug 190 mg/m^2 for 2 to 4 weeks.,1,INTERVENTION 1:  |   Pralatrexate |   Study drug 190 mg/m^2 for 2 to 4 weeks.
7d52734c-0801-413d-9ae2-d190b972cde5,7d52734c-0801-413d-9ae2-d190b972cde5,The results from the secondary trial and the primary trial can be compared by changing the units from days to months,"[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Complete Pathologic Response. </s>   Pathologic complete response (pCR): Absence of invasive breast cancer in the breast (mastectomy or lumpectomy) specimen at the time of definitive surgery. Presence of in situ cancer alone will be considered a pCR. </s>   Although clinical examination is the primary method of determining response, radiologic assessments (mammogram, ultrasound ± MRI) may be used to confirm response/non-response. </s>   Time frame: assess at 8 weeks </s> Results 1:  </s>   Arm/Group Title: Trastuzumab and Abraxane Followed Trastuzumab and Vinorelbine </s>   Arm/Group Description: Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta  ) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52. </s>   Overall Number of Participants Analyzed: 27 </s>   Measure Type: Number </s>   Unit of Measure: participants  13 [SECONDARY] Outcome Measurement:  </s>   Change in Masood Score </s>   Change in the semi-quantitative score assigned by the designated cytopathologist. </s>   Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4. </s>   Time frame: Baseline to 6 months </s> Results 1:  </s>   Arm/Group Title: Placebo </s>   Arm/Group Description: Placebo </s>   Placebo: matched tablet dialy </s>   Overall Number of Participants Analyzed: 84 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  -1.1         (1.9) </s> Results 2:  </s>   Arm/Group Title: Arzoxifene </s>   Arm/Group Description: LY353381, 20 mg daily </s>   arzoxifene: one tablet daily </s>   Overall Number of Participants Analyzed: 82 </s>   Mean (Standard Deviation) </s>   Unit of Measure: units on a scale  -0.8         (2.1)",0,"Outcome Measurement:  |   Number of Participants With Complete Pathologic Response. |   Pathologic complete response (pCR): Absence of invasive breast cancer in the breast (mastectomy or lumpectomy) specimen at the time of definitive surgery. Presence of in situ cancer alone will be considered a pCR. |   Although clinical examination is the primary method of determining response, radiologic assessments (mammogram, ultrasound ± MRI) may be used to confirm response/non-response. |   Time frame: assess at 8 weeks | Outcome Measurement:  |   Change in Masood Score |   Change in the semi-quantitative score assigned by the designated cytopathologist. |   Range 6-24. Score represents increasing abnormality (i.e., worse appearance) Sum composite of 6 cytomorphological features, each scored as 1-4. |   Time frame: Baseline to 6 months"
5de9caeb-9dd5-4535-8fe3-289450d9c626,5de9caeb-9dd5-4535-8fe3-289450d9c626,the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.,"[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse </s>   CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. </s>   Time frame: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012 </s> Results 1:  </s>   Arm/Group Title: Lapatinib Plus Capecitabine </s>   Arm/Group Description: Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. </s>   Overall Number of Participants Analyzed: 251 </s>   Measure Type: Number </s>   Unit of Measure: participants  8 </s> Results 2:  </s>   Arm/Group Title: Trastuzumab Plus Capecitabine </s>   Arm/Group Description: Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. </s>   Overall Number of Participants Analyzed: 250 </s>   Measure Type: Number </s>   Unit of Measure: participants  12",1,"Outcome Measurement:  |   Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse |   CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. |   Time frame: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012 | Results 1:  |   Arm/Group Title: Lapatinib Plus Capecitabine |   Arm/Group Description: Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. |   Overall Number of Participants Analyzed: 251 |   Measure Type: Number |   Unit of Measure: participants  8 | Results 2:  |   Arm/Group Title: Trastuzumab Plus Capecitabine |   Arm/Group Description: Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. |   Overall Number of Participants Analyzed: 250 |   Measure Type: Number |   Unit of Measure: participants  12"
bebfc78e-b35f-4677-8342-9567a7e795a1,bebfc78e-b35f-4677-8342-9567a7e795a1,There is one case of Diarrhea in the secondary trial and none in the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 59/373 (15.82%) </s>   Neutropenia 14/373 (3.75%) </s>   Febrile neutropenia 10/373 (2.68%) </s>   Leukopenia 1/373 (0.27%) </s>   Anaemia 2/373 (0.54%) </s>   Lymphadenopathy 0/373 (0.00%) </s>   cardiac failure 2/373 (0.54%) </s>   Atrial fibrillation 1/373 (0.27%) </s>   Pericardial effusion 2/373 (0.54%) </s>   Cardiac failure congestive 1/373 (0.27%) </s>   Cardiomyopathy 0/373 (0.00%) </s> Adverse Events 2: </s>   Total: 69/377 (18.30%) </s>   Neutropenia 17/377 (4.51%) </s>   Febrile neutropenia 10/377 (2.65%) </s>   Leukopenia 4/377 (1.06%) </s>   Anaemia 2/377 (0.53%) </s>   Lymphadenopathy 1/377 (0.27%) </s>   cardiac failure 1/377 (0.27%) </s>   Atrial fibrillation 1/377 (0.27%) </s>   Pericardial effusion 0/377 (0.00%) </s>   Cardiac failure congestive 0/377 (0.00%) </s>   Cardiomyopathy 1/377 (0.27%) [SECONDARY] Adverse Events 1: </s>   Total: 0/92 (0.00%) </s>   Diarrhea 0/92 (0.00%) </s> Adverse Events 2: </s>   Total: 1/93 (1.08%) </s>   Diarrhea 1/93 (1.08%),1,Adverse Events 1: |   Total: 59/373 (15.82%) |   Neutropenia 14/373 (3.75%) |   Febrile neutropenia 10/373 (2.68%) |   Leukopenia 1/373 (0.27%) |   Anaemia 2/373 (0.54%) |   Lymphadenopathy 0/373 (0.00%) |   cardiac failure 2/373 (0.54%) |   Atrial fibrillation 1/373 (0.27%) |   Pericardial effusion 2/373 (0.54%) |   Cardiac failure congestive 1/373 (0.27%) |   Cardiomyopathy 0/373 (0.00%) | Adverse Events 2: |   Total: 69/377 (18.30%) |   Neutropenia 17/377 (4.51%) |   Febrile neutropenia 10/377 (2.65%) |   Leukopenia 4/377 (1.06%) |   Anaemia 2/377 (0.53%) |   Lymphadenopathy 1/377 (0.27%) |   cardiac failure 1/377 (0.27%) |   Atrial fibrillation 1/377 (0.27%) |   Pericardial effusion 0/377 (0.00%) |   Cardiac failure congestive 0/377 (0.00%) |   Cardiomyopathy 1/377 (0.27%) | Adverse Events 1: |   Total: 0/92 (0.00%) |   Diarrhea 0/92 (0.00%) | Adverse Events 2: |   Total: 1/93 (1.08%) |   Diarrhea 1/93 (1.08%)
faa65e54-aa04-4595-8dae-05cf00b4c887,faa65e54-aa04-4595-8dae-05cf00b4c887,Only cohort 1 patients of the primary trial are administered Ipatasertib,[PRIMARY] INTERVENTION 1:  </s>   Ipatasertib + Paclitaxel </s>   Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). </s> INTERVENTION 2:  </s>   Placebo + Paclitaxel </s>   Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).,1,INTERVENTION 1:  |   Ipatasertib + Paclitaxel |   Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). | INTERVENTION 2:  |   Placebo + Paclitaxel |   Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
751fd763-89fa-4d52-8bda-f09b490a5e78,751fd763-89fa-4d52-8bda-f09b490a5e78,there were no recorded deaths in the primary trial cohorts.,"[PRIMARY] Outcome Measurement:  </s>   Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) </s>   Number of patients event-free </s>   Time frame: 12 month period following randomisation </s> Results 1:  </s>   Arm/Group Title: Fulvestrant + Anastrozole </s>   Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg </s>   Overall Number of Participants Analyzed: 6 </s>   Measure Type: Number </s>   Unit of Measure: Participants  6 </s> Results 2:  </s>   Arm/Group Title: Anastrozole </s>   Arm/Group Description: anastrozole 1 mg </s>   Overall Number of Participants Analyzed: 7 </s>   Measure Type: Number </s>   Unit of Measure: Participants  7",1,"Outcome Measurement:  |   Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) |   Number of patients event-free |   Time frame: 12 month period following randomisation | Results 1:  |   Arm/Group Title: Fulvestrant + Anastrozole |   Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg |   Overall Number of Participants Analyzed: 6 |   Measure Type: Number |   Unit of Measure: Participants  6 | Results 2:  |   Arm/Group Title: Anastrozole |   Arm/Group Description: anastrozole 1 mg |   Overall Number of Participants Analyzed: 7 |   Measure Type: Number |   Unit of Measure: Participants  7"
c40fdf91-9f81-454a-bba9-ec5c950cef6e,c40fdf91-9f81-454a-bba9-ec5c950cef6e,One patient cohort in the primary trial received a placebo intervention,"[PRIMARY] INTERVENTION 1:  </s>   Lapatinib 1500 mg </s>   Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. </s> INTERVENTION 2:  </s>   Placebo </s>   Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal.",1,"INTERVENTION 1:  |   Lapatinib 1500 mg |   Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. | INTERVENTION 2:  |   Placebo |   Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal."
31105b43-832b-48bc-a78d-ee90c155ca44,31105b43-832b-48bc-a78d-ee90c155ca44,"Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.","[PRIMARY] DISEASE CHARACTERISTICS: </s>   Women with a history of breast cancer (currently without malignant disease) </s>   Bothersome hot flashes (defined by their occurrence  28 times per week and of sufficient severity to make the patient desire therapeutic intervention) </s>   Presence of hot flashes for  30 days prior to study registration </s>   Willingness to provide the biologic specimens as required by the protocol </s>   Hormone receptor status not specified </s>   PATIENT CHARACTERISTICS: </s>   Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy </s>   Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL </s>   No women of childbearing potential or who are premenopausal </s>   Creatinine clearance > 30 mL/min </s>   Ability to complete questionnaire(s) by themselves or with assistance </s>   ECOG performance status 0 or 1 </s>   No history of allergic or other adverse reaction to magnesium </s>   No diabetes </s>   No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse) </s>   No patients who have diarrhea where magnesium might make it worse (per provider discretion) </s>   PRIOR CONCURRENT THERAPY: </s>   None of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for  28 days and must not be expected to stop the medication during the study period): </s>   Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed) </s>   Androgens </s>   Estrogens (any delivery route) </s>   Progestational agents </s>   No prior use of magnesium for hot flashes </s>   No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started > 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period) </s>   No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day) </s>   Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels </s>   No current ( 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed) [SECONDARY] Inclusion Criteria: </s>   female patients, >=18 years of age, with locally advanced breast cancer. </s> Exclusion Criteria: </s>   previous therapy for any invasive malignancy.",1,"  Presence of hot flashes for  30 days prior to study registration | Inclusion Criteria: |   female patients, >=18 years of age, with locally advanced breast cancer. | Exclusion Criteria: |   previous therapy for any invasive malignancy."
49ba06b2-576d-4db2-80b6-51673416f2ba,49ba06b2-576d-4db2-80b6-51673416f2ba,the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts,"[PRIMARY] Outcome Measurement:  </s>   Percent Change in Net Influx Constant (Ki) by FLT PET </s>   Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. </s>   Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response. </s>   Time frame: Baseline to up to 6 weeks </s> Results 1:  </s>   Arm/Group Title: Diagnostic (FLT PET) </s>   Arm/Group Description: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. </s>   Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. </s>   Positron Emission Tomography: Undergo FLT PET </s>   Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. </s>   Overall Number of Participants Analyzed: 28 </s>   Median (Full Range) </s>   Unit of Measure: % change  -32.0        (-82.4 to 3953.7) [SECONDARY] Outcome Measurement:  </s>   Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) </s>   PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. </s>   Time frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) </s> Results 1:  </s>   Arm/Group Title: Placebo+Fulvestrant </s>   Arm/Group Description: Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. </s>   Overall Number of Participants Analyzed: 176 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  5.39        (3.68 to 7.29) </s> Results 2:  </s>   Arm/Group Title: Taselisib+Fulvestrant </s>   Arm/Group Description: Participants received taselisib 4 mg taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. </s>   Overall Number of Participants Analyzed: 340 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.43        (7.26 to 9.07)",0,"Outcome Measurement:  |   Percent Change in Net Influx Constant (Ki) by FLT PET |   Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. |   Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response. |   Time frame: Baseline to up to 6 weeks | Outcome Measurement:  |   Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)"
3cb71095-8e01-40dc-bbf5-eeffed55f354,3cb71095-8e01-40dc-bbf5-eeffed55f354,Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically confirmed breast cancer </s>   Metastatic (stage IV) disease </s>   Measurable disease by RECIST criteria </s>   Irradiated lesions are not considered measurable disease </s>   Central nervous system (CNS) metastases allowed if disease is stable (no evidence of progression)  3 months after local therapy </s>   No lesions identifiable only by positron emission tomography (PET) scan </s>   HER2 nonoverexpressing disease by IHC (0 or 1) or non-gene amplified by Fluorescence In Situ Hybridization (FISH) </s>   HER2 2+ by IHC allowed </s>   Hormone receptor status: </s>   Estrogen receptor-negative and progesterone receptor-negative tumor </s>   Inclusion Criteria </s>   At least 18 years of age </s>   Metastatic breast cancer (Stage IV) with measurable disease by RECIST criteria </s>   No more than three prior chemotherapy regimens either in the adjuvant or metastatic setting. </s>   Histologically documented (either primary or metastatic site) breast cancer that is estrogen receptor- (ER-) negative, PR-negative, and HER-2 nonoverexpressing by immunohistochemistry (0,1) or non-gene amplified by FISH performed upon the primary tumor or metastatic lesion. HER-2 2+ by immunohistochemistry is usually negative by FISH, and this confirmatory test should be performed when possible, however may participate if fulfill other criteria. </s>   Completion of prior chemotherapy at least 3 weeks prior to study entry. </s>   Patients may have received therapy (ies) in the adjuvant or metastatic setting, however must have discontinued prior to entry. Patients may receive concurrent bisphosphonates, however if taking bisphosphonates, bone lesions may not be used for progression or response. </s>   Radiation therapy must be completed at least 2 weeks prior to study entry, and radiated lesions may not serve as measurable disease. </s>   Patients may have CNS metastases if stable (no evidence of progression) > 3 months after local therapy. </s>   Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and life expectancy of at least 6 months. </s>   Adequate organ function defined as:absolute neutrophil count (ANC) > 1500/mm3, plts > 100,000/mm3, creatinine clearance >50 mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x upper limit of normal (ULN) (or 5 x ULN in case of liver metastases); total bilirubin 1.5 mg/dL. </s>   Tissue block available for EGFR studies is recommended, although will not exclude patients from participating. </s>   Pregnant or lactating women will be excluded. Women of child bearing potential must have documented negative pregnancy test within two weeks of study entry and agree to acceptable birth control during the duration of the study therapy. </s>   Signed written informed consent. </s>   Exclusion Criteria </s>   Lesions identifiable only by PET. </s>   More than three prior chemotherapy regimens (including adjuvant). Sequential regimens such as doxorubicin and cyclophosphamide followed by paclitaxel (AC-paclitaxel) are considered one regimen. </s>   Prior therapy which specifically and directly targets the EGFR pathway with therapeutic intent. </s>   Prior platinum agent for metastatic disease. If platinum agent was used adjuvantly, the patient must have had at least 12 months disease-free interval prior to relapse. </s>   Prior severe infusion reaction to a monoclonal antibody. </s>   Major medical conditions that might affect study participation (uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection). </s>   Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy that is either symptomatic or asymptomatic but with decreased ejection fraction <45% </s>   Other significant comorbid condition which the investigator feels might compromise effective and safe participation in the study. </s>   Inability to comply with the requirements of the study.",0,DISEASE CHARACTERISTICS: |   Histologically confirmed breast cancer |   Metastatic (stage IV) disease
09fc4356-6154-427e-b710-ed5df6470aff,09fc4356-6154-427e-b710-ed5df6470aff,50% of cohort 2 patients in the primary trial suffered Keratitis,"[PRIMARY] Outcome Measurement:  </s>   Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel </s>   DLT is an AE or laboratory abnormality related to AZD8931, starting during the DLT evaluation period and meeting any of the following criteria (further detail in protocol): Symptomatic ocular surface lesion; CTCAE grade 4 haematological AE; CTCAE grade 3 of febrile neutropenia / neutropenia / thrombocytopenia / hyperkalaemia / hyperglycaemia / hypotension / urological toxicity / ILD / pneumonitis; QTcF interval > 500 msec, two ECGs  30 minutes apart; Symptomatic congestive cardiac failure and a drop in LVEF; Decrease in LVEF of 20% to below the LLN; CS rash remaining CTCAE grade 3 for 5 days despite optimal treatment; CTCAE grade 3 nausea, vomiting or diarrhoea, despite optimal therapy; Other CTCAE grade 3 toxicity which, in the opinion of the investigator, is CS and related to AZD8931; Delay to the administration of paclitaxel on D1 of Cycle 2 by 7 days. Patients could have more than one DLT. </s>   Time frame: Weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant </s> Results 1:  </s>   Arm/Group Title: AZD8931 160 mg bd </s>   Arm/Group Description: Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle </s>   Overall Number of Participants Analyzed: 6 </s>   Measure Type: Number </s>   Unit of Measure: Number of Dose Limiting Toxicities  Total: 2 </s>   Eye disorders: Keratitis: 1 </s>   Eye disorders: Photophobia: 1 </s>   Gastrointestinal disorders: Diarrhoea: 1 </s>   Gastrointestinal disorders: Oesophagitis: 0 </s>   Infections and infestations: Rash pustular: 0 </s> Results 2:  </s>   Arm/Group Title: AZD8931 120 mg bd </s>   Arm/Group Description: Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle </s>   Overall Number of Participants Analyzed: 2 </s>   Measure Type: Number </s>   Unit of Measure: Number of Dose Limiting Toxicities  Total: 1 </s>   Eye disorders: Keratitis: 0 </s>   Eye disorders: Photophobia: 0 </s>   Gastrointestinal disorders: Diarrhoea: 1 </s>   Gastrointestinal disorders: Oesophagitis: 0 </s>   Infections and infestations: Rash pustular: 0",0,"Results 2:  |   Arm/Group Title: AZD8931 120 mg bd |   Arm/Group Description: Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle |   Overall Number of Participants Analyzed: 2 |   Measure Type: Number |   Unit of Measure: Number of Dose Limiting Toxicities  Total: 1 |   Eye disorders: Keratitis: 0 |   Eye disorders: Photophobia: 0 |   Gastrointestinal disorders: Diarrhoea: 1 |   Gastrointestinal disorders: Oesophagitis: 0 |   Infections and infestations: Rash pustular: 0"
446f3c69-0de5-475c-a8e2-ff40ece90672,446f3c69-0de5-475c-a8e2-ff40ece90672,Only patients with HER2+ve breast cancer are eligible for the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Archival tumor samples must be obtained from primary and/or metastatic sites </s>   Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1) expression </s>   HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies </s>   Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC </s>   Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent) </s>   Progression must have occurred during or after most recent treatment for locally advanced/metastatic BC or within 6 months after completing adjuvant therapy </s>   Participants must have measurable disease that is evaluable as per RECIST v1.1 </s>   Eastern Cooperative Oncology Group Performance Status of 0 or 1 </s>   Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause </s>   Use of highly effective method of contraception as defined by the protocol </s> Exclusion Criteria: </s>   Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents </s>   Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteria </s>   Radiation therapy within 2 weeks prior to Cycle 1, Day 1 </s>   History of exposure to the cumulative doses of anthracyclines </s>   History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence </s>   Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites </s>   Participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia </s>   Current severe, uncontrolled systemic disease </s>   Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment </s>   Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus </s>   Need for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids) </s>   Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than (>) 2 weeks prior to randomization </s>   Participants with known central nervous system disease </s>   Leptomeningeal disease </s>   History of autoimmune disease </s>   Prior allogeneic stem cell or solid organ transplantation </s>   Active tuberculosis </s>   Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study </s>   Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization </s>   Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial </s>   Participants who are breastfeeding, or intending to become pregnant during the study",1,  HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies
cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2,cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2,the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects,"[PRIMARY] Outcome Measurement:  </s>   Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel </s>   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle. </s>   Time frame: From first dose date through day 28 </s> Results 1:  </s>   Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m  </s>   Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle. </s>   Overall Number of Participants Analyzed: 3 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  0   0.0% </s> Results 2:  </s>   Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m  </s>   Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle. </s>   Overall Number of Participants Analyzed: 5 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  0   0.0%",0,"Outcome Measurement:  |   Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel |   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle. |   Time frame: From first dose date through day 28"
f0e845f9-8991-45b5-a520-51e934756f7a,f0e845f9-8991-45b5-a520-51e934756f7a,The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.,[PRIMARY] INTERVENTION 1:  </s>   Letrozole </s>   Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. [SECONDARY] INTERVENTION 1:  </s>   Sentinel Lymph Node Biopsy </s> [Not Specified],1,INTERVENTION 1:  |   Letrozole |   Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. | INTERVENTION 1:  |   Sentinel Lymph Node Biopsy | [Not Specified]
a0065d58-e03b-4dd0-9c81-cbbf651a6d45,a0065d58-e03b-4dd0-9c81-cbbf651a6d45,any patient eligible for the secondary trial will also be eligible for the primary trial ,"[PRIMARY] Inclusion Criteria: </s>   Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC. </s>   For the phase I portion, patients with any ER/PR/HER2 disease status, no longer eligible for hormonal therapy or HER2-targeted therapy, will be eligible. </s>   For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status. Patients with any ER/PR disease status are eligible. </s>   A paraffin-embedded tissue block or unstained slides from prior surgery must be available. </s>   Evidence of recurrent or progressive locally advanced or metastatic breast cancer. </s>   Presence of: </s>   For the phase I portion: at least one evaluable or measurable metastatic lesion , </s>   For the phase II portion: at least one measurable metastatic lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable. Minimum indicator lesion size: > or = to 10 mm measured by spiral CT or > or = to 20 mm measured by conventional techniques. </s>   Prior therapies: </s>   For the phase I portion: Any number of prior endocrine or biologic therapies is permitted . In addition, patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. </s>   For the phase II portion: 0-2 prior therapies for metastatic disease are allowed. </s>   Prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be permitted. Prior therapy with bevacizumab will be allowed. All previous chemotherapy, radiotherapy and intravenous biphosphonates must have been discontinued at least 3 weeks prior to study entry, 3 weeks also for trastuzumab and bevacizumab. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTC (Version 3) Grade 1. </s>   Endocrine therapy with an aromatase inhibitor, SERM (ie, tamoxifen) or fulvestrant is permitted, however it must be discontinued before enrolling in the study. </s>   ECOG performance status of 0 or 1. </s>   Age > or = to 18 years old. Adequate Organ Function </s>   Total bilirubin  1.5 times the institutional Upper Limit of Normal (ULN) </s>   Hepatic enzymes (AST, ALT )  2.5 times the institutional ULN </s>   Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN) </s>   Serum Creatinine  1.5 time the institutional ULN </s>   Neutrophil count, Platelets, both Grade 0-1 </s>   PT (INR) and PTT Grade 0-1, except for patients on Coumadin or low molecular weight heparin </s>   Ability to take oral medication (dasatinib must be swallowed whole) </s>   Concomitant Medications: </s>   Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy </s>   Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia. Concomitant Medications, any of the following should be considered for exclusion: </s>   Patient agrees to discontinue QT-prolonging agents strongly associated with Torsades de Pointes including: (patients must discontinue drug  7 days prior to starting dasatinib) such as: </s>   quinidine, procainamide, disopyramide </s>   amiodarone, sotalol, ibutilide, dofetilide </s>   erythromycin, clarithromycin </s>   chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide </s>   cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. </s>   The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not recommended. The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. </s>   Patient may not be receiving any potent CYP3A4 inhibitors. These are prohibited (patients must discontinue drug 7 days prior to starting dasatinib) and include: </s>   itraconazole, ketoconazole, miconazole, coriconazole </s>   amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir </s>   ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid </s>   ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin </s>   Women of childbearing potential (WOCBP) must have: </s>   A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration </s>   Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped </s>   Pregnant or nursing women may not participate. Patients of reproductive potential may not participate unless they have agreed to use an effective method of contraception and to continue contraception for 30 days from the date of the last study drug administration. Postmenopausal woman must be amenorrheic for at least 12 months to be considered of non-childbearing potential. </s>   Signed written informed consent including a HIPAA form according to institutional guidelines. </s> Exclusion Criteria: </s>   Life expectancy < 3 months. </s>   Prior severe allergic reaction to paclitaxel therapy. </s>   Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4). </s>   Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment. </s>   Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be discontinued > or = to 3 weeks from the start of protocol treatment. </s>   Concurrent medical condition which may increase the risk of toxicity. </s>   Patients may not have any clinically significant cardiovascular disease including the following: </s>   myocardial infarction or ventricular tachyarrhythmia within 6 months </s>   prolonged QTc >480 msec (Fridericia correction) </s>   ejection fraction less than institutional normal </s>   major conduction abnormality (unless a cardiac pacemaker is present) </s>   Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation. The patient may be referred to a cardiologist at the discretion of the principal investigator. Patients with underlying cardiopulmonary dysfunction should be excluded from the study. </s>   Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration </s>   History of significant bleeding disorder unrelated to cancer, including: </s>   Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) </s>   Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII antibodies) </s>   Ongoing or recent ( 3 months) significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk. </s>   Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. </s>   History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake. </s>   Presence of uncontrolled gastrointestinal malabsorption syndrome. </s>   Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial. </s>   Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might allowed for pre-existing non-target lesions with approval from the principal investigator of the trial. </s>   Patients with > Grade 1 neuropathy will be excluded form this trial. [SECONDARY] Inclusion criteria: </s>   Signed Informed Consent </s>   ErbB2(HER2)overexpressing breast cancer. </s>   Brain lesion(s) which are progressing. </s>   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). </s>   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. </s>   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. </s>   Able to swallow an oral medication. </s>   Adequate kidney and liver function. </s>   Adequate bone marrow function. </s> Exclusion criteria: </s>   Pregnant or lactating females. </s>   Conditions that would effect the absorption of an oral drug. </s>   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. </s>   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. </s>   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.",0,"Inclusion Criteria: |   Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC. |   For the phase I portion, patients with any ER/PR/HER2 disease status, no longer eligible for hormonal therapy or HER2-targeted therapy, will be eligible. |   For the phase II portion, there needs to be documentation of negative HER2 (IHC 0-1+ or FISH/CISH negative) status. Patients with any ER/PR disease status are eligible. |   A paraffin-embedded tissue block or unstained slides from prior surgery must be available. |   Evidence of recurrent or progressive locally advanced or metastatic breast cancer. |   Presence of: |   For the phase I portion: at least one evaluable or measurable metastatic lesion , |   For the phase II portion: at least one measurable metastatic lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable. Minimum indicator lesion size: > or = to 10 mm measured by spiral CT or > or = to 20 mm measured by conventional techniques. |   Prior therapies: |   For the phase I portion: Any number of prior endocrine or biologic therapies is permitted . In addition, patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. |   For the phase II portion: 0-2 prior therapies for metastatic disease are allowed. |   Prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be permitted. Prior therapy with bevacizumab will be allowed. All previous chemotherapy, radiotherapy and intravenous biphosphonates must have been discontinued at least 3 weeks prior to study entry, 3 weeks also for trastuzumab and bevacizumab. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTC (Version 3) Grade 1. |   Endocrine therapy with an aromatase inhibitor, SERM (ie, tamoxifen) or fulvestrant is permitted, however it must be discontinued before enrolling in the study. |   ECOG performance status of 0 or 1. |   Age > or = to 18 years old. Adequate Organ Function |   Total bilirubin  1.5 times the institutional Upper Limit of Normal (ULN) |   Hepatic enzymes (AST, ALT )  2.5 times the institutional ULN |   Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN) |   Serum Creatinine  1.5 time the institutional ULN |   Neutrophil count, Platelets, both Grade 0-1 |   PT (INR) and PTT Grade 0-1, except for patients on Coumadin or low molecular weight heparin |   Ability to take oral medication (dasatinib must be swallowed whole) |   Concomitant Medications: |   Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy |   Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia. Concomitant Medications, any of the following should be considered for exclusion: |   Patient agrees to discontinue QT-prolonging agents strongly associated with Torsades de Pointes including: (patients must discontinue drug  7 days prior to starting dasatinib) such as: |   quinidine, procainamide, disopyramide |   amiodarone, sotalol, ibutilide, dofetilide |   erythromycin, clarithromycin |   chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide |   cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. |   The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is not recommended. The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. |   Patient may not be receiving any potent CYP3A4 inhibitors. These are prohibited (patients must discontinue drug 7 days prior to starting dasatinib) and include: |   itraconazole, ketoconazole, miconazole, coriconazole |   amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir |   ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid |   ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin |   Women of childbearing potential (WOCBP) must have: |   A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration |   Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped |   Pregnant or nursing women may not participate. Patients of reproductive potential may not participate unless they have agreed to use an effective method of contraception and to continue contraception for 30 days from the date of the last study drug administration. Postmenopausal woman must be amenorrheic for at least 12 months to be considered of non-childbearing potential. |   Signed written informed consent including a HIPAA form according to institutional guidelines. | Exclusion Criteria: |   Life expectancy < 3 months. |   Prior severe allergic reaction to paclitaxel therapy. |   Presence of new or recurrent pleural effusion which is symptomatic and/or requiring medical intervention (NCI CTC Grade 2, 3 or 4). |   Completion of previous chemotherapy regimen < 3 weeks prior to the start of study treatment. |   Prior hormonal therapy must be discontinued prior to treatment start. Biologic therapy (eg, bevacizumab, trastuzumab) for the treatment of metastatic disease must be discontinued > or = to 3 weeks from the start of protocol treatment. |   Concurrent medical condition which may increase the risk of toxicity. |   Patients may not have any clinically significant cardiovascular disease including the following: |   myocardial infarction or ventricular tachyarrhythmia within 6 months |   prolonged QTc >480 msec (Fridericia correction) |   ejection fraction less than institutional normal |   major conduction abnormality (unless a cardiac pacemaker is present) |   Patients with any cardiopulmonary symptoms of unknown cause (e.g. shortness of breath, chest pain, etc.) should be evaluated by a baseline echocardiogram with or without stress test as needed in addition to electrocardiogram (EKG) to rule out QTc prolongation. The patient may be referred to a cardiologist at the discretion of the principal investigator. Patients with underlying cardiopulmonary dysfunction should be excluded from the study. |   Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration |   History of significant bleeding disorder unrelated to cancer, including: |   Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) |   Diagnosed acquired bleeding disorder within one year (e.g., acquired antifactor VIII antibodies) |   Ongoing or recent ( 3 months) significant gastrointestinal bleeding Other medical condition which in the opinion of the Investigator might confer an unacceptable increase in risk. |   Patients with symptomatic CNS metastases that remain untreated by radiation therapy are excluded from this trial. The presence of asymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. |   History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake. |   Presence of uncontrolled gastrointestinal malabsorption syndrome. |   Unwillingness to give written informed consent or unwillingness to participate or inability to comply with the protocol for the duration of the study. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures are necessary for participation in this clinical trial. |   Concurrent radiotherapy is not permitted for disease progression on treatment on protocol, but might allowed for pre-existing non-target lesions with approval from the principal investigator of the trial. |   Patients with > Grade 1 neuropathy will be excluded form this trial. | Inclusion criteria: |   Signed Informed Consent |   ErbB2(HER2)overexpressing breast cancer. |   Brain lesion(s) which are progressing. |   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS). |   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy. |   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram. |   Able to swallow an oral medication. |   Adequate kidney and liver function. |   Adequate bone marrow function. | Exclusion criteria: |   Pregnant or lactating females. |   Conditions that would effect the absorption of an oral drug. |   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents. |   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel. |   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent."
b2cdbcb8-de26-4a44-8a94-dd68c13f7e41,b2cdbcb8-de26-4a44-8a94-dd68c13f7e41,ECOG score > 2 is necessary to be eligible for the primary trial,"[PRIMARY] Inclusion criteria: </s>   Histologically confirmed diagnosis of HER2-overexpression breast cancer </s>   Stage IV metastatic disease </s>   Must have progressed on one prior trastuzumab treatment </s>   no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line) </s>   Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer </s>   Must have (archived) tumour tissue sample available for central re-assessment of HER2-status </s>   At least one measurable lesion according to RECIST 1.1. </s>   Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 . </s> Exclusion criteria: </s>   Prior treatment with Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor(EGFR/HER2)-targeted small molecules or antibodies other than trastuzumab </s>   Prior treatment with vinorelbine </s>   Known pre-existing interstitial lung disease </s>   Active brain metastases </s>   History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation. </s>   Cardiac left ventricular function with resting ejection fraction of less than 50%. </s>   Patients unable to comply with the protocol. </s>   Any contraindications for therapy with vinorelbine or trastuzumab. </s>   Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs. </s>   Use of any investigational drug within 4 weeks of randomisation. </s>   Inadequate hepatic, renal and haematologic organ function",0,  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 .
973f090a-8967-4d75-bb8e-6166c868337c,973f090a-8967-4d75-bb8e-6166c868337c,cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients,[PRIMARY] INTERVENTION 1:  </s>   Ipatasertib + Paclitaxel </s>   Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). </s> INTERVENTION 2:  </s>   Placebo + Paclitaxel </s>   Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).,0,INTERVENTION 1:  |   Ipatasertib + Paclitaxel |   Participants received ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses). | INTERVENTION 2:  |   Placebo + Paclitaxel |   Participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2,79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2,Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial,"[PRIMARY] Inclusion Criteria Phase 1 </s>   Age greater than/equal to 18 years </s>   Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ </s>   Patient desire to undergo breast surgery </s>   3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. The cancer enhances on breast MRI imaging. </s>   Inclusion Criteria Phase 2 </s>   Age greater than/equal to 18 years </s>   Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ </s>   The tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter. </s>   . Determination by the surgeon that the neoplasm is non-palpable.A patient with a palpable hematoma from core biopsy, but a non-palpable neoplasm, will be eligible for study </s>   Patient desire to undergo breast conserving surgery </s>   Patients will have provided informed consent to participate, documented by their signature on the study consent form.The process of informed consent will be documented in the medical record and a copy of the signed consent form will be given to the patient. </s>   Exclusion Criteria (Phases 1 and 2) </s>   Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip or metallic foreign body in or near eyes </s>   Severe claustrophobia </s>   Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0) </s>   History of median sternotomy </s>   Pregnancy (Patient attestation that they are not pregnant will be acceptable, as per standard, as per standard policy for MRIs at DHMC). </s>   Multicentric breast cancer, defined as two or more tumors in different quadrants of the breast. An eligibility worksheet will be completed for each patient prior to enrollment and will be signed and dated by the surgeon investigator",0,  Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
1d1f57f8-85f7-448c-a4bb-15957da568fd,1d1f57f8-85f7-448c-a4bb-15957da568fd,the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression,"[PRIMARY] INTERVENTION 1:  </s>   Pemetrexed </s>   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression",1,"INTERVENTION 1:  |   Pemetrexed |   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression"
9f7d476e-9db3-4c00-abe6-4c2f0160470a,9f7d476e-9db3-4c00-abe6-4c2f0160470a,under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response,"[PRIMARY] Outcome Measurement:  </s>   Pathologic Complete Response </s>   [Not Specified] </s>   Time frame: 22 weeks </s> Results 1:  </s>   Arm/Group Title: Intervention Arm </s>   Arm/Group Description: Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery </s>   nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks </s>   trastuzumab: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks </s>   Doxorubicin: 60 MG/M2 every two weeks for a total of 4 cycles </s>   cyclophosphamide: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above) </s>   Growth Factor Support: - All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. </s>   - Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician. </s>   Surgery: -After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy. </s>   -All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection. </s>   Overall Number of Participants Analyzed: 32 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  26",1,"Outcome Measurement:  |   Pathologic Complete Response |   [Not Specified] |   Time frame: 22 weeks | Results 1:  |   Arm/Group Title: Intervention Arm |   Arm/Group Description: Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery |   nab-paclitaxel: 100 MG/M2 IV over 30 minutes once a week for 12 weeks |   trastuzumab: 4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks |   Doxorubicin: 60 MG/M2 every two weeks for a total of 4 cycles |   cyclophosphamide: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above) |   Growth Factor Support: - All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. |   - Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician. |   Surgery: -After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy. |   -All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection. |   Overall Number of Participants Analyzed: 32 |   Measure Type: Number |   Unit of Measure: percentage of participants  26"
a5e388b9-da3c-437e-a6af-7ba76ad8bf1d,a5e388b9-da3c-437e-a6af-7ba76ad8bf1d,"both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo","[PRIMARY] INTERVENTION 1:  </s>   Docetaxel 100 mg/m^2 Plus Placebo </s>   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. </s> INTERVENTION 2:  </s>   Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg </s>   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.",0,"INTERVENTION 1:  |   Docetaxel 100 mg/m^2 Plus Placebo |   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. | INTERVENTION 2:  |   Docetaxel 100 mg/m^2 Plus Bevacizumab 7.5 mg/kg |   Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal."
3adcc8fc-b76b-407a-a006-729a13f571fb,3adcc8fc-b76b-407a-a006-729a13f571fb,"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-","[PRIMARY] INTERVENTION 1:  </s>   Nivolumab + Daratumumab (TNBC) </s>   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) </s> INTERVENTION 2:  </s>   Nivolumab + Daratumumab (NSCLC) </s>   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",0,"INTERVENTION 1:  |   Nivolumab + Daratumumab (TNBC) |   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) | INTERVENTION 2:  |   Nivolumab + Daratumumab (NSCLC) |   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)"
68379456-775b-463b-bfdb-d8aa42c9124b,68379456-775b-463b-bfdb-d8aa42c9124b,Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Females with histologic or cytologic diagnosis of advanced breast cancer. Lesions should not be amenable to surgery or radiation of curative intent. </s>   Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) performance status scale. </s>   One prior chemotherapy containing anthracyclines as (neo)adjuvant or palliative 1st-line treatment. </s>   One prior chemotherapy containing taxanes as (neo) adjuvant or palliative 1st-line treatment. </s>   Prior radiation therapy is allowed to less than 25% of the bone marrow. Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry. Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy. </s>   At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Positron emission tomography [PET] scans and ultrasounds may not be used. </s>   Antitumoral hormonal treatment must be discontinued prior to enrollment. </s>   Estimated life expectancy of at least 3 months. </s>   Participant compliance and geographic proximity that allow adequate follow-up. </s>   Adequate organ function </s>   Female participants of childbearing potential must test negative for pregnancy within 7 days of enrollment based on a urine and/or serum pregnancy test and agree to use a reliable method of birth control during and for 6 months following the last dose of study drug. </s>   Participants must sign an informed consent document. </s>   Female participants must be at least 18 years of age. </s> Exclusion Criteria: </s>   Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. </s>   Have previously completed or withdrawn from this study or any other study investigating Pemetrexed, Gemcitabine, Carboplatin or Vinorelbine </s>   Have received more than one line of chemotherapy in Metastatic Breast Cancer. Participants having received more than one combination of anthracycline plus taxane. </s>   Are pregnant or breast-feeding. </s>   Have serious concomitant systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to complete the study. </s>   Have a prior malignancy other than breast cancer, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. </s>   Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam), unless the Creatinine Clearance is greater than or equal to 80 ml/min. </s>   Have central nervous system (CNS) metastases. </s>   Have clinically relevant (by physical exam) third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study entry. </s>   Are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. </s>   Concurrent administration of any other antitumor therapy. [SECONDARY] Inclusion Criteria: </s>   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women </s> Exclusion Criteria: </s>   Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).",1,"Inclusion Criteria: |   Females with histologic or cytologic diagnosis of advanced breast cancer. Lesions should not be amenable to surgery or radiation of curative intent. | Inclusion Criteria: |   Confirmed hormone receptor positive advanced breast cancer, postmenopausal women"
5d0ccb93-71ec-4079-92c6-d7cbf951a7bb,5d0ccb93-71ec-4079-92c6-d7cbf951a7bb,Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial,"[PRIMARY] Inclusion Criteria: </s>   No known soy intolerance </s>   At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following: </s>   Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following: </s>   Gail score >= 1.66% </s>   Gail score >= 0.1% for women age 20-29 years </s>   Gail score >= 1.0% for women age 30-39 years </s>   Estimated 5-year risk of developing breast cancer using the Claus model: </s>   Claus score >= 1.66% </s>   Claus score >= 0.1% for women age 20-29 years </s>   Claus score >= 1.0% for women age 30-39 years </s>   Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity </s>   History of lobular carcinoma in situ </s>   No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical </s>   No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago </s>   Pre- or postmenopausal </s>   ECOG performance status 0-1 </s>   Hemoglobin > 10.0 g/dL </s>   Platelet count > 100,000/mm^3 </s>   Absolute neutrophil count > 1,000/mm^3 </s>   Creatinine < 2.0 mg/dL </s>   SGPT < 82 U/L </s>   SGOT < 68 U/L </s>   Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator] </s>   Life expectancy > 2 years </s>   Not pregnant or nursing </s>   Negative pregnancy test </s>   Fertile patients must use effective barrier contraception </s>   Must be willing to keep a dietary diary </s>   No venous thrombosis within the past year </s>   No unrecognized or poorly controlled thyroid disease </s>   No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer </s>   No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained </s>   None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation: </s>   Oral contraceptives </s>   Soy supplements </s>   High soy-containing foods </s>   Fish oil supplements </s>   Multivitamins </s>   Vitamins C and E </s>   Daily aspirin or nonsteroidal </s>   Anti-inflammatory drugs </s>   No other concurrent investigational agents </s>   No concurrent warfarin or other blood thinners </s>   Female patient </s> Exclusion Criteria: </s>   Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously </s>   Currently pregnant, or planning to become pregnant during the study period </s>   History of venous thrombosis within past year </s>   Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained </s>   History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer </s>   Known soy intolerance </s>   Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled. </s>   Currently receiving any other investigational agents </s>   Currently on coumadin, or other blood thinners </s>   History of breast augmentation implants. </s>   Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study. [SECONDARY] Inclusion Criteria: </s>   Female aged  18 years. </s>   Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released. </s>   TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2. </s>   Patients must be newly diagnosed metastatic or must have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment </s>   Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1. </s>   Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1. </s>   Life expectancy of at least three months. </s>   Patients must be able to swallow and retain oral medication (intact tablet). </s>   Able to undergo all screening assessments outlined in the protocol. </s>   Adequate organ function (defined by the following parameters): </s>   Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min. </s>   Serum hemoglobin  9 g/dL; absolute neutrophil count  1.5 x 109/L; platelets  100 x 109/L. </s>   Serum bilirubin  1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome </s>   Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST)  2.5 x UNL but  5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP)  UNL but i)  2.5 x UNL in case of liver metastases and ii)  5 UNL in case of bone metastases; albumin  2.5 g/dl. </s>   No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease. </s>   No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status. </s>   Dated and signed IEC/IRB-approved informed consent. </s> Exclusion Criteria: </s>   Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease. </s>   Less than four weeks since last radiotherapy (excluding palliative radiotherapy). </s>   Pregnancy or lactation or unwillingness to use adequate method of birth control. </s>   Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures. </s>   Active or uncontrolled infection. </s>   Malabsorption syndrome, disease significantly affecting gastrointestinal function. </s>   G>1 pre-existing peripheral neuropathy </s>   Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer </s>   Hypersensitivity to: </s>   paclitaxel </s>   ibuprofen or to more than one non-steroidal anti-inflammatory drug. </s>   medications belonging to the class of sulfonamides, with the exception of sulfanilamides (e.g., sulfamethoxazole).",1,"Exclusion Criteria: |   Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously | Exclusion Criteria: |   Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease. |   Less than four weeks since last radiotherapy (excluding palliative radiotherapy)."
f04d9695-81b8-4d70-877b-59caddf901bd,f04d9695-81b8-4d70-877b-59caddf901bd,"Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial","[PRIMARY] Adverse Events 1: </s>   Total: 0/34 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 6/62 (9.68%) </s>   Musculoskeletal * 1/62 (1.61%) </s>   Mood Alteration: Depression * 1/62 (1.61%) </s>   renal - Other * 1/62 (1.61%) </s>   Obstruction, GU: Uterus * 1/62 (1.61%) </s>   Sexual * 0/62 (0.00%) </s>   Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) </s>   Ulceration * 1/62 (1.61%) </s> Adverse Events 2: </s>   Total: 1/64 (1.56%) </s>   Musculoskeletal * 0/64 (0.00%) </s>   Mood Alteration: Depression * 0/64 (0.00%) </s>   renal - Other * 0/64 (0.00%) </s>   Obstruction, GU: Uterus * 0/64 (0.00%) </s>   Sexual * 1/64 (1.56%) </s>   Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) </s>   Ulceration * 0/64 (0.00%)",1,"Adverse Events 1: |   Total: 0/34 (0.00%) | Adverse Events 1: |   Total: 6/62 (9.68%) |   Musculoskeletal * 1/62 (1.61%) |   Mood Alteration: Depression * 1/62 (1.61%) |   renal - Other * 1/62 (1.61%) |   Obstruction, GU: Uterus * 1/62 (1.61%) |   Sexual * 0/62 (0.00%) |   Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%) |   Ulceration * 1/62 (1.61%) | Adverse Events 2: |   Total: 1/64 (1.56%) |   Musculoskeletal * 0/64 (0.00%) |   Mood Alteration: Depression * 0/64 (0.00%) |   renal - Other * 0/64 (0.00%) |   Obstruction, GU: Uterus * 0/64 (0.00%) |   Sexual * 1/64 (1.56%) |   Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%) |   Ulceration * 0/64 (0.00%)"
f42e1874-343a-43ed-bb0c-884509c4793c,f42e1874-343a-43ed-bb0c-884509c4793c,the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death,"[PRIMARY] Outcome Measurement:  </s>   Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) </s>   The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method. </s>   Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) </s> Results 1:  </s>   Arm/Group Title: Ixabepilone 40 mg/m^2 </s>   Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks </s>   Overall Number of Participants Analyzed: 40 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  30.0        (16.6 to 46.5) </s> Results 2:  </s>   Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 </s>   Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks </s>   Overall Number of Participants Analyzed: 39 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  35.9        (21.2 to 52.8) [SECONDARY] Outcome Measurement:  </s>   Progression Free Survival </s>   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. </s>   Assessment period was from the day of randomisation until the first observation of lesion progression or death </s>   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, </s> Results 1:  </s>   Arm/Group Title: NK105 </s>   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.4        (7.0 to 9.9) </s> Results 2:  </s>   Arm/Group Title: Paclitaxel </s>   Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle </s>   Overall Number of Participants Analyzed: 211 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  8.5        (6.9 to 11.5)",0,"Outcome Measurement:  |   Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) |   The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method. |   Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) | Outcome Measurement:  |   Progression Free Survival |   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1. |   Assessment period was from the day of randomisation until the first observation of lesion progression or death |   Time frame: Baseline, every 6 weeks of study treatment period, and end of study,"
30483d7e-7703-459c-bd10-e2bd259c2a4f,30483d7e-7703-459c-bd10-e2bd259c2a4f,there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 4/65 (6.15%) </s>   Thrombocytopenia * 0/65 (0.00%) </s>   Anaemia * 20/65 (0.00%) </s>   Febrile neutropenia * 20/65 (0.00%) </s>   Leukopenia * 20/65 (0.00%) </s>   Neutropenia * 20/65 (0.00%) </s>   Pericardial effusion * 20/65 (0.00%) </s>   Tachycardia * 20/65 (0.00%) </s>   Nausea * 0/65 (0.00%) </s>   Vomiting * 21/65 (1.54%) </s>   Constipation * 20/65 (0.00%) </s>   Abdominal pain * 20/65 (0.00%) </s> Adverse Events 2: </s>   Total: 33/134 (24.63%) </s>   Thrombocytopenia * 10/134 (7.46%) </s>   Anaemia * 29/134 (6.72%) </s>   Febrile neutropenia * 21/134 (0.75%) </s>   Leukopenia * 21/134 (0.75%) </s>   Neutropenia * 21/134 (0.75%) </s>   Pericardial effusion * 21/134 (0.75%) </s>   Tachycardia * 21/134 (0.75%) </s>   Nausea * 5/134 (3.73%) </s>   Vomiting * 23/134 (2.24%) </s>   Constipation * 22/134 (1.49%) </s>   Abdominal pain * 21/134 (0.75%),1,Adverse Events 1: |   Total: 4/65 (6.15%) |   Thrombocytopenia * 0/65 (0.00%) |   Anaemia * 20/65 (0.00%) |   Febrile neutropenia * 20/65 (0.00%) |   Leukopenia * 20/65 (0.00%) |   Neutropenia * 20/65 (0.00%) |   Pericardial effusion * 20/65 (0.00%) |   Tachycardia * 20/65 (0.00%) |   Nausea * 0/65 (0.00%) |   Vomiting * 21/65 (1.54%) |   Constipation * 20/65 (0.00%) |   Abdominal pain * 20/65 (0.00%)
7cde9a22-a91f-4feb-892d-7cbd35f96a27,7cde9a22-a91f-4feb-892d-7cbd35f96a27,the primary trial reports the changes in tumor size for patients in its cohorts.,"[PRIMARY] Outcome Measurement:  </s>   Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 </s>   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment. </s>   Time frame: Baseline up to end of Cycle 2 (Day 42) </s> Results 1:  </s>   Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim </s>   Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]). </s>   Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care. </s>   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met. </s>   Overall Number of Participants Analyzed: 17 </s>   Mean (Standard Deviation) </s>   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08) </s> Results 2:  </s>   Arm/Group Title: Ixabepilone </s>   Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. </s>   Dosage determined by calculating participant's body surface area (40 mg/m^2). </s>   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met. </s>   Overall Number of Participants Analyzed: 11 </s>   Mean (Standard Deviation) </s>   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)",1,"Outcome Measurement:  |   Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 |   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment."
16c29502-4683-4087-9410-ff1b786556f5,16c29502-4683-4087-9410-ff1b786556f5,The least common adverse event in the primary trial was Constipation ,"[PRIMARY] Adverse Events 1: </s>   Total: 14/41 (34.15%) </s>   Anemia 1/41 (2.44%) </s>   Febrile neutropenia 1/41 (2.44%) </s>   Eye disorders - Other, Visual disturbance 1/41 (2.44%) </s>   Abdominal pain 1/41 (2.44%) </s>   Constipation 1/41 (2.44%) </s>   Nausea 1/41 (2.44%) </s>   Fever 1/41 (2.44%) </s>   Pain 1/41 (2.44%) </s>   Skin infection 2/41 (4.88%) </s>   Alkaline phosphatase increased 1/41 (2.44%) </s>   Aspartate aminotransferase increased 1/41 (2.44%)",0,"Adverse Events 1: |   Total: 14/41 (34.15%) |   Anemia 1/41 (2.44%) |   Febrile neutropenia 1/41 (2.44%) |   Eye disorders - Other, Visual disturbance 1/41 (2.44%) |   Abdominal pain 1/41 (2.44%) |   Constipation 1/41 (2.44%) |   Nausea 1/41 (2.44%) |   Fever 1/41 (2.44%) |   Pain 1/41 (2.44%) |   Skin infection 2/41 (4.88%) |   Alkaline phosphatase increased 1/41 (2.44%) |   Aspartate aminotransferase increased 1/41 (2.44%)"
5c975af8-6b7f-4a5d-b4a6-257c76763ce9,5c975af8-6b7f-4a5d-b4a6-257c76763ce9,"There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",[PRIMARY] Adverse Events 1: </s>   Total: 0/0 </s> Adverse Events 2: </s>     [SECONDARY] Adverse Events 1: </s>   Total: 59/199 (29.65%) </s>   Anaemia 7/199 (3.52%) </s>   Thrombocytopenia 2/199 (1.01%) </s>   Acute myocardial infarction 0/199 (0.00%) </s>   Atrial fibrillation 1/199 (0.50%) </s>   Cardiac arrest 1/199 (0.50%) </s>   Cardiac failure 1/199 (0.50%) </s>   Cardiopulmonary failure 1/199 (0.50%) </s>   Left ventricular failure 1/199 (0.50%) </s>   Supraventricular tachycardia 0/199 (0.00%) </s>   Ventricular tachycardia 1/199 (0.50%) </s> Adverse Events 2: </s>   Total: 16/36 (44.44%) </s>   Anaemia 2/36 (5.56%) </s>   Thrombocytopenia 1/36 (2.78%) </s>   Acute myocardial infarction 1/36 (2.78%) </s>   Atrial fibrillation 0/36 (0.00%) </s>   Cardiac arrest 0/36 (0.00%) </s>   Cardiac failure 0/36 (0.00%) </s>   Cardiopulmonary failure 0/36 (0.00%) </s>   Left ventricular failure 0/36 (0.00%) </s>   Supraventricular tachycardia 1/36 (2.78%) </s>   Ventricular tachycardia 0/36 (0.00%),1,Adverse Events 1: |   Total: 0/0 | Adverse Events 2: |     | Adverse Events 1: |   Acute myocardial infarction 1/36 (2.78%) |   Cardiopulmonary failure 0/36 (0.00%) |   Supraventricular tachycardia 1/36 (2.78%)
1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7,1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7,There were more total AEs in cohort 1 of  the primary trial than cohort 2,[PRIMARY] Adverse Events 1: </s>   Total: 13/61 (21.31%) </s>   Anaemia 1/61 (1.64%) </s>   Febrile neutropenia 1/61 (1.64%) </s>   Cardiac failure congestive 0/61 (0.00%) </s>   Pericardial effusion 0/61 (0.00%) </s>   Constipation 1/61 (1.64%) </s>   Intestinal perforation 1/61 (1.64%) </s>   Stomatitis 0/61 (0.00%) </s>   Non-cardiac chest pain 2/61 (3.28%) </s>   Condition aggravated 1/61 (1.64%) </s>   General physical health deterioration 1/61 (1.64%) </s> Adverse Events 2: </s>   Total: 12/60 (20.00%) </s>   Anaemia 1/60 (1.67%) </s>   Febrile neutropenia 0/60 (0.00%) </s>   Cardiac failure congestive 1/60 (1.67%) </s>   Pericardial effusion 1/60 (1.67%) </s>   Constipation 0/60 (0.00%) </s>   Intestinal perforation 0/60 (0.00%) </s>   Stomatitis 1/60 (1.67%) </s>   Non-cardiac chest pain 0/60 (0.00%) </s>   Condition aggravated 0/60 (0.00%) </s>   General physical health deterioration 1/60 (1.67%),0,Adverse Events 1: |   Total: 13/61 (21.31%) |   Anaemia 1/61 (1.64%) |   Febrile neutropenia 1/61 (1.64%) |   Cardiac failure congestive 0/61 (0.00%) |   Pericardial effusion 0/61 (0.00%) |   Constipation 1/61 (1.64%) |   Intestinal perforation 1/61 (1.64%) |   Stomatitis 0/61 (0.00%) |   Non-cardiac chest pain 2/61 (3.28%) |   Condition aggravated 1/61 (1.64%) |   General physical health deterioration 1/61 (1.64%) | Adverse Events 2: |   Total: 12/60 (20.00%) |   Anaemia 1/60 (1.67%) |   Febrile neutropenia 0/60 (0.00%) |   Cardiac failure congestive 1/60 (1.67%) |   Pericardial effusion 1/60 (1.67%) |   Constipation 0/60 (0.00%) |   Intestinal perforation 0/60 (0.00%) |   Stomatitis 1/60 (1.67%) |   Non-cardiac chest pain 0/60 (0.00%) |   Condition aggravated 0/60 (0.00%) |   General physical health deterioration 1/60 (1.67%)
8e91e404-086e-4063-8d54-83d1b8ebd969,8e91e404-086e-4063-8d54-83d1b8ebd969,over 1/6 patients in cohort 1 of the primary trial suffered adverse events,[PRIMARY] Adverse Events 1: </s>   Total: 6 </s>   Atrial fibrillation 1/67 (1.49%) </s>   Ventricular fibrillation 1/67 (1.49%) </s>   Gastrointestinal perforation 1/67 (1.49%) </s>   Periproctitis 1/67 (1.49%) </s>   General physical health deterioration 1/67 (1.49%) </s>   Escherichia sepsis 1/67 (1.49%) </s>   Pneumonia 1/67 (1.49%) </s>   Tumour pain 1/67 (1.49%) </s>   Renal failure acute 1/67 (1.49%) </s>   Pleurisy 1/67 (1.49%),0,Adverse Events 1: |   Total: 6
b8322b23-a4f6-4cba-9761-be826b509de7,b8322b23-a4f6-4cba-9761-be826b509de7,"There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial","[PRIMARY] Adverse Events 1: </s>   Total: 0/150 (0.00%) </s> Adverse Events 2: </s>   Total:  [SECONDARY] Adverse Events 1: </s>   Total: 14/41 (34.15%) </s>   Anemia 1/41 (2.44%) </s>   Febrile neutropenia 1/41 (2.44%) </s>   Eye disorders - Other, Visual disturbance 1/41 (2.44%) </s>   Abdominal pain 1/41 (2.44%) </s>   Constipation 1/41 (2.44%) </s>   Nausea 1/41 (2.44%) </s>   Fever 1/41 (2.44%) </s>   Pain 1/41 (2.44%) </s>   Skin infection 2/41 (4.88%) </s>   Alkaline phosphatase increased 1/41 (2.44%) </s>   Aspartate aminotransferase increased 1/41 (2.44%)",1,"Adverse Events 1: |   Total: 0/150 (0.00%) | Adverse Events 1: |   Total: 14/41 (34.15%) |   Anemia 1/41 (2.44%) |   Febrile neutropenia 1/41 (2.44%) |   Eye disorders - Other, Visual disturbance 1/41 (2.44%) |   Abdominal pain 1/41 (2.44%)"
4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3,4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3,There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts,[PRIMARY] Adverse Events 1: </s>   Total: 59/373 (15.82%) </s>   Neutropenia 14/373 (3.75%) </s>   Febrile neutropenia 10/373 (2.68%) </s>   Leukopenia 1/373 (0.27%) </s>   Anaemia 2/373 (0.54%) </s>   Lymphadenopathy 0/373 (0.00%) </s>   cardiac failure 2/373 (0.54%) </s>   Atrial fibrillation 1/373 (0.27%) </s>   Pericardial effusion 2/373 (0.54%) </s>   Cardiac failure congestive 1/373 (0.27%) </s>   Cardiomyopathy 0/373 (0.00%) </s> Adverse Events 2: </s>   Total: 69/377 (18.30%) </s>   Neutropenia 17/377 (4.51%) </s>   Febrile neutropenia 10/377 (2.65%) </s>   Leukopenia 4/377 (1.06%) </s>   Anaemia 2/377 (0.53%) </s>   Lymphadenopathy 1/377 (0.27%) </s>   cardiac failure 1/377 (0.27%) </s>   Atrial fibrillation 1/377 (0.27%) </s>   Pericardial effusion 0/377 (0.00%) </s>   Cardiac failure congestive 0/377 (0.00%) </s>   Cardiomyopathy 1/377 (0.27%) [SECONDARY] Adverse Events 1: </s>   Total: 0/92 (0.00%) </s>   Diarrhea 0/92 (0.00%) </s> Adverse Events 2: </s>   Total: 1/93 (1.08%) </s>   Diarrhea 1/93 (1.08%),0,Adverse Events 1: |   Total: 59/373 (15.82%) |   Neutropenia 14/373 (3.75%) |   Febrile neutropenia 10/373 (2.68%) |   Leukopenia 1/373 (0.27%) |   Anaemia 2/373 (0.54%) |   Lymphadenopathy 0/373 (0.00%) |   cardiac failure 2/373 (0.54%) |   Atrial fibrillation 1/373 (0.27%) |   Pericardial effusion 2/373 (0.54%) |   Cardiac failure congestive 1/373 (0.27%) |   Cardiomyopathy 0/373 (0.00%) | Adverse Events 2: |   Total: 69/377 (18.30%) |   Neutropenia 17/377 (4.51%) |   Febrile neutropenia 10/377 (2.65%) |   Leukopenia 4/377 (1.06%) |   Anaemia 2/377 (0.53%) |   Lymphadenopathy 1/377 (0.27%) |   cardiac failure 1/377 (0.27%) |   Atrial fibrillation 1/377 (0.27%) |   Pericardial effusion 0/377 (0.00%) |   Cardiac failure congestive 0/377 (0.00%) |   Cardiomyopathy 1/377 (0.27%) | Adverse Events 1: |   Total: 0/92 (0.00%) |   Diarrhea 0/92 (0.00%) | Adverse Events 2: |   Total: 1/93 (1.08%) |   Diarrhea 1/93 (1.08%)
4b97a844-8d52-48bb-8eda-ca205268f016,4b97a844-8d52-48bb-8eda-ca205268f016,Patients must have a Life expectancy of 75+ years to enroll in the primary trial,"[PRIMARY] Inclusion criteria: </s>   Female patients  18 years of age. </s>   Written informed consent given. </s>   Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed. </s>   Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months. </s>   Eastern Cooperative Oncology Group (ECOG) performance status 2 . </s>   Life expectancy  1 year. </s> Exclusion criteria: </s>   More than 3 months since last infusion of Zoledronic Acid (Zometa®). </s>   Treatments with other bisphosphonate than Zoledronic Acid (Zometa®) at any time prior to study entry. </s>   Serum creatinine > 3 mg/dL (265 μmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85 </s>   Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L). </s>   Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. </s>   Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants). </s>   Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide). </s>   History of non-compliance to medical regimens or potential unreliable behavior. </s>   Known sensitivity to study drug(s) or class of study drug(s). </s>   Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study </s>   Use of any other investigational agent in the last 30 days.",0,  Life expectancy  1 year.
2a03c17f-3afe-40f1-a0db-4b876ee8c700,2a03c17f-3afe-40f1-a0db-4b876ee8c700,the primary trial and the secondary trial have non-comparable outcome measurements for their results,"[PRIMARY] Outcome Measurement:  </s>   Percent Change in Net Influx Constant (Ki) by FLT PET </s>   Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. </s>   Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response. </s>   Time frame: Baseline to up to 6 weeks </s> Results 1:  </s>   Arm/Group Title: Diagnostic (FLT PET) </s>   Arm/Group Description: Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan. </s>   Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine. </s>   Positron Emission Tomography: Undergo FLT PET </s>   Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen. </s>   Overall Number of Participants Analyzed: 28 </s>   Median (Full Range) </s>   Unit of Measure: % change  -32.0        (-82.4 to 3953.7) [SECONDARY] Outcome Measurement:  </s>   Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) </s>   PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. </s>   Time frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) </s> Results 1:  </s>   Arm/Group Title: Placebo+Fulvestrant </s>   Arm/Group Description: Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. </s>   Overall Number of Participants Analyzed: 176 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  5.39        (3.68 to 7.29) </s> Results 2:  </s>   Arm/Group Title: Taselisib+Fulvestrant </s>   Arm/Group Description: Participants received taselisib 4 mg taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. </s>   Overall Number of Participants Analyzed: 340 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  7.43        (7.26 to 9.07)",1,"Outcome Measurement:  |   Percent Change in Net Influx Constant (Ki) by FLT PET |   Percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors will be computed. |   Association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response, using Ki-67 as the standard for early response. |   Time frame: Baseline to up to 6 weeks | Outcome Measurement:  |   Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)"
3ba42f68-a643-4d10-afd0-cbb358d05a6f,3ba42f68-a643-4d10-afd0-cbb358d05a6f,All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial,"[PRIMARY] INTERVENTION 1:  </s>   BKM120 and Paclitaxel </s>   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel </s> INTERVENTION 2:  </s>   Placebo and Paclitaxel </s>   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel [SECONDARY] INTERVENTION 1:  </s>   Active Breathing Coordinator </s>   Patients breathe through the ABC device </s>   Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.",1,"INTERVENTION 1:  |   BKM120 and Paclitaxel |   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel | INTERVENTION 2:  |   Placebo and Paclitaxel |   Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel | INTERVENTION 1:  |   Active Breathing Coordinator |   Patients breathe through the ABC device |   Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms."
0a079cca-abde-42cf-9cec-a76e7a380e14,0a079cca-abde-42cf-9cec-a76e7a380e14,neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention,[PRIMARY] INTERVENTION 1:  </s>   No Exercise </s>   Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week </s> INTERVENTION 2:  </s>   Exercise </s>   Exercise Arm: Exercise consisting of progressive walking and resistance band training </s>   Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise,1,INTERVENTION 1:  |   No Exercise |   Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week | INTERVENTION 2:  |   Exercise |   Exercise Arm: Exercise consisting of progressive walking and resistance band training |   Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise
9c033072-5f94-4d79-af47-126d531f0d6e,9c033072-5f94-4d79-af47-126d531f0d6e,There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial,[PRIMARY] Adverse Events 1: </s>   Total: 3/12 (25.00%) </s>   Atrial fibrillation 0/12 (0.00%) </s>   Cardiac ischemia/infarction  [1]0/12 (0.00%) </s>   Congestive Heart Failure  [2]0/12 (0.00%) </s>   Diverticulitis 0/12 (0.00%) </s>   Cholecystitis 0/12 (0.00%) </s>   Hyperbilirubinemia 0/12 (0.00%) </s>   Urosepsis 2/12 (16.67%) </s>   Brain hemorrhage complicating CNS metastasis 1/12 (8.33%) </s>   Rash  [3]0/12 (0.00%) [SECONDARY] Adverse Events 1: </s>   Total: 18/65 (27.69%) </s>   Anaemia 5/65 (7.69%) </s>   Febrile neutropenia 1/65 (1.54%) </s>   Leukocytosis 0/65 (0.00%) </s>   Neutropenia 4/65 (6.15%) </s>   Thrombocytopenia 6/65 (9.23%) </s>   Cardiac failure congestive 0/65 (0.00%) </s>   Epigastric discomfort 0/65 (0.00%) </s>   Nausea 1/65 (1.54%) </s>   Vomiting 3/65 (4.62%) </s>   Condition aggravated 0/65 (0.00%) </s>   Medical device complication 0/65 (0.00%) </s> Adverse Events 2: </s>   Total: 22/66 (33.33%) </s>   Anaemia 1/66 (1.52%) </s>   Febrile neutropenia 2/66 (3.03%) </s>   Leukocytosis 1/66 (1.52%) </s>   Neutropenia 2/66 (3.03%) </s>   Thrombocytopenia 0/66 (0.00%) </s>   Cardiac failure congestive 1/66 (1.52%) </s>   Epigastric discomfort 1/66 (1.52%) </s>   Nausea 0/66 (0.00%) </s>   Vomiting 1/66 (1.52%) </s>   Condition aggravated 1/66 (1.52%) </s>   Medical device complication 1/66 (1.52%),0,Adverse Events 1: |   Urosepsis 2/12 (16.67%) | Adverse Events 1: |   Total: 18/65 (27.69%) |   Anaemia 5/65 (7.69%) |   Febrile neutropenia 1/65 (1.54%) |   Leukocytosis 0/65 (0.00%) |   Neutropenia 4/65 (6.15%) |   Thrombocytopenia 6/65 (9.23%) |   Cardiac failure congestive 0/65 (0.00%) |   Epigastric discomfort 0/65 (0.00%) |   Nausea 1/65 (1.54%) |   Vomiting 3/65 (4.62%) |   Condition aggravated 0/65 (0.00%) |   Medical device complication 0/65 (0.00%) | Adverse Events 2: |   Total: 22/66 (33.33%) |   Anaemia 1/66 (1.52%) |   Febrile neutropenia 2/66 (3.03%) |   Leukocytosis 1/66 (1.52%) |   Neutropenia 2/66 (3.03%) |   Thrombocytopenia 0/66 (0.00%) |   Cardiac failure congestive 1/66 (1.52%) |   Epigastric discomfort 1/66 (1.52%) |   Nausea 0/66 (0.00%) |   Vomiting 1/66 (1.52%) |   Condition aggravated 1/66 (1.52%) |   Medical device complication 1/66 (1.52%)
a52b2d4f-0b06-4960-a9c3-88cb92df0980,a52b2d4f-0b06-4960-a9c3-88cb92df0980,the primary trial participants receive Capecitabine less often than they receive Lapatinib,[PRIMARY] INTERVENTION 1:  </s>   Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 </s>   Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.,0,INTERVENTION 1:  |   Lapatinib 1250 mg and Capecitabine 2000 mg/m^2 |   Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.
a792bbac-0e8a-4bf7-9cc5-56fad481e2fb,a792bbac-0e8a-4bf7-9cc5-56fad481e2fb,"eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial","[PRIMARY] Inclusion Criteria: </s>   women >=18 years of age; </s>   newly diagnosed; </s>   infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer. </s> Exclusion Criteria: </s>   evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes; </s>   previous systemic or local primary treatment.",0,Inclusion Criteria: |   women >=18 years of age;
1842904b-5371-49ee-b6f4-8831b879098b,1842904b-5371-49ee-b6f4-8831b879098b,"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",[PRIMARY] Adverse Events 1: </s>   Total: 11/56 (19.64%) </s>   Febrile Neutropenia * 3/56 (5.36%) </s>   Neutropenia * 1/56 (1.79%) </s>   Pancytopenia * 1/56 (1.79%) </s>   Atrial Fibrillation * 1/56 (1.79%) </s>   Coronary Artery Disease * 1/56 (1.79%) </s>   Constipation * 1/56 (1.79%) </s>   Chest Pain * 1/56 (1.79%) </s>   Non-Cardiac Chest Pain * 1/56 (1.79%) </s>   Edema due to Cardiac Disease * 1/56 (1.79%) </s>   Cellulitis * 1/56 (1.79%),1,Adverse Events 1: |   Total: 11/56 (19.64%) |   Febrile Neutropenia * 3/56 (5.36%) |   Neutropenia * 1/56 (1.79%) |   Pancytopenia * 1/56 (1.79%) |   Atrial Fibrillation * 1/56 (1.79%) |   Coronary Artery Disease * 1/56 (1.79%) |   Constipation * 1/56 (1.79%) |   Chest Pain * 1/56 (1.79%) |   Non-Cardiac Chest Pain * 1/56 (1.79%) |   Edema due to Cardiac Disease * 1/56 (1.79%) |   Cellulitis * 1/56 (1.79%)
324562e6-2b61-4a07-b937-86f99689f2d5,324562e6-2b61-4a07-b937-86f99689f2d5,"Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",[PRIMARY] Adverse Events 1: </s>   Total: 17/65 (26.15%) </s>   Febrile neutropenia 3/65 (4.62%) </s>   Neutropenia 2/65 (3.08%) </s>   Pancytopenia 1/65 (1.54%) </s>   Thrombocytopenia 1/65 (1.54%) </s>   Cardiac arrest 2/65 (3.08%) </s>   Myocardial infarction 1/65 (1.54%) </s>   Diarrhoea 5/65 (7.69%) </s>   Stomatitis 1/65 (1.54%) </s>   Vomiting 2/65 (3.08%) </s>   Fatigue 1/65 (1.54%) </s>   Jaundice 1/65 (1.54%) </s>   Neutropenic infection 2/65 (3.08%) [SECONDARY] Adverse Events 1: </s>   Total: 173/472 (36.65%) </s>   Anaemia 6/472 (1.27%) </s>   Febrile neutropenia 4/472 (0.85%) </s>   Iron deficiency anaemia 1/472 (0.21%) </s>   Leukopenia 2/472 (0.42%) </s>   Neutropenia 2/472 (0.42%) </s>   Thrombocytopenia 4/472 (0.85%) </s>   Acute myocardial infarction 1/472 (0.21%) </s>   Aortic valve incompetence 0/472 (0.00%) </s>   Atrial fibrillation 2/472 (0.42%) </s>   Cardiac arrest 1/472 (0.21%) </s> Adverse Events 2: </s>   Total: 40/238 (16.81%) </s>   Anaemia 0/238 (0.00%) </s>   Febrile neutropenia 1/238 (0.42%) </s>   Iron deficiency anaemia 0/238 (0.00%) </s>   Leukopenia 0/238 (0.00%) </s>   Neutropenia 2/238 (0.84%) </s>   Thrombocytopenia 0/238 (0.00%) </s>   Acute myocardial infarction 0/238 (0.00%) </s>   Aortic valve incompetence 1/238 (0.42%) </s>   Atrial fibrillation 0/238 (0.00%) </s>   Cardiac arrest 0/238 (0.00%),1,Adverse Events 1: |   Total: 17/65 (26.15%) |   Febrile neutropenia 3/65 (4.62%) |   Neutropenia 2/65 (3.08%) |   Pancytopenia 1/65 (1.54%) |   Thrombocytopenia 1/65 (1.54%) |   Cardiac arrest 2/65 (3.08%) |   Myocardial infarction 1/65 (1.54%) |   Diarrhoea 5/65 (7.69%) |   Stomatitis 1/65 (1.54%) |   Vomiting 2/65 (3.08%) |   Fatigue 1/65 (1.54%) |   Jaundice 1/65 (1.54%) |   Neutropenic infection 2/65 (3.08%) | Adverse Events 1: |   Total: 173/472 (36.65%) |   Anaemia 6/472 (1.27%) |   Febrile neutropenia 4/472 (0.85%) |   Iron deficiency anaemia 1/472 (0.21%) |   Leukopenia 2/472 (0.42%) |   Neutropenia 2/472 (0.42%) |   Thrombocytopenia 4/472 (0.85%) |   Acute myocardial infarction 1/472 (0.21%) |   Aortic valve incompetence 0/472 (0.00%) |   Atrial fibrillation 2/472 (0.42%) |   Cardiac arrest 1/472 (0.21%) | Adverse Events 2: |   Total: 40/238 (16.81%) |   Anaemia 0/238 (0.00%) |   Febrile neutropenia 1/238 (0.42%) |   Iron deficiency anaemia 0/238 (0.00%) |   Leukopenia 0/238 (0.00%) |   Neutropenia 2/238 (0.84%) |   Thrombocytopenia 0/238 (0.00%) |   Acute myocardial infarction 0/238 (0.00%) |   Aortic valve incompetence 1/238 (0.42%) |   Atrial fibrillation 0/238 (0.00%) |   Cardiac arrest 0/238 (0.00%)
74e376d7-5713-43f3-93f1-9608059c9547,74e376d7-5713-43f3-93f1-9608059c9547,"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications","[PRIMARY] Outcome Measurement:  </s>   Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment </s>   ORR is defined as the percentage of patients who exhibit a Complete Response (CR) or Partial Response (PR). Complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. Partial Response is at least a 50% reduction of all measurable lesions as measured by the product of the perpendicular diameters of the greatest dimensions of tumor size, with no new lesions appearing for at least four weeks. </s>   Time frame: 18 Months </s> Results 1:  </s>   Arm/Group Title: Arm A -Liposomal Doxorubicin Then Docetaxel </s>   Arm/Group Description: Liposomal doxorubicin (Arm A) </s>   Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle. </s>   Patients demonstrating progression on Liposomal Doxorubicin were eligible for cross over to treatment on Docetaxel, provided the patient still met the eligibility laboratory and performance status criteria. </s>   Overall Number of Participants Analyzed: 42 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  28        (16 to 42) </s> Results 2:  </s>   Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin </s>   Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. This dosing schedule will define one cycle. </s>   Patients demonstrating progression on Docetaxel were eligible for cross over to treatment on Liposomal Doxorubicin, provided the patient still met the eligibility laboratory and performance status criteria. </s>   Overall Number of Participants Analyzed: 44 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  31        (18 to 45)",0,"Outcome Measurement:  |   Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment |   ORR is defined as the percentage of patients who exhibit a Complete Response (CR) or Partial Response (PR). Complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. Partial Response is at least a 50% reduction of all measurable lesions as measured by the product of the perpendicular diameters of the greatest dimensions of tumor size, with no new lesions appearing for at least four weeks. |   Time frame: 18 Months | Results 1:  |   Arm/Group Title: Arm A -Liposomal Doxorubicin Then Docetaxel |   Arm/Group Description: Liposomal doxorubicin (Arm A) |   Liposomal doxorubicin 40 mg/m2 IV day 1 over one hour, repeated q 28 days thru peripheral vein or central venous access. This will define one cycle. |   Patients demonstrating progression on Liposomal Doxorubicin were eligible for cross over to treatment on Docetaxel, provided the patient still met the eligibility laboratory and performance status criteria. |   Overall Number of Participants Analyzed: 42 |   Measure Type: Number |   Unit of Measure: percentage of patients  28        (16 to 42) | Results 2:  |   Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin |   Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. This dosing schedule will define one cycle. |   Patients demonstrating progression on Docetaxel were eligible for cross over to treatment on Liposomal Doxorubicin, provided the patient still met the eligibility laboratory and performance status criteria. |   Overall Number of Participants Analyzed: 44 |   Measure Type: Number |   Unit of Measure: percentage of patients  31        (18 to 45)"
0e609fad-9a28-4fb6-90b6-32a731e3b02c,0e609fad-9a28-4fb6-90b6-32a731e3b02c,the primary trial and the secondary trial report their results as perecentages but use different units of measure.,"[PRIMARY] Outcome Measurement:  </s>   Objective Response Rate </s>   The objective response rate (ORR) was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. </s>   Time frame: Evaluated every 6 weeks from the time of their first treatment, per RECIST 1.1. Duration of therapy will depend on individual response, evidence of disease progression and tolerance, up to 1 year </s> Results 1:  </s>   Arm/Group Title: Cisplatin + AZD1775 </s>   Arm/Group Description: Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later. </s>   AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days. </s>   At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3). </s>   Overall Number of Participants Analyzed: 34 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  26        (13 to 44) [SECONDARY] Outcome Measurement:  </s>   Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods </s>   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. </s>   Time frame: Baseline </s> Results 1:  </s>   Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer) </s>   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery. </s>   Overall Number of Participants Analyzed: 92 </s>   Measure Type: Number </s>   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86 </s>   Proportion of SNs (PICG) detected by ICG method: 0.95",0,  Unit of Measure: percentage of participants  26        (13 to 44) |   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86
236780db-9e59-4dc9-8da0-e786287011cf,236780db-9e59-4dc9-8da0-e786287011cf,the primary trial intervention protocol lasts a total of 14 days,"[PRIMARY] INTERVENTION 1:  </s>   Pemetrexed </s>   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression",0,"INTERVENTION 1:  |   Pemetrexed |   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression"
6d621974-c719-46df-8a50-d94e49583e33,6d621974-c719-46df-8a50-d94e49583e33,all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy,"[PRIMARY] Inclusion Criteria: </s>   Adult Women ( 18 years old). </s>   Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease. </s>   Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease. </s>   HER2+ patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive). </s>   Prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued > 12 months prior to randomization. </s>   Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment. </s>   Documentation of negative pregnancy test. </s>   Organ functions at time of inclusion. </s> Exclusion Criteria: </s>   Prior mTOR inhibitors for the treatment of cancer. </s>   Other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. </s>   Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc). </s>   Radiotherapy to  25% of the bone marrow within 4 weeks prior to randomization </s>   History of central nervous system metastasis. </s>   Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract. </s>   Serious peripheral neuropathy. </s>   Cardiac disease or dysfunction. </s>   Uncontrolled hypertension. </s> HIV. </s> Pregnant,",1,  Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. Patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment.
a9907a2e-254a-45ca-af50-3e44fd2f7af3,a9907a2e-254a-45ca-af50-3e44fd2f7af3,There was one case of  Neutropenia in both cohorts of the primary trial,[PRIMARY] Adverse Events 1: </s>   Total: 3/39 (7.69%) </s>   Neutropenia  1/39 (2.56%) </s>   Bilateral Pulmonary Thromboembolism  0/39 (0.00%) </s>   Fever  1/39 (2.56%) </s>   Empyema associated with a permanent thoracic catheter  1/39 (2.56%) </s> Adverse Events 2: </s>   Total: 3/21 (14.29%) </s>   Neutropenia  1/21 (4.76%) </s>   Bilateral Pulmonary Thromboembolism  1/21 (4.76%) </s>   Fever  1/21 (4.76%) </s>   Empyema associated with a permanent thoracic catheter  0/21 (0.00%),1,Adverse Events 1: |   Total: 3/39 (7.69%) |   Neutropenia  1/39 (2.56%) | Adverse Events 2: |   Total: 3/21 (14.29%) |   Neutropenia  1/21 (4.76%)
40f699a1-fbc6-40de-8e80-85b28f71632f,40f699a1-fbc6-40de-8e80-85b28f71632f,"Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.","[PRIMARY] Outcome Measurement:  </s>   Severity of Adverse Events </s>   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. </s>   Time frame: From cycle 1 up to approximately 3 years </s> Results 1:  </s>   Arm/Group Title: Trastuzumab Emtansine </s>   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. </s>   Overall Number of Participants Analyzed: 70 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  Grade 1: 53  75.7% </s>   Grade 2: 40  57.1% </s>   Grade 3: 18  25.7% </s>   Grade 4: 2   2.9% </s>   Grade 5: 12  17.1%",0,"Outcome Measurement:  |   Severity of Adverse Events |   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. |   Time frame: From cycle 1 up to approximately 3 years | Results 1:  |   Arm/Group Title: Trastuzumab Emtansine |   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. |   Overall Number of Participants Analyzed: 70 |   Measure Type: Count of Participants |   Unit of Measure: Participants  Grade 1: 53  75.7% |   Grade 2: 40  57.1% |   Grade 3: 18  25.7% |   Grade 4: 2   2.9% |   Grade 5: 12  17.1%"
6499b181-7a23-4073-8459-ad46ff02b20f,6499b181-7a23-4073-8459-ad46ff02b20f,Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days),"[PRIMARY] INTERVENTION 1:  </s>   Abraxane, Avastin and Gemcitabine </s>   Each treatment cycle is 28 days. Participants will be treated until disease progression: </s>   Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; </s>   Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; </s>   Avastin: 10 mg/kg IV on days 1 and 15 of each cycle.",0,"INTERVENTION 1:  |   Abraxane, Avastin and Gemcitabine |   Each treatment cycle is 28 days. Participants will be treated until disease progression: |   Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; |   Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by; |   Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
2da13cd4-7189-4f85-be4d-5c1e213ae293,2da13cd4-7189-4f85-be4d-5c1e213ae293,"The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",[PRIMARY] Adverse Events 1: </s>   Total: 13/61 (21.31%) </s>   Anaemia 1/61 (1.64%) </s>   Febrile neutropenia 1/61 (1.64%) </s>   Cardiac failure congestive 0/61 (0.00%) </s>   Pericardial effusion 0/61 (0.00%) </s>   Constipation 1/61 (1.64%) </s>   Intestinal perforation 1/61 (1.64%) </s>   Stomatitis 0/61 (0.00%) </s>   Non-cardiac chest pain 2/61 (3.28%) </s>   Condition aggravated 1/61 (1.64%) </s>   General physical health deterioration 1/61 (1.64%) </s> Adverse Events 2: </s>   Total: 12/60 (20.00%) </s>   Anaemia 1/60 (1.67%) </s>   Febrile neutropenia 0/60 (0.00%) </s>   Cardiac failure congestive 1/60 (1.67%) </s>   Pericardial effusion 1/60 (1.67%) </s>   Constipation 0/60 (0.00%) </s>   Intestinal perforation 0/60 (0.00%) </s>   Stomatitis 1/60 (1.67%) </s>   Non-cardiac chest pain 0/60 (0.00%) </s>   Condition aggravated 0/60 (0.00%) </s>   General physical health deterioration 1/60 (1.67%),1,Adverse Events 1: |   Total: 13/61 (21.31%) |   Anaemia 1/61 (1.64%) |   Febrile neutropenia 1/61 (1.64%) |   Cardiac failure congestive 0/61 (0.00%) |   Pericardial effusion 0/61 (0.00%) |   Constipation 1/61 (1.64%) |   Intestinal perforation 1/61 (1.64%) |   Stomatitis 0/61 (0.00%) |   Non-cardiac chest pain 2/61 (3.28%) |   Condition aggravated 1/61 (1.64%) |   General physical health deterioration 1/61 (1.64%) | Adverse Events 2: |   Total: 12/60 (20.00%) |   Anaemia 1/60 (1.67%) |   Febrile neutropenia 0/60 (0.00%) |   Cardiac failure congestive 1/60 (1.67%) |   Pericardial effusion 1/60 (1.67%) |   Constipation 0/60 (0.00%) |   Intestinal perforation 0/60 (0.00%) |   Stomatitis 1/60 (1.67%) |   Non-cardiac chest pain 0/60 (0.00%) |   Condition aggravated 0/60 (0.00%) |   General physical health deterioration 1/60 (1.67%)
a9bb6de9-c6f8-4c99-81cd-f101cbaab387,a9bb6de9-c6f8-4c99-81cd-f101cbaab387,Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial,"[PRIMARY] DISEASE CHARACTERISTICS: </s>   Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain </s>   Extracranial metastases allowed </s>   Must have demonstrated progression of brain metastases after prior treatment for brain metastases, including any of the following: </s>   External beam radiotherapy </s>   Brachytherapy </s>   Stereotactic radiosurgery </s>   Surgery </s>   Chemotherapy </s>   Treatments with investigational drugs, biologics, or devices </s>   Disease progression in the CNS must meet  1 of the following criteria: </s>   New lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI) </s>   Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI) </s>   New or progressive lesions that do not meet measurable disease definition allowed </s>   Leptomeningeal disease allowed if concurrent progression or parenchymal brain metastases </s>   Not a candidate for surgical resection and/or further stereotactic radiosurgery </s>   Hormone receptor status not specified </s>   PATIENT CHARACTERISTICS: </s>   Menopausal status not specified </s>   ECOG performance status 0-2 </s>   Life expectancy  1 month </s>   Hemoglobin  10 g/dL (transfusion allowed) </s>   ANC  1,500/mm³ </s>   Granulocyte count  1,500/mm³ </s>   Platelet count  100,000/mm³ </s>   Creatinine  1.5 mg/dL </s>   Total bilirubin  1.5 times upper limit of normal (ULN) </s>   AST and ALT  3 times ULN </s>   Must be able to swallow and retain oral medications </s>   No other active malignancy except for any of the following: </s>   Curatively treated basal or squamous cell carcinoma of the skin </s>   Carcinoma in situ of the cervix </s>   Other malignancies considered disease-free </s>   Not pregnant or nursing </s>   Negative pregnancy test </s>   Fertile patients must use effective contraception </s>   No history of immediate or delayed-type hypersensitivity reaction to gadolinium contrast agents or other contraindication to gadolinium contrast </s>   No other known contraindication to MRI including, but not limited to, any of the following: </s>   Cardiac pacemaker </s>   Implanted cardiac defibrillator </s>   Brain aneurysm clips </s>   Cochlear implant </s>   Ocular foreign body </s>   Shrapnel </s>   No active or uncontrolled infection </s>   PRIOR CONCURRENT THERAPY: </s>   See Disease Characteristics </s>   Recovered from the side effects of prior chemotherapy, surgery, or radiotherapy for extracranial disease or brain metastases </s>   Concurrent trastuzumab, bisphosphonate, and/or corticosteroid therapy allowed </s>   At least 1 week since prior or on current stable dose of corticosteroid therapy </s>   Patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication </s>   Concurrent coumadin allowed </s>   No prophylactic use of filgrastim (G-CSF) during first course of treatment",0,  Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain
7e5fd062-6ec3-480f-ab0e-e117eba2ffe7,7e5fd062-6ec3-480f-ab0e-e117eba2ffe7,"All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.","[PRIMARY] Outcome Measurement:  </s>   Complete Response + Partial Response + Stable Disease > 24 Weeks </s>   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. </s>   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. </s>   Time frame: 24 weeks </s> Results 1:  </s>   Arm/Group Title: Sorafenib and Anastrozole </s>   Arm/Group Description: All patients receive sorafenib and anastrozole. </s>   Overall Number of Participants Analyzed: 35 </s>   Measure Type: Number </s>   Unit of Measure: participants  35",1,"Outcome Measurement:  |   Complete Response + Partial Response + Stable Disease > 24 Weeks |   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. |   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. |   Time frame: 24 weeks | Results 1:  |   Arm/Group Title: Sorafenib and Anastrozole |   Arm/Group Description: All patients receive sorafenib and anastrozole. |   Overall Number of Participants Analyzed: 35 |   Measure Type: Number |   Unit of Measure: participants  35"
016943fa-57ea-4293-8131-03292ea1836c,016943fa-57ea-4293-8131-03292ea1836c,"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm","[PRIMARY] Inclusion Criteria: </s>   Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria. </s>   Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules </s>   Subjects must be of female gender and >= 18 years of age </s>   Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics: </s>   node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR </s>   node-negative AND at least one of the following features: </s>   Tumor >2 cm or </s>   Tumor >1 cm and </s>   Negative estrogen receptor/progesterone receptor (ER/PR) or </s>   Malignancy Grade 2-3 or </s>   Presence of peritumoral vascular invasion or </s>   Age <35 years </s>   HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using </s>   immunohistochemistry </s>   Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s]) </s>   Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55% </s>   Easter Cooperative Oncology Group (ECOG)-performance status of 0-1 </s>   Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN) </s>   Adequate renal function: calculated creatinine clearance >=50 ml/min </s>   Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN </s>   Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations </s>   Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening </s>   Subjects must be able to provide written informed consent </s> Exclusion Criteria: </s>   Subject who meets any of the following exclusion criteria will be disqualified from participation in the study: </s>   Clinical or radiological evidence of metastatic disease </s>   Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization </s>   Clinically significant pericardial effusion </s>   Serious cardiac illness including, but not confined to </s>   history of documented congestive heart failure </s>   history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy </s>   history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication </s>   serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias </s>   clinically significant valvular disease </s>   poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg) </s>   Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC) </s>   Pregnancy, or intending to become pregnant during the study </s>   Nursing (breastfeeding) or intending to be nursing during the study </s>   Any of the following clinical conditions: </s>   Chronic obstructive pulmonary disease, requiring chronic treatment </s>   Clinically significant active infections </s>   A history of a psychological illness of condition, preventing the subject to understand the requirements of the study </s>   Unstable regulation of diabetes mellitus </s>   A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study </s>   Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study </s>   Usage of any investigational product within 30 days prior to enrollment </s>   Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study. </s>   Allergy to or sensitivity to the study drug or its excipients",0,"  node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR |   node-negative AND at least one of the following features: |   Tumor >2 cm or |   Tumor >1 cm and"
402f0dbf-cf67-4425-b300-a0a3df4d59d3,402f0dbf-cf67-4425-b300-a0a3df4d59d3,the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ,"[PRIMARY] Outcome Measurement:  </s>   Objective Response Rate (ORR) </s>   An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. </s>   Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization </s>   Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) </s> Results 1:  </s>   Arm/Group Title: Fulvestrant 250 mg </s>   Arm/Group Description: Fulvestrant 250 mg </s>   Overall Number of Participants Analyzed: 45 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  11.1 </s> Results 2:  </s>   Arm/Group Title: Fulvestrant 250 mg + Loading Dose </s>   Arm/Group Description: Fulvestrant 250 mg + Loading Dose </s>   Overall Number of Participants Analyzed: 51 </s>   Measure Type: Number </s>   Unit of Measure: percentage of participants  17.6 [SECONDARY] Outcome Measurement:  </s>   Objective Response (OR) </s>   OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST). OR was primary endpoint only for Cohort B. </s>   Time frame: Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter. </s> Results 1:  </s>   Arm/Group Title: Cohort B </s>   Arm/Group Description: Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd </s>   Overall Number of Participants Analyzed: 21 </s>   Measure Type: Number </s>   Unit of Measure: Participants with OR  0",1,"Outcome Measurement:  |   Objective Response Rate (ORR) |   An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. |   Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization |   Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008) | Outcome Measurement:  |   Objective Response (OR) |   OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST). OR was primary endpoint only for Cohort B. |   Time frame: Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter."
62be4676-099f-4c42-8029-773af8fde6f7,62be4676-099f-4c42-8029-773af8fde6f7,Patients must be bedbound or severaly disabled to participate in the primary trial,"[PRIMARY] Inclusion Criteria: </s>   Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy </s>   Locally advanced breast cancer, not stage IV, and with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam) </s>   No obvious contraindications for primary chemotherapy </s>   Residual tumor planned to be removed surgically following completion of neoadjuvant therapy </s>   Able to lie still for 1.5 hours for PET scanning </s>   Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) </s>   Leukocytes >= 3,000/ul </s>   Absolute neutrophil count >= 1,500/ul </s>   Platelets >= 100,000/ul </s>   Total bilirubin within normal institutional limits </s>   Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times the institutional upper limit of normal </s>   Creatinine within normal institutional limits OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal </s>   If female, postmenopausal for a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care (SOC) pregnancy test, and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation </s>   Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines </s> Exclusion Criteria: </s>   Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy </s>   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements </s>   Medically unstable </s>   Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours </s>   History of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine </s>   Pregnant or nursing </s>   Previous malignancy, other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, from which the patient has been disease free for less than 5 years </s>   Currently on hormone therapy as the primary systemic neoadjuvant therapy",0,"Inclusion Criteria: |   Pathologically confirmed breast cancer, determined to be a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy |   Locally advanced breast cancer, not stage IV, and with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam) |   No obvious contraindications for primary chemotherapy |   Residual tumor planned to be removed surgically following completion of neoadjuvant therapy |   Able to lie still for 1.5 hours for PET scanning |   Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) |   Leukocytes >= 3,000/ul |   Absolute neutrophil count >= 1,500/ul |   Platelets >= 100,000/ul |   Total bilirubin within normal institutional limits |   Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times the institutional upper limit of normal |   Creatinine within normal institutional limits OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal |   If female, postmenopausal for a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care (SOC) pregnancy test, and willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation |   Able to understand and willing to sign a written informed consent document and a Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines | Exclusion Criteria: |   Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy |   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements |   Medically unstable |   Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours |   History of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine |   Pregnant or nursing |   Previous malignancy, other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, from which the patient has been disease free for less than 5 years |   Currently on hormone therapy as the primary systemic neoadjuvant therapy"
1180dd58-61b8-4c48-ab00-7d458e68c85b,1180dd58-61b8-4c48-ab00-7d458e68c85b,the results of the secondary trial and the primary trial report the same outcome measures,"[PRIMARY] Outcome Measurement:  </s>   Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks </s>   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. </s>   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity. </s>   The development of clinical fat necrosis. </s>   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically. </s>   The data is shown as the number of participants that experienced each of the specific toxicities. </s>   Time frame: 2 years </s> Results 1:  </s>   Arm/Group Title: Partial Breast Irradiation </s>   Arm/Group Description: Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks </s>   External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks </s>   Overall Number of Participants Analyzed: 53 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  Grade 3 or 4 Skin/ Subcutaneous toxicity: 0   0.0% </s>   Grade 3 or 4 Pulmonary Toxicity: 0   0.0% </s>   Fat Necrosis: 0   0.0% </s>   Rib fractures on ipsilateral treated side: 0   0.0% [SECONDARY] Outcome Measurement:  </s>   Overall Tumor Response </s>   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (""respond""), stay the same (""stable""), or worsen (""progression"") during treatment. </s>   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression </s> Results 1:  </s>   Arm/Group Title: Pemetrexed </s>   Arm/Group Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression </s>   Overall Number of Participants Analyzed: 35 </s>   Measure Type: Number </s>   Unit of Measure: participants  Complete Response: 1 </s>   Partial Response: 8 </s>   Stable Disease: 14 </s>   Progressive Disease: 9 </s>   Best Response Not Evaluable: 3",0,"Outcome Measurement:  |   Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks |   The safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks. The study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. |   Grade 3 or 4 skin/subcutaneous or pulmonary toxicity. |   The development of clinical fat necrosis. |   The development of rib fracture on the ipsilateral treated side, detected either clinically and/or radiographically. |   The data is shown as the number of participants that experienced each of the specific toxicities. |   Time frame: 2 years | Outcome Measurement:  |   Overall Tumor Response |   Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (""respond""), stay the same (""stable""), or worsen (""progression"") during treatment. |   Time frame: every 3 cycles (approximately 6-7 weeks) or until patient has disease progression"
566bdc2d-7c4a-4547-87da-ac81447ecca8,566bdc2d-7c4a-4547-87da-ac81447ecca8,"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.","[PRIMARY] Outcome Measurement:  </s>   Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse </s>   CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. </s>   Time frame: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012 </s> Results 1:  </s>   Arm/Group Title: Lapatinib Plus Capecitabine </s>   Arm/Group Description: Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. </s>   Overall Number of Participants Analyzed: 251 </s>   Measure Type: Number </s>   Unit of Measure: participants  8 </s> Results 2:  </s>   Arm/Group Title: Trastuzumab Plus Capecitabine </s>   Arm/Group Description: Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. </s>   Overall Number of Participants Analyzed: 250 </s>   Measure Type: Number </s>   Unit of Measure: participants  12",0,"Outcome Measurement:  |   Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse |   CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features (e.g., associated T2W signal abnormality); the appearance of any enhancing lesion on T1W MRI with CNS symptoms; unequivocal finding of leptomeningeal disease (defined as the dissemination of cancer throughout the spinal fluid), with or without symptoms; and unequivocal finding of multifocal intraparenchymal lesions with or without symptoms. In the event of the appearance of a <6 mm lesions(s) without CNS lesions, or equivocal findings potentially suggesting leptomeningeal disease, these findings were followed with a subsequent scan within 6 weeks. If unequivocal progression was determined with the subsequent scan and/or CNS symptoms occurred, then CNS relapse crieria were met. |   Time frame: From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012 | Results 1:  |   Arm/Group Title: Lapatinib Plus Capecitabine |   Arm/Group Description: Participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. Participants also received capecitabine 2000 mg/m^2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. |   Overall Number of Participants Analyzed: 251 |   Measure Type: Number |   Unit of Measure: participants  8 | Results 2:  |   Arm/Group Title: Trastuzumab Plus Capecitabine |   Arm/Group Description: Participants received an IV infusion of trastuzumab 8 mg/kg on Day 1, followed by a 6 mg/kg infusion every 3 weeks. Participants also received capecitabine 2500 mg/m^2 per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. Capecitabine was taken with food or within 30 minutes after food. Participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. |   Overall Number of Participants Analyzed: 250 |   Measure Type: Number |   Unit of Measure: participants  12"
d310ec4e-993e-4827-8dc5-9aca053972db,d310ec4e-993e-4827-8dc5-9aca053972db,The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.,[PRIMARY] INTERVENTION 1:  </s>   Letrozole </s>   Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. [SECONDARY] INTERVENTION 1:  </s>   Sentinel Lymph Node Biopsy </s> [Not Specified],0,INTERVENTION 1:  |   Letrozole |   Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. | INTERVENTION 1:  |   Sentinel Lymph Node Biopsy | [Not Specified]
a5617ae4-05a3-42d0-9e14-141de5f8c010,a5617ae4-05a3-42d0-9e14-141de5f8c010,"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any","[PRIMARY] Adverse Events 1: </s>   Total: 16/48 (33.33%) </s>   Febrile neutropenia grade 3 3/48 (6.25%) </s>   Neutropenia grade 3 1/48 (2.08%) </s>   Holocraneal cephalea 1/48 (2.08%) </s>   Hypersensibility reaction grade 3 2/48 (4.17%) </s>   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) </s>   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) </s>   Catheter - related infection grade 3 1/48 (2.08%) [SECONDARY] Adverse Events 1: </s>   Total: 21/519 (4.05%) </s>   Anaemia 1/519 (0.19%) </s>   Blood bilirubin 0/519 (0.00%) </s>   Leukopenia 0/519 (0.00%) </s>   Neutropenia 1/519 (0.19%) </s>   Arrhythmia 0/519 (0.00%) </s>   Carotid artery thrombosis 1/519 (0.19%) </s>   Ear infection 0/519 (0.00%) </s>   Conjunctivitis 0/519 (0.00%) </s>   Abdominal pain 1/519 (0.19%) </s>   Anal fissure 0/519 (0.00%) </s>   Constipation 0/519 (0.00%) </s>   Diarrhoea 1/519 (0.19%) </s> Adverse Events 2: </s>   Total: 119/532 (22.37%) </s>   Anaemia 1/532 (0.19%) </s>   Blood bilirubin 1/532 (0.19%) </s>   Leukopenia 1/532 (0.19%) </s>   Neutropenia 5/532 (0.94%) </s>   Arrhythmia 1/532 (0.19%) </s>   Carotid artery thrombosis 0/532 (0.00%) </s>   Ear infection 1/532 (0.19%) </s>   Conjunctivitis 1/532 (0.19%) </s>   Abdominal pain 1/532 (0.19%) </s>   Anal fissure 1/532 (0.19%) </s>   Constipation 1/532 (0.19%) </s>   Diarrhoea 6/532 (1.13%)",1,"Adverse Events 1: |   Total: 16/48 (33.33%) |   Febrile neutropenia grade 3 3/48 (6.25%) |   Neutropenia grade 3 1/48 (2.08%) |   Holocraneal cephalea 1/48 (2.08%) |   Hypersensibility reaction grade 3 2/48 (4.17%) |   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%) |   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%) |   Catheter - related infection grade 3 1/48 (2.08%) | Adverse Events 1: |   Conjunctivitis 0/519 (0.00%) | Adverse Events 2: |   Conjunctivitis 1/532 (0.19%)"
42d1fcd3-8faa-4065-bbba-42cc90ab67fb,42d1fcd3-8faa-4065-bbba-42cc90ab67fb,the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.,"[PRIMARY] Outcome Measurement:  </s>   Number of Patients With Pathological Complete Response Rate </s>   Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. </s>   Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization) </s> Results 1:  </s>   Arm/Group Title: Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) </s>   Arm/Group Description: Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6). </s>   Overall Number of Participants Analyzed: 98 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  35  35.7% </s> Results 2:  </s>   Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)) </s>   Arm/Group Description: Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab </s>   Overall Number of Participants Analyzed: 113 </s>   Measure Type: Count of Participants </s>   Unit of Measure: Participants  24  21.2% [SECONDARY] Outcome Measurement:  </s>   Disease Free Survival. </s>   Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years </s>   Time frame: 8 years </s> Results 1:  </s>   Arm/Group Title: Arm 1: Clodronate </s>   Arm/Group Description: Patient receives 2 tablets once daily for 3 years. </s>   clodronate: 1600 mg PO daily </s>   Overall Number of Participants Analyzed: 1655 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  81.0 </s> Results 2:  </s>   Arm/Group Title: Arm 2: Placebo </s>   Arm/Group Description: Patient receives 2 tablets once daily for 3 years. </s>   placebo: 2 pills PO daily </s>   Overall Number of Participants Analyzed: 1656 </s>   Measure Type: Number </s>   Unit of Measure: percentage of patients  79.6",1,"Outcome Measurement:  |   Number of Patients With Pathological Complete Response Rate |   Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. |   Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization) | Outcome Measurement:  |   Disease Free Survival. |   Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years |   Time frame: 8 years"
d01fda83-5dc8-4ad5-92b8-7553dabd7046,d01fda83-5dc8-4ad5-92b8-7553dabd7046,"the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse","[PRIMARY] Outcome Measurement:  </s>   Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. </s>   The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months. </s>   Time frame: up to 3 years </s> Results 1:  </s>   Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel </s>   Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ] </s>   Overall Number of Participants Analyzed: 26 </s>   Median (95% Confidence Interval) </s>   Unit of Measure: months  14.3        (9.3 to 35)",1,"Outcome Measurement:  |   Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen."
985bc5a0-bc21-447f-92f1-150e23ede3f5,985bc5a0-bc21-447f-92f1-150e23ede3f5,All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions,"[PRIMARY] Outcome Measurement:  </s>   Complete Response + Partial Response + Stable Disease > 24 Weeks </s>   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. </s>   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. </s>   Time frame: 24 weeks </s> Results 1:  </s>   Arm/Group Title: Sorafenib and Anastrozole </s>   Arm/Group Description: All patients receive sorafenib and anastrozole. </s>   Overall Number of Participants Analyzed: 35 </s>   Measure Type: Number </s>   Unit of Measure: participants  35",0,"Outcome Measurement:  |   Complete Response + Partial Response + Stable Disease > 24 Weeks |   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. |   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. |   Time frame: 24 weeks | Results 1:  |   Arm/Group Title: Sorafenib and Anastrozole |   Arm/Group Description: All patients receive sorafenib and anastrozole. |   Overall Number of Participants Analyzed: 35 |   Measure Type: Number |   Unit of Measure: participants  35"
